US9700704B2 - Drug releasing coatings for balloon catheters - Google Patents

Drug releasing coatings for balloon catheters Download PDF

Info

Publication number
US9700704B2
US9700704B2 US15154662 US201615154662A US9700704B2 US 9700704 B2 US9700704 B2 US 9700704B2 US 15154662 US15154662 US 15154662 US 201615154662 A US201615154662 A US 201615154662A US 9700704 B2 US9700704 B2 US 9700704B2
Authority
US
Grant status
Grant
Patent type
Prior art keywords
additive
balloon catheter
therapeutic agent
peg
hydrophobic therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US15154662
Other versions
US20160250452A1 (en )
Inventor
Lixiao Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lutonix Inc
Original Assignee
Lutonix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Grant date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/10Balloon catheters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L29/00Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/08Materials for coatings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L29/00Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/08Materials for coatings
    • A61L29/085Macromolecular materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L29/00Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08Materials for coatings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16Biologically active materials, e.g. therapeutic substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/428Vitamins, e.g. tocopherol, riboflavin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/606Coatings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/606Coatings
    • A61L2300/608Coatings having two or more layers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/80Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special chemical form
    • A61L2300/802Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/10Balloon catheters
    • A61M2025/1043Balloon catheters with special features or adapted for special applications
    • A61M2025/105Balloon catheters with special features or adapted for special applications having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00Catheters; Hollow probes
    • A61M25/10Balloon catheters
    • A61M2025/1043Balloon catheters with special features or adapted for special applications
    • A61M2025/1075Balloon catheters with special features or adapted for special applications having a balloon composed of several layers, e.g. by coating or embedding

Abstract

Balloon catheters, methods for preparing balloon catheters, and uses of balloon catheters are disclosed. The balloon catheter includes an elongate member, an expandable balloon, and a coating layer overlying an exterior surface of the expandable balloon. The coating layer includes a total drug load of a hydrophobic therapeutic agent and a combination of additives including a first additive and a second additive. The hydrophobic therapeutic agent is paclitaxel, rapamycin, or paclitaxel and rapamycin. The first additive is a surfactant. The second additive is a chemical compound having one or more hydroxyl, amino, carbonyl, carboxyl, acid, amide, or ester groups.

Description

CROSS-REFERENCES TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. application Ser. No. 15/067,739, filed Mar. 11, 2016, which is a continuation of U.S. application Ser. No. 14/683,612 filed Apr. 10, 2015, now U.S. Pat. No. 9,289,539, issued Mar. 22, 2016, which is a continuation of U.S. application Ser. No. 13/846,143, filed Mar. 18, 2013, now U.S. Pat. No. 9,005,161, issued Apr. 14, 2015, which is a continuation of U.S. application Ser. No. 12/731,835, filed Mar. 25, 2010, now U.S. Pat. No. 8,414,910, issued Apr. 9, 2013, which is a continuation-in-part of U.S. application Ser. No. 12/121,986, filed May 16, 2008, now U.S. Pat. No. 8,414,525, issued Apr. 9, 2013, which is a continuation-in-part of U.S. application Ser. No. 11/942,452, filed Nov. 19, 2007, now U.S. Pat. No. 8,414,909, issued Apr. 9, 2013, which claims the benefit of priority of U.S. Provisional Application No. 60/860,084, filed Nov. 20, 2006, of U.S. Provisional Application No. 60/880,742, filed Jan. 17, 2007, of U.S. Provisional Application No. 60/897,427, filed Jan. 25, 2007, of U.S. Provisional Application No. 60/903,529, filed Feb. 26, 2007, of U.S. Provisional Application No. 60/904,473, filed Mar. 2, 2007, of U.S. Provisional Application No. 60/926,850, filed Apr. 30, 2007, of U.S. Provisional Application No. 60/981,380, filed Oct. 19, 2007, and of U.S. Provisional Application No. 60/981,384, filed Oct. 19, 2007; and this application is also a continuation-in-part of U.S. application Ser. No. 14/932,033, filed Nov. 4, 2015, which is a continuation of U.S. application Ser. No. 13/846,358, filed Mar. 18, 2013, now U.S. Pat. No. 9,180,485, issued Nov. 10, 2015, which is a continuation of U.S. application Ser. No. 12/549,180, filed Aug. 27, 2009, now U.S. Pat. No. 8,430,055, issued Apr. 30, 2013, which claims the benefit of priority of U.S. Provisional Application No. 61/092,872, filed Aug. 29, 2008. The full disclosures of all of the foregoing applications are incorporated by reference herein.

TECHNICAL FIELD

The present disclosure relates to balloon catheters, methods of preparing balloon catheters, and uses of balloon catheters. More specifically, the present disclosure relates to balloon catheters for delivering a therapeutic agent to a blood vessel, wherein the balloon catheters have a coating layer having a hydrophobic therapeutic agent and a combination of additives.

BACKGROUND

It has become increasingly common to treat a variety of medical conditions by introducing a medical device into the vascular system or other lumen within a human. While such treatment initially appears successful, the initial success is often compromised by the recurrence of disease, such as stenosis (i.e., restenosis) after such treatment. Restenosis involves a physiological response to vascular injury caused by angioplasty. Over time, de-endothelization and injury to smooth muscle cells results in thrombus deposition, leukocyte and macrophage infiltration, smooth muscle cell proliferation/migration, fibrosis, and extracellular matrix deposition. In response to the incidence of restenosis, numerous local drug delivery systems have been developed for the treatment restenosis after balloon angioplasty.

Balloon catheters are one such local delivery system that has been found to be effective in the treatment and prevention of restenosis. Generally, balloons coated with an active agent are pressed against the wall of a blood vessel when the blood vessel is dilated to deliver the active agent. Accordingly, it may be advantageous for the active agent in the coating to be rapidly released and absorbed by blood vessel tissues. Any component in the coating which inhibits rapid release of the active agent may be disadvantageous.

The iodine contrast agent iopromide has been used with paclitaxel to coat balloon catheters and has met some success in the treatment of restenosis. While it has been reported that such contrast agent improves adhesion of paclitaxel to the balloon surface, iodinated contrast agents suffer from a variety of disadvantages. For example, when used for diagnostic procedures, iodinated contrast agents have complication rates of 5-30%. Additionally, iodinated contrast agents are associated with the risk of bradycardia, ventricular arrthymia, and fibrillation, and may also induce renal failure. Further, the Food and Drug Administration issued a second public health advisory in 2006 concerning a serious late adverse reaction to contrast agents known as Nephrogenic Systemic Fibrosis or Mephrogenic Fibrosing Dermopathy.

Moreover, iodinated X-ray contrast agents are unable to cross membrane lipid bilayers in order to enter cells of the vasculature. As a result, they are not optimally effective at carrying hydrophobic therapeutic agents such as paclitaxel into cells. The percentage of paclitaxel reported to be taken up by vascular tissue after deployment of these devices is only 5-20%. Additionally, the compatibility and/or miscibility of paclitaxel and iopromide is not optimal, and the integrity and uniformity of coating is poor. Such deficiencies adversely affect the amount and uniformity of hydrophobic therapeutic agent delivered to target tissue. Accordingly, additional embodiments of coating layers for balloon catheters are desired.

SUMMARY

In one embodiment, a balloon catheter for delivering a therapeutic agent to a blood vessel is disclosed. The balloon catheter delivers a therapeutic agent to the blood vessel while the balloon catheter is deployed at a target site of the blood vessel. The balloon catheter includes an elongate member, an expandable balloon, and a coating layer. The elongate member has a lumen and a distal end. The expandable balloon is attached to the distal end of the elongate member and is in fluid communication with the lumen of the elongate member. The coating layer overlies an exterior surface of the expandable balloon. The coating layer includes a total drug load of a hydrophobic therapeutic agent and a combination of additives including a first additive and a second additive. The hydrophobic therapeutic agent is one of paclitaxel, rapamycin, or combinations thereof. The first additive is one of PEG sorbitan monolaurates, PEG sorbitan monooleates, or combinations thereof. The second additive is one of sorbitol, sorbitan, xylitol, gluconolactone, lactobionic acid, or combinations thereof.

In another embodiment, a balloon catheter for delivering a therapeutic agent to a blood vessel is disclosed. The balloon catheter delivers a therapeutic agent to the blood vessel while the balloon catheter is deployed at a target site of the blood vessel. In this embodiment, the balloon catheter includes an elongate member, an expandable balloon, and a coating layer. The elongate member has a lumen and a distal end. The expandable balloon is attached to the distal end of the elongate member and is in fluid communication with the lumen of the elongate member. The coating layer overlies an exterior surface of the expandable balloon. In this embodiment, the coating layer includes a total drug load of a hydrophobic therapeutic agent and a combination of additives including a first additive and a second additive. The total drug load of the hydrophobic therapeutic agent is from 2.5 μg to 6 μg per square millimeter of the expandable balloon. The hydrophobic therapeutic agent is one of paclitaxel, rapamycin, or combinations thereof. The first additive is one of PEG-20 sorbitan monolaurate, PEG-20 sorbitan monooleate, or combinations thereof. The second additive is one of sorbitol, gluconolactone, or combinations thereof. The ratio by weight of the combination of additives in the coating layer to the hydrophobic therapeutic agent in the coating layer is about 10 to 0.5.

It is understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the present disclosure as claimed.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a perspective view of an exemplary embodiment of a balloon catheter according to the present disclosure; and

FIG. 2 is a cross-sectional view of an embodiment of the distal portion of the balloon catheter of FIG. 1, taken along line A-A, showing an exemplary coating layer.

Skilled artisans should appreciate that elements in the figures are illustrated for simplicity and clarity and are not necessarily drawn to scale. For example, the dimensions of some of the elements in the figures may be exaggerated relative to other elements, as well as conventional parts removed, to help to improve understanding of the various embodiments described herein.

DETAILED DESCRIPTION

Embodiments of the present disclosure relate to balloon catheters for delivering a therapeutic agent to a blood vessel. In one embodiment, the balloon catheter includes an elongate member, an expandable balloon, and a coating layer. Reference will now be made in detail to balloon catheters. More particularly, embodiments of the balloon catheter and, more specifically, the elongate member and the expandable balloon of the balloon catheter will now be described in detail with reference to FIG. 1. Thereafter, embodiments of the coating layer will be described in detail with reference to FIG. 2.

I. Balloon Catheters with Coating Layer

Referring to FIG. 1, a balloon catheter 10 is disclosed. The balloon catheter 10 has a proximal end 18 and a distal end 20. The balloon catheter 10 may be any suitable catheter for desired use, including conventional balloon catheters known to one of ordinary skill in the art. For example, the balloon catheter 10 may be a rapid exchange or over-the-wire catheter. The balloon catheter 10 may be made of any suitable biocompatible material.

As shown in FIGS. 1 and 2, in one embodiment, the balloon catheter 10 includes an expandable balloon 12 and an elongate member 14. The elongate member 14 extends between the proximal end 18 and the distal end 20 of the balloon catheter 10. The elongate member 14 has at least one lumen 26 a, 26 b and a distal end 22. The elongate member 14 may be a flexible member which is a tube made of suitable biocompatible material. The elongate member 14 may have one lumen or, as shown in FIGS. 1 and 2, more than one lumen 26 a, 26 b therein. For example, the elongate member 14 may include a guide-wire lumen 26 b that extends to the distal end 20 of the balloon catheter 10 from a guide-wire port 15 at the proximal end 18 of the balloon catheter 10. The elongate member 14 may also include an inflation lumen 26 a that extends from an inflation port 17 of the balloon catheter 10 to the inside of the expandable balloon 12 to enable inflation of the expandable balloon 12. From the embodiment of FIGS. 1 and 2, even though the inflation lumen 26 a and the guide-wire lumen 26 b are shown as side-by-side lumens, it should be understood that the one or more lumens present in the elongate member 14 may be configured in any manner suited to the intended purposes of the lumens including, for example, introducing inflation media and/or introducing a guide-wire. Many such configurations are well known in the art.

The expandable balloon 12 is attached to the distal end 22 of the elongate member 14. The expandable balloon 12 has an exterior surface 24 and is inflatable. The expandable balloon 12 is in fluidic communication with a lumen of the elongate member 14, (for example, with the inflation lumen 26 a). At least one lumen of the elongate member 14 is configured to receive inflation media and to pass such media to the expandable balloon 12 for its expansion. Examples of inflation media include air, saline, and contrast media.

Still referring to FIG. 1, in one embodiment, the balloon catheter 10 includes a handle assembly such as a hub 16. The hub 16 may be attached to the balloon catheter 10 at the proximal end 18 of the balloon catheter 10. The hub 16 may connect to and/or receive one or more suitable medical devices, such as a source of inflation media or a guide wire. For example, a source of inflation media (not shown) may connect to the inflation port 17 of the hub 16 (for example, through the inflation lumen 26 a), and a guide wire (not shown) may be introduced to the guide-wire port 15 of the hub 16, (for example through the guide-wire lumen 26 b).

Referring now to FIG. 2, a balloon catheter 10 having a coating layer 30 is disclosed. The coating layer 30 overlies an exterior surface 24 of the expandable balloon 12. The coating layer 30 includes a hydrophobic therapeutic agent and a combination of additives. In one particular embodiment, the coating layer 30 consists essentially of the hydrophobic therapeutic agent and the combination of additives. Stated another way, in this particular embodiment, the coating layer 30 includes only the therapeutic agent and the combination of additives, without any other materially significant components. In another particular embodiment, the coating layer 30 is from about 0.1 μm to 15 μm thick.

A. Hydrophobic Therapeutic Agent

In one embodiment, the coating layer 30 includes a hydrophobic therapeutic agent. However, the coating layer 30 may also include two or more hydrophobic therapeutic agents. The hydrophobic therapeutic agent may be a lipophilic substantially water insoluble therapeutic agent. For example, the hydrophobic therapeutic agent may be paclitaxel, rapamycin, daunorubicin, doxorubicin, lapachone, vitamin D2 and analogues and derivative thereof, and vitamin D3 and analogues and derivatives thereof. Additional suitable hydrophobic therapeutic agents generally include glucocorticoids (e.g., dexamethasone, betamethasone), hirudin, angiopeptin, aspirin, growth factors, antisense agents, polynucleotides, RNAi, siRNA, anti-cancer agents, anti-proliferative agents, oligonucleotides, and, more generally, anti-platelet agents, anti-coagulant agents, anti-mitotic agents, anti-metabolite agents, antioxidants, antiobiotic agents, anti-chemotactic, anti-inflammatory agents, photosensitizing agents, and collagen synthesis inhibitors.

With regard to antisense agents, polynucleotides, RNAi, and siRNA, suitable hydrophobic therapeutic agents include agents that inhibit inflammation and/or smooth muscle cell or fibroblast proliferation. With regard to anti-proliferative agents, suitable hydrophobic therapeutic agents include amlodipine and doxazosin. With regard to anti-platelet agents, suitable hydrophobic therapeutic agents include aspirin and dipyridamole. Aspirin may also be classified as an anti-platelet and an anti-inflammatory agent. Additionally, dipyridamole also exhibits anti-platelet characteristics. With regard to anti-coagulant agents, suitable hydrophobic therapeutic agents include heparin, protamine, hirudin, and tick anticoagulant protein.

With regard to anti-mitotic agents and anti-metabolite agents, suitable hydrophobic therapeutic agents include methotrexate, azathioprine, vincristine, vinblastine, 5-fluorouracil, adriamycin, and mutamycin. With regard to antioxidants, suitable hydrophobic therapeutic agents include probucol. With regard to antibiotic agents, suitable hydrophobic therapeutic agents include penicillin, cefoxitin, oxacillin, tobramycin, and gentamicin. With regard to photosensitizing agents, suitable hydrophobic therapeutic agents include agents for photodynamic or radiation therapy, including various porphyrin compounds such as porfimer. With regard to collagen synthesis inhibitors, suitable hydrophobic therapeutic agents include tranilast.

In one embodiment, the hydrophobic therapeutic agent includes at least one of paclitaxel or analogs thereof, rapamycin or analogs thereof, beta-lapachone or analogues thereof, biological vitamin D or analogs thereof, and combinations thereof. In one particular embodiment, the hydrophobic therapeutic agent is paclitaxel, rapamycin, or combinations thereof. In a further embodiment, the hydrophobic therapeutic agent is paclitaxel. Alternatively, in another further embodiment, the hydrophobic therapeutic agent is rapamycin.

As used herein, “derivative” refers to a chemically or biologically modified version of a chemical compound that is structurally similar to a parent compound and (actually or theoretically) derivable from that parent compound. A derivative may or may not have different chemical or physical properties of the parent compound. For example, the derivative may be more hydrophilic or it may have altered reactivity as compared to the parent compound. Derivatization (i.e., modification) may involve substitution of one or more moieties within the molecule (e.g., a change in functional group). For example, a hydrogen may be substituted with a halogen, such as fluorine or chlorine, or a hydroxyl group (—OH) may be replaced with a carboxylic acid moiety (—COOH). The term “derivative” also includes conjugates, and prodrugs of a parent compound (i.e., chemically modified derivatives which can be converted into the original compound under physiological conditions). For example, the prodrug may be an inactive form of an active agent. Under physiological conditions, the prodrug may be converted into the active form of the compound. Prodrugs may be formed, for example, by replacing one or two hydrogen atoms on nitrogen atoms by an acyl group (acyl prodrugs) or a carbamate group (carbamate prodrugs). More detailed information relating to prodrugs is found, for example, in Fleisher et al., Advanced Drug Delivery Reviews 19 (1996) 115; Design of Prodrugs, H. Bundgaard (ed.), Elsevier, 1985; or H. Bundgaard, Drugs of the Future 16 (1991) 443. The term “derivative” is also used to describe all solvates, for example hydrates or adducts (e.g., adducts with alcohols), active metabolites, and salts of the parent compound. The type of salt that may be prepared depends on the nature of the moieties within the compound. For example, acidic groups, for example carboxylic acid groups, can form alkali metal salts or alkaline earth metal salts (e.g., sodium salts, potassium salts, magnesium salts and calcium salts, as well as salts with physiologically tolerable quaternary ammonium ions and acid addition salts with ammonia and physiologically tolerable organic amines such as triethylamine, ethanolamine or tris-(2-hydroxyethyl)amine). Basic groups can form acid addition salts, for example with inorganic acids such as hydrochloric acid, sulfuric acid or phosphoric acid, or with organic carboxylic acids and sulfonic acids such as acetic acid, citric acid, benzoic acid, maleic acid, fumaric acid, tartaric acid, methanesulfonic acid or p-toluenesulfonic acid. Compounds which simultaneously contain a basic group and an acidic group, for example a carboxyl group in addition to basic nitrogen atoms, can be present as zwitterions. Salts can be obtained by customary methods known to those skilled in the art, for example by combining a compound with an inorganic or organic acid or base in a solvent or diluent, or from other salts by cation exchange or anion exchange.

As used herein, “analog” or “analogue” refers to a chemical compound that is structurally similar to another but differs slightly in composition (as in the replacement of one atom by an atom of a different element or in the presence of a particular functional group), but may or may not be derivable from the parent compound. A “derivative” differs from an “analog” or “analogue” in that a parent compound may be the starting material to generate a “derivative,” whereas the parent compound may not necessarily be used as the starting material to generate an “analog.”

Numerous paclitaxel analogs are known in the art. Examples of paclitaxel include docetaxol (TAXOTERE, Merck Index entry 3458), and 3′-desphenyl-3′-(4-ntirophenyl)-N-debenzoyl-N-(t-butoxycarbonyl)-10-deacetyltaxol. Further representative examples of paclitaxel analogs that can be used as therapeutic agents include 7-deoxy-docetaxol, 7,8-cyclopropataxanes, N-substituted 2-azetidones, 6,7-epoxy paclitaxels, 6,7-modified paclitaxels, 10-desacetoxytaxol, 10-deacetyltaxol (from 10-deacetylbaccatin III), phosphonooxy and carbonate derivatives of taxol, taxol 2′,7-di(sodium 1,2-benzenedicarboxylate, 10-desacetoxy-11,12-dihydrotaxol-10,12(18)-diene derivatives, 10-desacetoxytaxol, Protaxol (2′- and/or 7-O-ester derivatives), (2′- and/or 7-O-carbonate derivatives), asymmetric synthesis of taxol side chain, fluoro taxols, 9-deoxotaxane, (13-acetyl-9-deoxobaccatine III, 9-deoxotaxol, 7-deoxy-9-deoxotaxol, 10-desacetoxy-7-deoxy-9-deoxotaxol), derivatives containing hydrogen or acetyl group and a hydroxy and tert-butoxycarbonylamino, sulfonated 2′-acryloyltaxol and sulfonated 2′-O-acyl acid taxol derivatives, succinyltaxol, 2′-γ-aminobutyryltaxol formate, 2′-acetyl taxol, 7-acetyl taxol, 7-glycine carbamate taxol, 2′-OH-7-PEG(5000) carbamate taxol, 2′-benzoyl and 2′,7-dibenzoyl taxol derivatives, other prodrugs (2′-acetyltaxol; 2′,7-diacetyltaxol; 2′succinyltaxol; 2′-(beta-alanyl)-taxol); 2′gamma-aminobutyryltaxol formate; ethylene glycol derivatives of 2′-succinyltaxol; 2′-glutaryltaxol; 2′-(N,N-dimethylglycyl)taxol; 2′-(2-(N,N-dimethylamino)propionyl)taxol; 2′orthocarboxybenzoyl taxol; 2′aliphatic carboxylic acid derivatives of taxol, Prodrugs {2′(N,N-diethylaminopropionyl)taxol, 2′(N,N-dimethylglycyl)taxol, 7(N,N-dimethylglycyl)taxol, 2′,7-di-(N,N-dimethylglycyl)taxol, 7(N,N-diethylaminopropionyl)taxol, 2′,7-di(N,N-diethylaminopropionyl)taxol, 2′-(L-glycyl)taxol, 7-(L-glycyl)taxol, 2′,7-di(L-glycyl)taxol, 2′-(L-alanyl)taxol, 7-(L-alanyl)taxol, 2′,7-di(L-alanyl)taxol, 2′-(L-leucyl)taxol, 7-(L-leucyl)taxol, 2′,7-di(L-leucyl)taxol, 2′-(L-isoleucyl)taxol, 7-(L-isoleucyl)taxol, 2′,7-di(L-isoleucyl)taxol, 2′-(L-valyl)taxol, 7-(L-valyl)taxol, 2′7-di(L-valyl)taxol, 2′-(L-phenylalanyl)taxol, 7-(L-phenylalanyl)taxol, 2′,7-di(L-phenylalanyl)taxol, 2′-(L-prolyl)taxol, 7-(L-prolyl)taxol, 2′,7-di(L-prolyl)taxol, 2′-(L-lysyl)taxol, 7-(L-lysyl)taxol, 2′,7-di(L-lysyl)taxol, 2′-(L-glutamyl)taxol, 7-(L-glutamyl)taxol, 2′,7-di(L-glutamyl)taxol, 2′-(L-arginyl)taxol, 7-(L-arginyl)taxol, 2′,7-di(L-arginyl)taxol, taxol analogues with modified phenylisoserine side chains, TAXOTERE, (N-debenzoyl-N-tert-(butoxycaronyl)-10-deacetyltaxol, and taxanes (e.g., baccatin III, cephalomannine, 10-deacetylbaccatin III, brevifoliol, yunantaxusin and taxusin); and other taxane analogues and derivatives, including 14-beta-hydroxy-10 deacetybaccatin III, debenzoyl-2-acyl paclitaxel derivatives, benzoate paclitaxel derivatives, phosphonooxy and carbonate paclitaxel derivatives, sulfonated 2′-acryloyltaxol; sulfonated 2′-O-acyl acid paclitaxel derivatives, 18-site-substituted paclitaxel derivatives, chlorinated paclitaxel analogues, C4 methoxy ether paclitaxel derivatives, sulfenamide taxane derivatives, brominated paclitaxel analogues, Girard taxane derivatives, nitrophenyl paclitaxel, 10-deacetylated substituted paclitaxel derivatives, 14-beta-hydroxy-10 deacetylbaccatin III taxane derivatives, C7 taxane derivatives, C10 taxane derivatives, 2-debenzoyl-2-acyl taxane derivatives, 2-debenzoyl and -2-acyl paclitaxel derivatives, taxane and baccatin III analogues bearing new C2 and C4 functional groups, n-acyl paclitaxel analogues, 10-deacetylbaccatin III and 7-protected-10-deacetylbaccatin III derivatives from 10-deacetyl taxol A, 10-deacetyl taxol B, and 10-deacetyl taxol, benzoate derivatives of taxol, 2-aroyl-4-acyl paclitaxel analogues, orthro-ester paclitaxel analogues, 2-aroyl-4-acyl paclitaxel analogues and 1-deoxy paclitaxel and 1-deoxy paclitaxel analogues.

Other examples of paclitaxel analogs suitable for use herein include those listed in U.S. Pat. App. Pub. No. 2007/0212394, and U.S. Pat. No. 5,440,056, each of which is incorporated herein by reference.

Many rapamycin analogs are known in the art. Non-limiting examples of analogs of rapamycin include, but are not limited to, everolimus, tacrolimus, CCI-779, ABT-578, AP-23675, AP-23573, AP-23841, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin, 32-demethoxy-rapamycin, 2-desmethyl-rapamycin, prerapamycin, temsirolimus, and 42-O-(2-hydroxy)ethyl rapamycin.

Other analogs of rapamycin include: rapamycin oximes (U.S. Pat. No. 5,446,048); rapamycin aminoesters (U.S. Pat. No. 5,130,307); rapamycin dialdehydes (U.S. Pat. No. 6,680,330); rapamycin 29-enols (U.S. Pat. No. 6,677,357); O-alkylated rapamycin derivatives (U.S. Pat. No. 6,440,990); water soluble rapamycin esters (U.S. Pat. No. 5,955,457); alkylated rapamycin derivatives (U.S. Pat. No. 5,922,730); rapamycin amidino carbamates (U.S. Pat. No. 5,637,590); biotin esters of rapamycin (U.S. Pat. No. 5,504,091); carbamates of rapamycin (U.S. Pat. No. 5,567,709); rapamycin hydroxyesters (U.S. Pat. No. 5,362,718); rapamycin 42-sulfonates and 42-(N-carbalkoxy)sulfamates (U.S. Pat. No. 5,346,893); rapamycin oxepane isomers (U.S. Pat. No. 5,344,833); imidazolidyl rapamycin derivatives (U.S. Pat. No. 5,310,903); rapamycin alkoxyesters (U.S. Pat. No. 5,233,036); rapamycin pyrazoles (U.S. Pat. No. 5,164,399); acyl derivatives of rapamycin (U.S. Pat. No. 4,316,885); reduction products of rapamycin (U.S. Pat. Nos. 5,102,876 and 5,138,051); rapamycin amide esters (U.S. Pat. No. 5,118,677); rapamycin fluorinated esters (U.S. Pat. No. 5,100,883); rapamycin acetals (U.S. Pat. No. 5,151,413); oxorapamycins (U.S. Pat. No. 6,399,625); and rapamycin silyl ethers (U.S. Pat. No. 5,120,842), each of which is specifically incorporated by reference.

Other analogs of rapamycin include those described in U.S. Pat. Nos. 7,560,457; 7,538,119; 7,476,678; 7,470,682; 7,455,853; 7,446,111; 7,445,916; 7,282,505; 7,279,562; 7,273,874; 7,268,144; 7,241,771; 7,220,755; 7,160,867; 6,329,386; RE37,421; 6,200,985; 6,015,809; 6,004,973; 5,985,890; 5,955,457; 5,922,730; 5,912,253; 5,780,462; 5,665,772; 5,637,590; 5,567,709; 5,563,145; 5,559,122; 5,559,120; 5,559,119; 5,559,112; 5,550,133; 5,541,192; 5,541,191; 5,532,355; 5,530,121; 5,530,007; 5,525,610; 5,521,194; 5,519,031; 5,516,780; 5,508,399; 5,508,290; 5,508,286; 5,508,285; 5,504,291; 5,504,204; 5,491,231; 5,489,680; 5,489,595; 5,488,054; 5,486,524; 5,486,523; 5,486,522; 5,484,791; 5,484,790; 5,480,989; 5,480,988; 5,463,048; 5,446,048; 5,434,260; 5,411,967; 5,391,730; 5,389,639; 5,385,910; 5,385,909; 5,385,908; 5,378,836; 5,378,696; 5,373,014; 5,362,718; 5,358,944; 5,346,893; 5,344,833; 5,302,584; 5,262,424; 5,262,423; 5,260,300; 5,260,299; 5,233,036; 5,221,740; 5,221,670; 5,202,332; 5,194,447; 5,177,203; 5,169,851; 5,164,399; 5,162,333; 5,151,413; 5,138,051; 5,130,307; 5,120,842; 5,120,727; 5,120,726; 5,120,725; 5,118,678; 5,118,677; 5,100,883; 5,023,264; 5,023,263; 5,023,262; all of which are incorporated herein by reference. Additional rapamycin analogs and derivatives can be found in the following U.S. Patent Application Pub. Nos., all of which are herein specifically incorporated by reference: 20080249123, 20080188511; 20080182867; 20080091008; 20080085880; 20080069797; 20070280992; 20070225313; 20070203172; 20070203171; 20070203170; 20070203169; 20070203168; 20070142423; 20060264453; and 20040010002.

In another embodiment, the hydrophobic therapeutic agent is provided as a total drug load in the coating layer 20. The total drug load of the hydrophobic therapeutic agent in the coating layer 30 may be from 1 μg to 20 μg, or alternatively from 2 μg to 10 μg, or alternatively from 2 μg to 6 μg, or alternatively from 2.5 μg to 6 μg per square millimeter of the expandable balloon 12. The hydrophobic therapeutic agent may also be uniformly distributed in the coating layer. Additionally, the hydrophobic therapeutic agent may be provided in a variety of physical states. For example, the hydrophobic therapeutic agent may be a molecular distribution, crystal form, or cluster form.

B. Combination of Additives

The coating layer 30 also includes a combination of additives. The combination of additives includes a first additive and a second additive. In one embodiment, the first additive is a surfactant and the second additive is a chemical compound having one or more hydroxyl, amino, carbonyl, carboxyl, acid, amide, or ester groups.

1. First Additive

In one embodiment, the first additive is a surfactant. However, the first additive may also include mixtures of surfactants. Such surfactants may be anionic, cationic, zwitterionic, or non-ionic. Examples of suitable non-ionic surfactants include polyethylene glycol fatty acids, polyethylene glycol fatty acid mono and diesters, polyethylene glycol glycerol fatty acid esters, alcohol-oil transesterification products, polyglyceryl fatty acids, propylene glycol fatty acid esters, sterol and sterol derivatives, polyethylene glycol sorbitan fatty acid esters, polyethylene glycol alkyl ethers, sugar and derivatives thereof, polyethylene glycol alkyl phenols, polyoxyethylene-polyoxypropylene block copolymers, and sorbitan fatty acid esters. Examples of suitable ionic surfactants include quarternary ammonium salts, fatty acid salts, and bile salts.

With regard to polyethylene glycol (hereinafter “PEG”) fatty acids, suitable hydrophilic surfactants include monoesters, esters of lauric acid, oleic acid, and stearic acid. Examples of such surfactants include PEG-8 laurate, PEG-8 oleate, PEG-8 stearate, PEG-9 oleate, PEG-10 laurate, PEG-10 oleate, PEG-12 laurate, PEG-12 oleate, PEG-15 oleate, PEG-20 laurate, and PEG-20 oleate. With regard to PEG fatty acid diesters, suitable hydrophilic surfactants include PEG-20 dilaurate, PEG-20 dioleate, PEG-20 distearate, PEG-32 dilaurate, and PEG-32 dioleate. With regard to PEG fatty acids, suitable hydrophilic surfactants include PEG-20 glyceryl laurate, PEG-30 glyceryl laurate, PEG-40 glyceryl laurate, PEG-20 glyceryl oleate, and PEG-30 glyceryl oleate.

With regard to alcohol-oil transesterification products, suitable surfactants can be prepared by reaction of alcohol or polyalcohol with a variety of natural and/or hydrogenated oils. Examples of such alcohols include glycerol, propylene glycol, ethylene glycol, PEG, sorbitol, and pentaerythritol. Examples of such oils include castor oil, hydrogenated castor oil, corn oil, olive oil, peanut oil, palm kernel oil, apricot kernel oil, or almond oil. Examples of hydrophilic surfactants prepared by such reaction include PEG-35 castor oil, PEG-40 hydrogenated castor oil, PEG-25 trioleate, PEG-60 corn glycerides, PEG-60 almond oil, PEG-40 palm kernel oil, PEG-50 castor oil, PEG-50 hydrogenated castor oil, PEG-8 caprylic/capric glycerides, and PEG-6 caprylic/capric glycerides. Examples of hydrophobic surfactants prepared by such reaction include PEG-5 hydrogenated castor oil, PEG-7 hydrogenated castor oil, PEG-9 hydrogenated castor oil, PEG-6 corn oil, PEG-6 almond oil, PEG-6 apricot kernel oil, PEG-6 olive oil, PEG-6 peanut oil, PEG-6 hydrogenated palm kernel oil, PEG-6 palm kernel oil, PEG-6 triolein, PEG-8 corn oil, PEG-20 corn glycerides, and PEG-20 almond glycerides.

With regard to polyglyceryl fatty acids, suitable hydrophobic surfactants include polyglyceryl oleate, polyglyceryl-2 dioleate, polyglyceryl-10 trioleate, polyglyceryl oleate, polyglyceryl-2 diolate, polyglyceryl-10 trioleate, polyglyceryl stearate, polyglyceryl laurate, polyglyceryl myristate, polyglyceryl palmitate, and polyglyceryl linoleate. Suitable hydrophilic surfactants include polyglyceryl-10 laurate, polyglyceryl-10 oleate, and polyglyceryl-10 mono, diolate, polyglyceryl-10 stearate, polyglyceryl-10 linoleate, polyglyceryl-6 stearate, polyglyceryl-6 palmitate, and polyglyceryl-6 linoleate. Polyglyceryl polyricinoleates (i.e. polymuls) are also suitable surfactants.

With regard to propylene glycol fatty acid esters, suitable hydrophobic surfactants include propylene glycol monolaurate, propylene glycol ricinoleate, propylene glycol monooleate, propylene glycol dicaprylate/dicaprate, and propylene glycol dioctanoate. With regard to sterol and sterol derivatives, suitable surfactants include PEG derivatives such as PEG-24 cholesterol ether.

With regard to PEG sorbitan fatty acid esters, suitable surfactants include PEG sorbitan monolaurates, PEG sorbitan monopalmitates, PEG sorbitan monooleates, and PEG sorbitan monostearates. Examples of such surfactants include PEG-20 sorbitan monolaurate, PEG-20 sorbitan monopalmitate, PEG-20 sorbitan monooleate, and PEG-20 sorbitan monostearate. With regard to PEG alkyl ethers, suitable surfactants include PEG-3 oleyl ether and PEG-4 lauryl-ether.

With regard to sugars and derivatives thereof, suitable surfactants include sucrose monopalmitate, sucrose monolaurate, decanoyl-N-methylglucamide, n-decyl-β-D-glucopyranoside, n-decyl-β-D-maltopyranoside, n-dodecyl-β-D-glucopyranoside, n-dodecyl-β-D-maltoside, heptanoyl-N-methylglucamide, n-heptyl-β-D-glucopyranoside, n-heptyl-β-D-thioglucoside, n-hexyl-β-D-glucopyranoside, nonanoyl-N-methylglucamide, n-noyl-β-D-glucopyranoside, octanoyl-N-methylglucamide, n-octyl-β-D-glucopyranoside, and octyl-β-D-thioglucopyranoside. With regard to PEG alkyl phenols, suitable surfactants include PEG-10-100 nonyl phenol, PEG-15-100 octyl phenol ether, tyloxapol, octoxynol, and nonoxynol.

With regard to polyoxyethylene-polyoxypropylene (hereinafter “POE-POP”) block copolymers, such block copolymers include hydrophilic polyoxyethylene and hydrophobic polyoxypropylene moieties having the formula HO(C2H4O)a(C3H6O)b(C2H4O)aH where “a” and “b” denote the number of polyoxyethylene and polyoxypropylene units, respectively. Such polymers are referred to as poloxamers. Suitable hydrophilic poloxamers include Poloxamers 108, 188, 217, 238, 288, 338, and 407. Suitable hydrophobic poloxamers include Poloxamers 124, 182, 183, 212, 313, and 335. With regard to sorbitan fatty acid esters, suitable hydrophobic surfactants include sorbitan monolaurate, sorbitan monopalmitate, sorbitan monooleate, and sorbitan monostearate.

With regard to ionic surfactants, suitable ionic surfactants include benzalkonium chloride, benzethonium chloride, cetylpyridinium chloride, docecyl trimethyl ammonium bromide, sodium docecylsulfates, dialkyl methylbenzyl ammonium chloride, edrophonium chloride, domiphen bromide, dialkylesters of sodium sulfonsuccinic acid, sodium dioctyl sulfosuccinate, sodium cholate, and sodium taurocholate.

Such surfactants are stable under heating and are capable of surviving an ethylene oxide sterilization process (which may be employed in preparing the balloon catheters). Moreover, such surfactants do not react with paclitaxel or rapamycin under the sterilization process. Additionally, such surfactants may protect the hydrophobic therapeutic agents from premature release during the device delivery process while facilitating rapid release and elution of the hydrophobic therapeutic agent.

In one embodiment, the surfactant is a PEG sorbitan monolaurate, a PEG sorbitan monooleate, or a combination thereof. In one particular embodiment, the surfactant is a PEG sorbitan monolaurate, and in a further embodiment, the surfactant is PEG-20 sorbitan monolaurate (i.e. Tween-20). In another particular embodiment, the surfactant is a PEG sorbitan monooleate, and in a further embodiment, the surfactant is PEG-20 sorbitan monooleate (i.e. Tween-80).

2. Second Additive

In one embodiment, the second additive is a chemical compound having one or more hydroxyl, amino, carbonyl, carboxyl, acid, amide, or ester groups. However, the second additive may also include mixtures of chemical compounds having one or more hydroxyl, amino, carbonyl, carboxyl, acid, amide or ester groups. The chemical compound has at least one hydroxyl group. The hydroxyl group is suitable as the hydrophilic moiety because it is unlikely to react with the hydrophobic therapeutic agent. In one particular embodiment, the chemical compound has a molecular weight less than 5,000-10,000, or alternatively less than 750-1,000, or alternatively less than 750. In a further embodiment, the chemical compound has a molecular weight of greater than 80. In an exemplary embodiment, the chemical compound has a molecular weight less than that of the hydrophobic therapeutic agent.

In one embodiment, the chemical compound has four or more hydroxyl groups. In one particular embodiment, the chemical compound having more than four hydroxyl groups has a melting point of 120° C. or less. In another particular embodiment, the chemical compound has three adjacent hydroxyl groups that in stereo configuration are all on one side of the molecule. Without being bound by the theory, it is believed that the stereo configuration of the three adjacent hydroxyl groups may enhance drug binding.

Large molecules diffuse slowly. If the molecular weight of the additive or the chemical compound is high, for example above 800, above 1000, above 1200, above 1500, or above 2000, the chemical compound may elute off of the exterior surface 24 of the expandable balloon 12 too slowly. For example, the hydrophobic therapeutic agent may be released in greater than two minutes. However, if the chemical compound has more than four hydroxyl groups it will have increased hydrophilic properties such that the hydrophobic therapeutic agent may elute off of the exterior surface 24 of the expandable balloon 12 quickly. For example, the hydrophobic therapeutic agent may be released at the target site in less than two minutes. Without being bound by the theory, it is believed that the increased hydrophilicity may play a role in: (1) aiding in the elution of the coating layer 30 off of the exterior surface 24 of the expandable balloon 12; (2) accelerating the release of the hydrophobic therapeutic agent; and (3) improving or facilitating the movement of the hydrophobic therapeutic agent through the water barriers and the polar head groups of lipid bilayers in cells membranes to penetrate tissues.

Examples of chemical compounds having one or more hydroxyl, amino, carbonyl, carboxyl, acid, amide, or ester moieties include amino alcohols, hydroxyl carboxylic acids, esters, and anhydrides, hydroxyl ketones, hydroxyl lactones, hydroxyl esters, sugar phosphates, sugar sulfate ethyl oxides, ethyl glycols, amino acids and salts thereof, peptides, proteins, sorbitan, glycerol, polyalcohols, phosphates, sulfates, organic acids, esters, salts, vitamins, and combinations of amino alcohols and organic acids.

With regard to amino acids and salts thereof, suitable chemical compounds include alanine, arginine, asparagines, aspartic acid, cysteine, cystine, glutamic acid, glutamine, glycine, histidine, proline, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tryptophan, tyrosine, valine, and derivatives thereof. Additionally, amino acid dimers, sugar conjugates, and derivatives thereof may also be suitable chemical compounds. For example, catecholamines such as dopamine, levodopa, carbidoga, and DOPA may also be suitable chemical compounds.

With regard to peptides, oligopeptides and peptides are suitable as chemical compounds because hydrophobic and hydrophilic amino acids may be coupled to create various sequences of amino acids, facilitating permeation of tissue by the hydrophobic therapeutic agent. With regard to proteins, suitable chemical compounds include albumins, immunoglobulins, caseins, hemoglobins, lysozymes, immunoglobins, a-2-macroglobulin, fibronectins, vitronectins, firbinogens, and lipases. In an exemplary embodiment, the chemical compound is serum albumin. Such protein is suitable because it is water soluble and contains significant hydrophobic portions to bind the hydrophobic therapeutic agent.

With regard to vitamins, suitable chemical compounds include fat-soluble vitamins and salts thereof and water-soluble vitamins and amphiphilic derivatives thereof. Suitable examples of fat-soluble vitamins and salts thereof include alpha-tocopherol, beta-tocopherol, gamma-tocopherol, delta-tocopherol, tocopherol acetate, ergosterol, 1-alpha-hydroxycholecal-ciferol, vitamin D2, vitamin D3, alpha-carotene, beta-carotene, gamma-carotene, vitamin A, fursultiamine, methylolriboflavin, octotiamine, pro sultiamine, riboflavine, vintiamol, dihydrovitamin K1, menadiol diacetate, menadiol dibutyrate, menadiol disulfate, menadiol, vitamin K1, vitamin K1 oxide, vitamins K2, vitamin K-S(II), and folic acid in free acid form. Suitable examples of water-soluble vitamins and amphiphilic derivatives thereof include acetiamine, benfotiamine, pantothenic acid, cetotiamine, cyclothiamine, dexpanthenol, niacinamide, nicotinic acid, pyridoxal 5-phosphate, nicotinamide ascorbate, riboflavin, riboflavin phosphate, thiamine, folic acid, menadiol diphosphate, menadione sodium bisulfite, menadoxime, vitamin B 12, vitamin K5, vitamin K6, vitamin K6, and vitamin U.

With regard to organic acids, esters, and anhydrides, suitable chemical compounds include acetic acid and anhydride, benzoic acid and anhydride, diethylenetriaminepentaacetic acid dianhydride, ethylenediaminetetraacetic dianhydride, maleic acid and anhydride, succinic acid and anhydride, diglycolic anhydride, glutaric anhydride, ascorbic acid, citric acid, tartaric acid, lactic acid, oxalic acid, aspartic acid, nicotinic acid, 2-pyrrolidone-5-carboxylic acid, and 2-pyrrolidone.

With regard to amino alcohols, alcohols, amines, acids, amides, and hydroxyl acids, suitable chemical compounds include L-ascorbic acid and salts thereof, D-glucoascorbic acid and salts thereof, tromethamine, triethanolamine, diethanolamine, meglumine, glucamine, amine alcohols, glucoheptonic acid, glucomic acid, hydroxyl ketone, hydroxyl lactone, gluconolactone, glucoheptonolactone, glucooctanoic lactone, gulonic acid lactone, mannoic lactone, ribonic acid lactone, lactobionic acid, glucosamine, glutamic acid, benzyl alcohol, benzoic acid, hydroxybenzoic acid, propyl 4-hydroxybenzoate, lysine acetate salt, gentisic acid, lactitol, sorbitol, glucitol, sugar phosphates, glucopyranose phosphate, sugar sulphates, sinapic acid, vanillic acid, vanillin, methyl paraben, propyl paraben, xylitol, 2-ethoxyethanol, sugars, galactose, glucose, ribose, mannose, xylose, sucrose, lactose, maltose, arabinose, lyxose, fructose, cyclodextrin, (2-hydroxypropyl)-cyclodextrin, acetaminophen, ibuprofen, retinoic acid, lysine acetate, gentisic acid, catechin, catechin gallate, tiletamine, ketamine, propofol, lactic acids, acetic acid, salts of any organic acid and amine described above, polyglycidol, glycerols, multiglycerols, galactitol, di(ethylene glycol), tri(ethylene glycol), tetra(ethylene glycol), penta(ethylene glycol), poly(ethylene glycol) oligomers, di(propylene glycol), tri(propylene glycol), tetra(propylene glycol, and penta(propylene glycol), poly(propylene glycol) oligomers, a block copolymer of PEG and polypropylene glycol, derivatives thereof, and combinations thereof.

Such chemical compounds are stable under heating and are capable of surviving an ethylene oxide sterilization process. Moreover, such chemical compounds do not react with paclitaxel or rapamycin under the sterlization process. In particular, without being bound by the theory, it is believed that hydroxyl, ester, and amide groups are unlikely to react with hydrophobic therapeutic agents such as paclitaxel or rapamycin. However, with specific regard to L-ascorbic acid and salts thereof as well as diethanolamine, such chemical compounds do not necessarily survive such sterilization processes and do react with paclitaxel. Additionally, in some instances, amine and acid groups (e.g., benzoic acid, gentisic acid, diethanolamine, and ascorbic acid) do react with hydrophobic therapeutic agents such as paclitaxel and may not be stable under ethylene oxide sterilization, heating, and aging processes. Accordingly, different sterilization methods should be employed with regard to such specific chemical compounds. Finally, while the chemical compounds described herein rapidly elute the hydrophobic therapeutic agent off of the expandable balloon 12 during deployment at the target site, absorption of the hydrophobic therapeutic agent by tissue is unexpectedly high. Such is particularly apparent with regard to hydroxyl lactones including ribonic acid lactone and gluconolactone.

In one embodiment, the chemical compound is sorbitol, sorbitan, xylitol, gluconolactone, lactobionic acid, or a combination thereof. In one particular embodiment, the chemical compound is sorbitol, gluconolactone, or combinations thereof. In a further embodiment, the chemical compound is sorbitol. Alternatively, in a further particular embodiment, the chemical compound is gluconolactone.

Additionally, the surfactants and combinations of surfactants described herein may also be employed in combination with the chemical compounds and combinations of chemical compounds described herein. For example, in one particular embodiment, the coating layer includes a hydrophobic therapeutic agent, a first additive, and a second additive, wherein the hydrophobic therapeutic agent is paclitaxel, the first additive is PEG-20 sorbitan monolaurate, PEG-20 sorbitan monooleate, or combinations thereof, and the second additive is one of sorbitol, gluconolactone, or combinations thereof. In another particular embodiment, the coating layer includes a hydrophobic therapeutic agent, a first additive, and a second additive, wherein the hydrophobic therapeutic agent is paclitaxel, the first additive is PEG-20 sorbitan monolaurate, and the second additive is sorbitol. In yet another particular embodiment, the coating layer includes a hydrophobic therapeutic agent, a first additive, and a second additive, wherein the hydrophobic therapeutic agent is paclitaxel, and the second additive is gluconolactone.

In one embodiment, the combination of additives in the coating layer 30 is from 1 μg to 20 μg. In another embodiment, the combination of additives and the hydrophobic therapeutic agent are provided in specific weight ratios in the coating layer 30. For example, the ratio by weight of the combination of additives in the coating layer 30 to the hydrophobic therapeutic agent in the coating layer 30 is about 20 to 0.05, or alternatively about 10 to 0.5, or alternatively about 5 to 0.8. Alternatively, in another embodiment, the ratio by weight of the hydrophobic therapeutic agent in the coating layer 30 to the combination of additives is about 0.5 to 3. In yet another embodiment, the balloon catheter 10 is capable of releasing the hydrophobic therapeutic agent and the combination of additives to the tissue in about 0.1 to 30 minutes, or alternatively in about 0.1 to 10 minutes, or alternatively in about 0.2 to 2 minutes, or alternatively in about 0.1 to 1 minute. Such timing of release refers to the timing during which the expandable balloon 12 is inflated and pressing the coating layer 30 into contact with the target tissue.

C. Solvents

The hydrophobic therapeutic agent is water insoluble. The combination of additives is soluble in aqueous solvent and polar organic solvent. Such aqueous solvent and polar organic solvents may be employed in preparing the coating layer. Suitable aqueous solvents include water. Suitable polar organic solvents include alkanes, aromatic solvents, alcohols, ethers, esters/acetates, ketones, and mixtures thereof.

With regard to alkanes, suitable solvents include hexane, octane, cyclohexane, and heptane. With regard to aromatic solvents, suitable solvents include benzene, toluene, and xylene. With regard to alcohols, suitable solvents include methanol, ethanol, propanol, and isopropanol, diethylamide, ethylene glycol monoethyl ether, trascutol, and benzyl alcohol. With regard to ethers, suitable solvents include dioxane, dimethyl ether and tetrahydrofuran. With regard to esters/acetates, suitable solvents include ethyl acetate and isobutyl acetate. With regard to ketones, suitable solvents include acetone, acetonitrile, diethyl ketone, and methyl ethyl ketone. Suitable solvents also include mixtures of aqueous solvents and polar organic solvents. For example, suitable mixtures of aqueous solvents and polar organic solvents may include water and ethanol, water and acetone, and water and methanol, water and tetrahydrofuran.

Embodiments of the balloon catheter have been described in detail. Further embodiments directed to methods of preparing balloon catheters will now be described.

II. Methods for Preparing Balloon Catheters

Methods for preparing a balloon catheter 10 may include (1) preparing a coating solution including a solvent, a therapeutic agent, and a combination of additives, (2) loading a metering dispenser with the coating solution, (3) inflating the balloon catheter 10 to 0 to 3 atm, and rotating the balloon catheter 10 about the longitudinal axis of the catheter and/or moving the balloon catheter 10 in a linear direction along the longitudinal or transverse axis of the balloon catheter 10, (4) dispensing the coating solution from the metering dispenser onto an exterior surface 24 of the balloon catheter 10 and flowing the coating solution on the surface of the balloon catheter 10 while the balloon catheter 10 is rotating and/or linearly moving, (5) evaporating the solvent, forming a coating layer 30 on the balloon catheter 10, (6) drying, folding, and wrapping the balloon catheter 10, and (7) sterilizing the balloon catheter 10. In one embodiment, the method for preparing the balloon catheter 10 further includes (8) drying the balloon catheter 10 after sterilization.

The coating solution includes a solvent, a hydrophobic therapeutic agent, and a combination of additives. In one particular embodiment, the coating solution consists essentially of the solvent, the hydrophobic therapeutic agent, and the combination of additives. The solvent, the hydrophobic therapeutic agent, and the combination of additives are as previously discussed. The content of the hydrophobic therapeutic agent in the coating solution can be from 0.5-50% by weight based on the total weight of the solution. The content of the combination of additives in the coating solution can be from 1-45% by weight, from 1 to 40% by weight, or from 1-15% by weight based on the total weight of the solution. The amount of solvent employed is dependent upon the coating process and viscosity.

In one particular embodiment, loading the metering dispenser with the coating solution, inflating the balloon catheter 10 to 0 atm to 3 atm, dispensing the coating solution from the metering dispenser, and evaporating the solvent, (as set forth in (2)-(5) above), occur concomitantly. In another embodiment, loading the metering dispenser with the coating solution, inflating the balloon catheter 10 to 0 atm to 3 atm, dispensing the coating solution from the metering dispenser, and evaporating the solvent, (as set forth in (2)-(5) above) are repeated until a therapeutically effective amount of the hydrophobic therapeutic agent in the coating solution is deposited on the exterior surface 24 of the balloon catheter 10.

A. Preparing a Coating Solution

With regard to preparing the coating solution, suitable techniques for preparing the coating solution include dispersing, dissolving, diffusing, or otherwise mixing the solvent, the hydrophobic therapeutic agent, and the combination of additives (as previously discussed). In one embodiment, the coating solution is prepared by mixing the solvent, the hydrophobic therapeutic agent, and the combination of additives together simultaneously.

Alternatively, in another embodiment, the coating solution may be prepared by adding the hydrophobic therapeutic agent and the combination of additives sequentially to the solvent. Such technique of sequentially adding components to the solvent may be based upon solubility of such components and/or other parameters known in the art. For example, the coating solution may be prepared by first adding the hydrophobic therapeutic agent to the solvent and then adding the combination of additives. Alternatively, the combination of additives may be added first to the solvent, after which the hydrophobic therapeutic agent may be added. Adding the combination of additives first to the solvent may be beneficial wherein a hydrophobic therapeutic does not sufficiently dissolve in a solvent (when added prior to the combination of additives). Without being bound by the theory, it is believed that the combination of additives will increase the solubility of the hydrophobic therapeutic agent in the solvent. In some embodiments, preparation of the coating solution may also involve homogenization under high shear conditions and optionally under pressure. In some embodiments, the preparation of the coating solution may also involve filtering the coating solution. For example, in one particular embodiment, the coating solution is prepared by: (1) mixing a fixed amount of the hydrophobic therapeutic agent, the combination of additives, and the solvent, (2) stirring the resulting mixture at room temperature, for example, or with slight heating such as to less than 60° C. until a homogenous solution is obtained, and (3) filtering the solution through a 0.45 μm filter.

Alternatively, in another embodiment, combinations of two or more solvents may be used, for example, by combining two solvents prior to addition of a hydrophobic therapeutic agent and a combination of additives. As another example, combinations of two or more solvents may be used by adding a hydrophobic therapeutic agent to one solvent and a combination of additives to another solvent and then combining. As still another example, combinations of two or more solvents may be used by adding only one of the hydrophobic therapeutic agent or the combination of additives to one solvent and then adding the second solvent and the remaining hydrophobic therapeutic agent or the combination of additives.

B. Loading a Metering Dispenser with the Coating Solution

With regard to loading a metering dispenser with the coating solution, suitable metering dispensers are as disclosed in U.S. Pub. No. 2010/0055294, the disclosure of which is incorporated by reference in its entirety. In one embodiment, the metering dispenser is a portion of an apparatus for coating a balloon catheter 10. The apparatus for coating a balloon catheter 10 may be semi-manual or automated. Briefly, in one embodiment, such apparatus includes an apparatus capable of rotating the balloon catheter 10 around its longitudinal axis and moving the balloon catheter 10 back and forth in the direction of its longitudinal or transverse axis, a controller coordinating the dispenser and the apparatus, and a coating solution storage container.

In one embodiment, the metering dispenser includes a dispensing tip connected to the metering dispenser for easy coating application. The dispensing tip may include a hub and a tip. In one particular embodiment, the hub is connected to the metering dispenser. The tip may be used to apply coating on the balloon catheter 10 either by contact or non-contact. The tip opening may have different shapes including, but not limited to, circular, oval, square, and rectangular. Additionally, the tip may be straight or with an angle (135°, 45° or 90°) and may be rigid or flexible. The tip may be tapered, non-tapered, Teflon-lined, Teflon-coated, and Teflon-lined and crimped or may be a brush. In one embodiment, the dispensing tip is made of metals, metal alloys, and a metal with a polymer coating or lining. For example, in one embodiment, the dispensing tip is made of stainless steel, polyethylene, polypropylene, polyesters, polyamides, polyurethanes, PTFE, metal with a PTFE coating or lining.

In another embodiment, the dispensing tip has an opening and a flexible tail. The flexible tail may be threaded through the tip opening of the dispensing tip or may be attached to the side of the tip. In embodiments, the flexible tail contacts the expandable balloon 12 to be coated. In some embodiments, the metering dispenser is a syringe, a syringe pump, a metering pipette, or an automatic metering system. In another embodiment, the automatic metering system includes a micro linear pump module, a dispensing controller module, a dispensing tip and other accessories from IVEK Corporation.

C. Inflating the Balloon Catheter

With regard to inflating the expandable balloon 12 of the balloon catheter 10, in one embodiment, the expandable balloon 12 is inflated from 0 atm to about 3 atm. Additionally, the balloon catheter 10 may be rotated about the longitudinal axis thereof and/or moved in a linear direction along the longitudinal or transverse axis thereof.

In one particular embodiment, the apparatus for coating the balloon catheter 10 concurrently rotates the balloon catheter 10 around its longitudinal axis at uniform rotational or tangential speed and translocates the balloon catheter 10 back and forth at uniform frequency in a longitudinal direction. More particularly, in this particular embodiment, the apparatus for coating the balloon catheter 10 moves the balloon catheter 10 linearly back and forth along a rail with uniform frequency while rotating the balloon catheter 10 at uniform rotational/tangential speed.

In an alternative embodiment, the metering dispenser moves linearly back and forth along a rail with uniform frequency while the apparatus capable of rotating the balloon catheter 10 rotates the balloon catheter 10 at uniform rotational/tangential speed.

D. Dispensing the Coating Solution from the Metering Dispenser onto an Exterior Surface 24 of the Balloon Catheter 10

With regard to dispensing the coating solution from the metering dispenser onto an exterior surface 24 of the balloon catheter 10, in one embodiment, the coating solution is dispensed from the metering dispenser while the balloon catheter 10 is rotating and/or linearly moving. During dispensing, the coating solution flows continuously to the exterior surface 24 of the balloon catheter 10 without forming droplets. In one embodiment, the drops of the coating solution move back and forth longitudinally and transversely over the exterior surface 24 of the balloon catheter 10 while the solvent evaporates, resulting in the consistent and uniform deposition of coating solution over the exterior surface 24 of the balloon catheter 10 and resulting in a uniform dry coating layer over the exterior surface 24 of the balloon catheter 10. Without being bound by the theory, it is believed that the rotational and traversal movements allow the flexible tail to break the surface tension between the coating and the expandable balloon 12, forming a uniform coating on the exterior surface 24 of the balloon catheter 10.

During dispensing, in one embodiment, the balloon catheter 10 and/or the dispensing tip of the metering dispenser move transversely and rotationally. In one particular embodiment, the rotation speed is from 0.1 to 10 revolutions per second, or alternatively from 0.5 to 5 revolutions per second, or alternatively from 0.8 to 2 revolutions per second. The linear or transverse speed is from 0.1 mm per second to 100 mm per second, or alternatively from 1 mm per second to 75 mm per second, or from 2 mm per second to 50 mm per second. The dispensing time is from 2 seconds to 300 seconds, or alternatively from 5 seconds to 120 second. The dispensing time is dependent upon the dispensing coating volume and diameters and lengths of the balloon catheter 10.

E. Evaporating the Solvent Forming a Coating Layer 30 on the Balloon Catheter 10

With regard to evaporating the solvent, in one embodiment, the solvent is evaporated while the coating solution is moving at a uniform speed. Without being bound by the theory, it is believed that such technique forms a substantially uniform dry coating layer 30 on the exterior surface 24 of the balloon catheter 10. In one particular embodiment, the apparatus for coating the balloon catheter 10 includes a fan for accelerating solvent evaporation.

F. Drying, Folding, and Wrapping the Balloon Catheter 10

With regard to drying, folding, and wrapping the balloon catheter 10, the coating solution may solidify on the exterior surface 24 of the balloon catheter 10 during the transverse and rotational motion of the balloon catheter 10. In one embodiment, the time of solidifying of the coating layer 30 on the expandable balloon 12 after dispensing of the liquid coating is from 0.1 minutes to 10 minutes, or alternatively from 0.5 minutes to 5 minutes. Following solidification, in one embodiment, the coated balloon catheter 10 is dried at room temperature for 12 hours to 24 hours.

The expandable balloon 12 may be folded after drying. Upon folding, the dried and folded balloon catheter 10 is rewrapped. Additionally, in one particular embodiment, a properly sized balloon protector is placed upon the wrapped balloon catheter 10 and the balloon catheter 10 is packaged.

G. Sterilizing the Balloon Catheter 10

With regard to sterilizing the balloon catheter 10, suitable sterilization techniques may include, but should not be limited to, sterilization with ethylene oxide and sterilization with an electron beam. In one particular embodiment, the balloon catheter 10 is sterilized with ethylene oxide.

H. Drying the Balloon Catheter 10 after Sterilization

After sterilizing the balloon catheter 10, in one embodiment, the balloon catheter 10 is dried. More particularly, in one embodiment, the balloon catheter 10 is dried under vacuum at about 0° C. to 100° C. for approximately 2 hours to 56 hours. In another embodiment, the balloon catheter 10 is dried under vacuum at about 5° C. to about 45° C. Without being bound by the theory, it is believed that the drying process improves integrity of the coating layer 30, protects loss of coating components during transit through body passages to the target treatment site, and improves drug absorption in the tissue.

I. Optional Post Treatment with DMSO

After depositing the coating layer 30 on the balloon catheter 10, in one embodiment, DMSO or other solvent is applied to the surface of the coating layer 20. The DMSO or other solvent may be applied to the surface by dipping, spraying, or any other suitable method known in the art. DMSO readily dissolves hydrophobic therapeutic agents and penetrates the membranes of target cells. DMSO may also enhance tissue absorption. More particularly, without being bound by the theory, it is believed that DMSO displaces water from the lipid head groups and protein domains of the lipid bilayer of the cell membrane of target cells, which indirectly loosens the lipid structure and accelerates absorption and penetration of the hydrophobic therapeutic agent.

Embodiments of the preparation of balloon catheters have been described in detail. Further embodiments directed to uses of balloon catheters will now be described.

III. Uses of Balloon Catheters

Uses of the balloon catheters as previously discussed are disclosed. Generally, the balloon catheter 10 is employed to deliver a hydrophobic therapeutic agent to a blood vessel while the balloon catheter 10 is deployed at a target site of the blood vessel. More particularly, the balloon catheter 10 is employed to deliver an anti-proliferative hydrophobic therapeutic agent (such as paclitaxel or rapamycin) to vascular tissue through brief, direct pressure contact at high drug concentration during balloon angioplasty. Such techniques may be employed in treating a total occlusion or a narrowing of passages. Such techniques may also be employed to inhibit hyperplasia and restenosis, as the hydrophobic therapeutic agent may be retained in the target tissue at the delivery site.

The balloon catheter 10 may also be employed in combination with other methods for treating the vasculature, such as with photodynamic therapy or atherectomy. With regard to photodynamic therapy, photodynamic therapy is a procedure where light or irradiated energy is used to kill target cells in a patient. A light-activated photosensitizing hydrophobic therapeutic agent may be delivered to specific areas of tissue by the balloon catheter 10. A targeted light or radiation source selectively activates the hydrophobic therapeutic agent to produce a cytotoxic response and mediate a therapeutic anti-proliferative effect.

With regard to atherectomy, atherectomy is a procedure employed to remove plaque from arteries. More specifically, atherectomy removes plaque from peripheral and coronary arteries. The medical device used for peripheral or coronary atherectomy may be a laser catheter, a rotational atherectomy device such as a Rotablator® (Boston Scientific, Quincy, Mass.), or a direct atherectomy device on the end of a catheter. During atherectomy, a catheter is inserted into the body and advanced through an artery to the area of narrowing. After the atherectomy has removed some of the plaque, balloon angioplasty using the coated balloon catheter 10 may be performed. In addition, stenting may also be performed thereafter, or simultaneous with expansion of the coated expandable balloon 12 as described above.

EXAMPLES

The following examples include embodiments of balloon catheters and coating layers within the scope of the present disclosure. While the following examples are considered to embody the present disclosure, the examples should not be interpreted as limitations upon the present disclosure.

Example 1 Preparation of Coating Solutions

Experimental Protocol.

Coating solutions for balloon catheters were prepared. More particularly, coating solutions for balloon catheters including Formulations I-XI were prepared. Formulations I-XI are set forth in Table 1 below.

TABLE 1
HYDROPHOBIC
FORMULATION THERAPEUTIC
NO. AGENT ADDITIVE(S) SOLVENT
I Paclitaxel Gluconolactone Acetone, Ethanol,
Water
II Paclitaxel Tween 20, N-octanoyl N- Acetone, Ethanol
methylglucamine
III Paclitaxel Tween 20, Sorbitol Acetone, Ethanol,
Water
IV Paclitaxel Meglumine, Gensitic Acid Acetone, Ethanol
V Paclitaxel Lactobionic Acid, Acetone, Ethanol,
Diethanolamine Water
VI Paclitaxel N-Octanoyl-N- Acetone, Ethanol
methylglucamine
VII Paclitaxel Meglumine, Lactic Acid Acetone, Ethanol,
Water
VIII Paclitaxel Gensitic Acid, Diethanolamine Acetone, Ethanol,
Water
IX Paclitaxel Triton X-100, N-heptanoyl N- Acetone, Ethanol
Methylglucamine
X Paclitaxel Ultravist 370 Ethanol, Acetone
XI Paclitaxel N/A Ethanol, Acetone

Preparation of Coating Solution Formulations I-XI in Table I is set forth below.

Formulation I.

50-100 mg (0.06-0.12 mmole) paclitaxel, 1-1.6 ml acetone, 1-1.6 ml ethanol, 0.4-1.0 ml water, and 50-200 mg gluconolactone were mixed.

Formulation II.

35-70 mg (0.042-0.084 mmole) paclitaxel, 0.5-1.0 ml acetone, 0.5-1.0 ml ethanol, 35-70 mg Tween 20, and 35-70 mg N-octanoyl N-methylglucamine were mixed.

Formulation III.

35-70 mg (0.042-0.084 mmole) paclitaxel, 0.4-1.0 ml acetone, 0.4-1.0 ml ethanol, 0.2-0.4 ml water, 35-70 mg Tween 20, and 35-70 mg sorbitol were mixed.

Formulation IV.

40-80 mg (0.048-0.096 mmole) paclitaxel, 0.5-1.0 ml acetone, 0.5-1.0 ml ethanol, 40-80 mg meglumine, and 32-64 mg gensitic acid (equal molar ratio with meglumine) were mixed.

Formulation V.

35-70 mg (0.042-0.084 mmole) paclitaxel, 0.4-0.8 ml acetone, 0.4-0.8 ml ethanol, 0.25-0.50 ml water, 35-70 mg lactobionic acid, and 10-20 mg diethanolamine (equal molar ratio with lactobionic acid) were mixed.

Formulation VI.

35-70 mg (0.042-0.084 mmole) paclitaxel, 0.5-1.0 ml acetone, 0.5-1.0 ml ethanol, and 70-140 mg N-octanoyl N-methylglucamine were mixed.

Formulation VII.

35-70 mg (0.042-0.084 mmole) paclitaxel, 0.4-0.8 ml acetone, 0.4-0.8 ml ethanol, 0.2-0.4 ml water, 35-70 mg meglumine, and 18-36 mg lactic acid (equal molar ratio with meglumine) were mixed.

Formulation VIII.

50-100 mg (0.06-0.12 mmole) paclitaxel, 0.8-1.6 ml acetone, 0.8-1.6 ml ethanol, 0.4-1.0 ml water, 50-100 mg gensitic acid, and 30-60 mg diethanolamine (equal molar ratio with gensitic acid) were mixed.

Formulation IX.

35-70 mg (0.042-0.084 mmole) paclitaxel, 0.5-1.0 ml acetone, 0.5-1.0 ml ethanol, 35-70 mg Triton X-100, and 35-70 mg N-heptanoyl N-methylglucamine were mixed.

Formulation X—Comparison Solution 1.

50 mg (0.06 mmole) paclitaxel, 1 ml ethanol, 0.2 ml acetone, 0.042 ml Ultravist 370 were mixed.

Formulation XI—Comparison Solution 2.

40 mg (0.048 mmole) paclitaxel, 0.5 ml ethanol, 0.5 ml acetone were mixed.

Example 2 Coating of PTCA Balloon Catheters

Experimental Protocol.

PTCA balloon catheters were coated with the coating solutions including Formulations I-XI prepared in Example 1. More specifically, 6 PTCA balloon catheters (3.5 and 3.0 mm in diameter and 20 mm in length) were inflated at 1-3 atm. The inflated balloon was loaded with one of the coating solutions including Formulations I-XI from Example 1. A sufficient amount of paclitaxel on the balloon (3 microgram per square mm) was obtained. The inflated balloons were folded, and then dried. The coated folded balloon was then rewrapped and sterilized for animal testing.

Example 3 Delivering Paclitaxel from the Coated PTCA Balloon Catheters to Target Sites

Experimental Protocol.

Paclitaxel was delivered to target sites in the coronary vasculature of pigs from the coated PTCA balloon catheters prepared in Example 2. More specifically, the coated PTCA balloon catheters from Example 2 were inserted into a target site in the coronary vasculature (LAD, LCX and RCA) of a 25-45 pound pig. The balloons were inflated to about 12 atm. The overstretch ratio (the ratio of balloon diameter to vessel diameter) was about 1.15-1.20. The paclitaxel delivered into the target tissue during 30-60 seconds of inflation. The balloon catheter was then deflated and withdrawn from the animal body. The target blood vessel was harvested 0.25-24 hours after the procedure. The paclitaxel content in the target tissue and the residual paclitaxel remaining on the balloon were analyzed by tissue extraction and HPLC.

In some of these animal studies, a stent was crimped on the coated balloon catheters from Example 2 prior to deployment. In chronic animal tests, angiography was performed before and after all interventions and at 28-35 days after the procedure. Luminal diameters were measured and late lumen loss was calculated. Late lumen loss is the difference between the minimal lumen diameter measured after a period of follow-up time (usually weeks to months after an intervention, such as angioplasty and stent placement in the case of this example) and the minimal lumen diameter measured immediately after the intervention. Restenosis may be quantified by the diameter stenosis, which is the difference between the mean lumen diameters at follow-up and immediately after the procedure divided by the mean lumen diameter immediately after the procedure. The animal test results for the Formulations I-XI from Example 1 are reported below.

Experimental Results.

All data is an average of five or six experimental data points.

Formulation I.

The paclitaxel content of the Formulation I from Example 1 on the 3.5 mm balloon catheters was 3.26 μg/mm2. After the procedure, the paclitaxel on the balloon was 15.92 μg, or 2.3% of the total paclitaxel loaded on the balloon. The paclitaxel content in tissue harvested 15-30 minutes after the procedure was 64.79 μg, or 9.2% of the total paclitaxel content originally loaded on the balloon. When an 18 mm stent was deployed by the coated balloon, the residual paclitaxel on the balloon was 31.96 μg, or 4.5% of paclitaxel load, and the paclitaxel content in tissue harvested 15-30 minutes after the procedure was 96.49 μg, or 13.7% of paclitaxel load. The stretch ratio is 1.3 in the procedure. The late lumen loss after 28-35 days was 0.10 (sd 0.2) mm. The diameter stenosis is 3.3%.

Formulation II.

The paclitaxel content of the Formulation II from Example 1 on the 3.5 mm balloon catheters was 3.08 μg/mm2. After the procedure, the residual paclitaxel on the balloon was 80.58 μg, or 11.4% of the total paclitaxel load. The paclitaxel content in tissue harvested 15-30 minutes after the procedure was 42.23 μg, or 6.0% of the total paclitaxel load. After 28-35 days late lumen loss was 0.30 (sd 0.23) mm. The diameter stenosis was 5.4%.

Formulation III.

The paclitaxel content of the Formulation III from Example 1 on the 3.5 mm balloon catheters was 3.61 μg/mm2. After the procedure, the residual paclitaxel on the balloon was 174.24 μg, or 24.7% of the total paclitaxel load. The paclitaxel content in tissue harvested 15-30 minutes after the procedure was 83.83 μg, or 11.9% of the total drug load. When deployed with a pre-crimped 18 mm stent, the residual paclitaxel on the balloon is 114.53 μg, or 16.1% of the total paclitaxel load, and the paclitaxel content in tissue harvested 15-30 minutes post procedure was 147.95 μg, or 18.1% of the total paclitaxel load. The stretch ratio was 1.3 in the procedure. The late lumen loss after 28-35 days was 0.10 (sd 0.1) mm. The diameter stenosis was 3.4%.

Formulation IV.

The paclitaxel content of the Formulation IV from Example 1 on the 3.5 mm balloon catheters was 4.71 μg/mm2. After the procedure, the residual paclitaxel on the balloon was 44.39 μg, or 6.3% of the total paclitaxel load. The paclitaxel content in the tissue harvested 15-30 minutes after the procedure was 77.87 μg, or 11.0% of the total paclitaxel load. After 28-35 days late lumen loss was 0.23 (sd 0.44) mm. The diameter stenosis was 7.3%.

Formulation V.

The paclitaxel content of the Formulation V from Example 1 on the 3.5 mm balloon catheters was 3.85 μg/mm2. After the procedure, residual paclitaxel on the balloon was 24.59 μg, or 3.5% of the total paclitaxel load. The paclitaxel content in tissue harvested 15-30 minutes after the procedure was 37.97 μg, or 5.4% of the total paclitaxel load. After 28-35 days late lumen loss was 0.33 (sd 0.14) mm. The diameter stenosis was 6.7%.

Formulation VI.

The paclitaxel content of the Formulation VI from Example 1 on the 3.5 mm balloon catheters was 3.75 μg/mm2. After the procedure, residual paclitaxel on the balloon was 0.82 μg, or 0.1% of the total paclitaxel load. The paclitaxel content in tissue harvested 60 minutes after the procedure was 45.23 μg, or 5.5% of the total paclitaxel load. After 28-35 days late lumen loss was 0.49 (sd 0.26) mm. The diameter stenosis was 11.3%.

Formulation VII.

The paclitaxel content of the Formulation VII from Example 1 on the 3.5 mm balloon catheters was 3.35 μg/mm2. After the procedure, the residual paclitaxel on the balloon was 62.07 μg, or 7.5% of the total paclitaxel load. The paclitaxel content in tissue harvested 60 minutes after the procedure was 40.55 μg, or 4.9% of the total paclitaxel load. After 28-35 days late lumen loss was 0.47 (sd 0.33) mm. The diameter stenosis was 9.9%.

Formulation VIII.

The paclitaxel content of the Formulation VIII from Example 1 on the 3.5 mm balloon catheters was 3.41 μg/mm2. After the procedure, residual paclitaxel on the balloon was 50.0 μg, or 6.0% of the total paclitaxel load. The paclitaxel content in tissue harvested 60 minutes post procedure was 26.72 μg, or 3.2% of the total paclitaxel load. After 28-35 days late lumen loss was 0.36 (sd 0.41) mm. The diameter stenosis was 9.3%.

Formulation IX.

The paclitaxel content of the Formulation IX from Example 1 on the 3.5 mm balloon catheters was 3.10 μg/mm2. After the procedure, residual paclitaxel on the balloon was 1.9% of the total paclitaxel load. The paclitaxel content in tissue harvested 2 hours after the procedure was 34.17 μg, or 5.0% of the total paclitaxel load. In tissue harvested 24 hours after the procedure, the paclitaxel content in tissue was 28.92 μg, or 4.2% of the total paclitaxel load.

Control Formulation.

The drug content of control formulation (uncoated balloon) on the 3.5 mm balloon catheters was 0.0 μg/mm2. After the procedure, residual drug on the balloon was 0% of the total drug load. The drug content in tissue harvested 15 minutes after the procedure was 0 μg. In tissue harvested 24 hours after the procedure, the drug content in tissue was 0 μg. After 28-35 days late lumen loss was 0.67 (sd 0.27) mm. The diameter stenosis is 20.8%. In the second repeat experiment, the stretch ratio was 1.3. The late lumen loss was 1.1 (sd 0.1). The diameter stenosis was 37.5%.

Formulation X—Comparison Solution 1.

The paclitaxel content of the Formulation X from Example 1 on the 3.5 mm balloon catheters was 3.21 μg/mm2. After the procedure, residual paclitaxel on the balloon was 13.52 μg, or 1.9% of the total paclitaxel load. The paclitaxel content in the tissue was 28.32 μg, or 4.0% of the total paclitaxel load. When the balloon was deployed with a pre-crimped 18 mm stent, residual paclitaxel on the balloon was 26.45 μg, or 3.7% of the total paclitaxel load. The paclitaxel content in tissue was 113.79 μg, or 16.1% of drug load. After 28-35 days, late lumen loss was 0.27 (sd 0.15) mm. The diameter stenosis was 7.1%.

Formulation XI—Comparison Solution 2.

The paclitaxel content of the Formulation XI (without additive) on the 3.5 mm balloon catheters was 4.22 μg/mm2. After the procedure, residual paclitaxel on the balloon was 321.97 μg, or 45.6% of the total paclitaxel load. The paclitaxel content in the tissue was 12.83 μg, or 1.8% of the total paclitaxel load.

Surprisingly, the concentration of paclitaxel absorbed by porcine coronary artery tissue after deployment of balloons coated with the Formulations I-IX from Example 1 according to embodiments of the present disclosure was higher than that delivered by balloons coated with the Formulation X from Example 1 and higher than those coated with paclitaxel alone, the Formulation XI from Example 1. The late lumen loss after 28-35 days follow up was less than the control (uncoated balloon).

Claims (20)

What is claimed is:
1. A balloon catheter for delivering a therapeutic agent to a blood vessel while the balloon catheter is deployed at a target site of the blood vessel, the balloon catheter comprising:
an elongate member having a lumen and a distal end,
an expandable balloon attached to the distal end of the elongate member and in fluidic communication with the lumen; and
a dried coating layer overlying an exterior surface of the expandable balloon, wherein:
the dried coating layer comprises a total drug load of a hydrophobic therapeutic agent and a combination of additives comprising a first additive and a second additive;
the hydrophobic therapeutic agent is one of paclitaxel or analogs thereof, rapamycin or analogs thereof, daunorubicin, doxorubicin, beta-lapachone, biologically active vitamin D, or combinations thereof;
the first additive is one of PEG sorbitan monolaurates, PEG sorbitan monooleates, or combinations thereof; and
the second additive is one of sorbitol, sorbitan, xylitol, gluconolactone, lactobionic acid, or combinations thereof.
2. The balloon catheter of claim 1, wherein the hydrophobic therapeutic agent is chosen from paclitaxel or analogs thereof.
3. The balloon catheter of claim 1, wherein the hydrophobic therapeutic agent is chosen from rapamycin or analogs thereof.
4. The balloon catheter of claim 1, wherein the hydrophobic therapeutic agent is uniformly distributed in the dried coating layer.
5. The balloon catheter of claim 1, wherein the total drug load of the hydrophobic therapeutic agent is from 1 μg to 20 μg per square millimeter of the expandable balloon.
6. The balloon catheter of claim 1, wherein the total drug load of the hydrophobic therapeutic agent is from 2.5 μg to 6 μg per square millimeter of the expandable balloon.
7. The balloon catheter of claim 1, wherein the first additive is a PEG sorbitan monolaurate.
8. The balloon catheter of claim 7, wherein the PEG sorbitan monolaurate is PEG-20 sorbitan monolaurate.
9. The balloon catheter of claim 1, wherein the first additive is a PEG sorbitan monooleate.
10. The balloon catheter of claim 9, wherein the PEG sorbitan monooleate is PEG-20 sorbitan monooleate.
11. The balloon catheter of claim 1, wherein the first additive is one of PEG-20 sorbitan monolaurate, PEG-20 sorbitan monooleate, or combinations thereof.
12. The balloon catheter of claim 1, wherein the second additive is one of sorbitol, gluconolactone, or combinations thereof.
13. The balloon catheter of claim 1, wherein the second additive is sorbitol.
14. The balloon catheter of claim 1, wherein the second additive is gluconolactone.
15. The balloon catheter of claim 1, wherein the ratio by weight of the combination of additives in the dried coating layer to the hydrophobic therapeutic agent in the dried coating layer is about 10 to 0.5.
16. The balloon catheter of claim 1, wherein:
the dried coating layer consists essentially of the hydrophobic therapeutic agent, the first additive, and the second additive;
the hydrophobic therapeutic agent is chosen from paclitaxel or analogs thereof;
the first additive is one of PEG-20 sorbitan monolaurate, PEG-20 sorbitan monooleate, or combinations thereof; and
the second additive is one of sorbitol, gluconolactone, or combinations thereof.
17. The balloon catheter of claim 1, wherein:
the dried coating layer consists essentially of the hydrophobic therapeutic agent, the first additive, and the second additive;
the hydrophobic therapeutic agent is chosen from paclitaxel or analogs thereof;
the first additive is PEG-20 sorbitan monolaurate; and
the second additive is sorbitol.
18. The balloon catheter of claim 1, wherein:
the dried coating layer consists essentially of the hydrophobic therapeutic agent, the first additive, and the second additive;
the hydrophobic therapeutic agent is chosen from paclitaxel or analogs thereof;
the second additive is gluconolactone; and
the total drug load of the hydrophobic therapeutic agent is from 2 μg to 6 μg per square millimeter of the expandable balloon.
19. The balloon catheter of claim 1, wherein the dried coating layer has a thickness of from about 0.1 μm to 15 μm.
20. A balloon catheter for delivering a therapeutic agent to a blood vessel while the balloon catheter is deployed at a target site of the blood vessel, the balloon catheter comprising:
an elongate member having a lumen and a distal end,
an expandable balloon attached to the distal end of the elongate member and in fluid communication with the lumen; and
a dried coating layer overlying an exterior surface of the expandable balloon, wherein:
the dried coating layer comprises a total drug load of a hydrophobic therapeutic agent and a combination of additives comprising a first additive and a second additive;
the total drug load of the hydrophobic therapeutic agent is from 2.5 μg to 6 μg per square millimeter of the expandable balloon;
the hydrophobic therapeutic agent is one of paclitaxel or analogs thereof, rapamycin or analogs thereof, daunorubicin, doxorubicin, beta-lapachone, biologically active vitamin D, or combinations thereof;
the first additive is one of PEG-20 sorbitan monolaurate, PEG-20 sorbitan monooleate, or combinations thereof;
the second additive is one of sorbitol, gluconolactone, or combinations thereof; and
the ratio by weight of the combination of additives in the dried coating layer to the hydrophobic therapeutic agent in the dried coating layer is about 10 to 0.5.
US15154662 2006-11-20 2016-05-13 Drug releasing coatings for balloon catheters Active US9700704B2 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
US86008406 true 2006-11-20 2006-11-20
US88074207 true 2007-01-17 2007-01-17
US89742707 true 2007-01-25 2007-01-25
US90352907 true 2007-02-26 2007-02-26
US90447307 true 2007-03-02 2007-03-02
US92685007 true 2007-04-30 2007-04-30
US98138407 true 2007-10-19 2007-10-19
US98138007 true 2007-10-19 2007-10-19
US11942452 US8414909B2 (en) 2006-11-20 2007-11-19 Drug releasing coatings for medical devices
US12121986 US8414525B2 (en) 2006-11-20 2008-05-16 Drug releasing coatings for medical devices
US9287208 true 2008-08-29 2008-08-29
US12549180 US8430055B2 (en) 2008-08-29 2009-08-27 Methods and apparatuses for coating balloon catheters
US12731835 US8414910B2 (en) 2006-11-20 2010-03-25 Drug releasing coatings for medical devices
US13846358 US9180485B2 (en) 2008-08-29 2013-03-18 Methods and apparatuses for coating balloon catheters
US13846143 US9005161B2 (en) 2006-11-20 2013-03-18 Drug releasing coatings for medical devices
US14683612 US9289539B2 (en) 2006-11-20 2015-04-10 Drug releasing coatings for medical devices
US14932033 US9770576B2 (en) 2008-08-29 2015-11-04 Methods and apparatuses for coating balloon catheters
US15067739 US9757544B2 (en) 2006-11-20 2016-03-11 Drug releasing coatings for medical devices
US15154662 US9700704B2 (en) 2006-11-20 2016-05-13 Drug releasing coatings for balloon catheters

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15154662 US9700704B2 (en) 2006-11-20 2016-05-13 Drug releasing coatings for balloon catheters
US15617786 US20180028791A1 (en) 2006-11-20 2017-06-08 Drug releasing coatings for balloon catheters

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US14932033 Continuation-In-Part US9770576B2 (en) 2008-08-29 2015-11-04 Methods and apparatuses for coating balloon catheters
US15067739 Continuation-In-Part US9757544B2 (en) 2006-11-20 2016-03-11 Drug releasing coatings for medical devices

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11942452 Division US8414909B2 (en) 2006-11-20 2007-11-19 Drug releasing coatings for medical devices
US15617786 Continuation US20180028791A1 (en) 2006-11-20 2017-06-08 Drug releasing coatings for balloon catheters

Publications (2)

Publication Number Publication Date
US20160250452A1 true US20160250452A1 (en) 2016-09-01
US9700704B2 true US9700704B2 (en) 2017-07-11

Family

ID=56798608

Family Applications (2)

Application Number Title Priority Date Filing Date
US15154662 Active US9700704B2 (en) 2006-11-20 2016-05-13 Drug releasing coatings for balloon catheters
US15617786 Pending US20180028791A1 (en) 2006-11-20 2017-06-08 Drug releasing coatings for balloon catheters

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15617786 Pending US20180028791A1 (en) 2006-11-20 2017-06-08 Drug releasing coatings for balloon catheters

Country Status (1)

Country Link
US (2) US9700704B2 (en)

Citations (416)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929992A (en) 1972-09-29 1975-12-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US4252969A (en) 1979-09-27 1981-02-24 National Distillers And Chemical Corp. Process for regulating particle size of finely divided thermoplastic resins
US4308184A (en) 1978-04-01 1981-12-29 Bayer Aktiengesellschaft Heat cross linkable polyurethane coating compositions
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4364921A (en) 1979-03-08 1982-12-21 Schering, Aktiengesellschaft Novel triiodinated isophthalic acid diamides as nonionic X-ray contrast media
US4921483A (en) 1985-12-19 1990-05-01 Leocor, Inc. Angioplasty catheter
US5023262A (en) 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
US5023263A (en) 1990-08-09 1991-06-11 American Home Products Corporation 42-oxorapamycin
US5023264A (en) 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
US5026607A (en) 1989-06-23 1991-06-25 C. R. Bard, Inc. Medical apparatus having protective, lubricious coating
US5061738A (en) 1988-04-18 1991-10-29 Becton, Dickinson And Company Blood compatible, lubricious article and composition and method therefor
US5080899A (en) 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5092841A (en) 1990-05-17 1992-03-03 Wayne State University Method for treating an arterial wall injured during angioplasty
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5102876A (en) 1991-05-07 1992-04-07 American Home Products Corporation Reduction products of rapamycin
US5102402A (en) 1991-01-04 1992-04-07 Medtronic, Inc. Releasable coatings on balloon catheters
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5120727A (en) 1991-05-29 1992-06-09 American Home Products Corporation Rapamycin dimers
US5120726A (en) 1991-03-08 1992-06-09 American Home Products Corporation Rapamycin hydrazones
US5120725A (en) 1991-05-29 1992-06-09 American Home Products Corporation Bicyclic rapamycins
US5120322A (en) 1990-06-13 1992-06-09 Lathrotec, Inc. Method and apparatus for treatment of fibrotic lesions
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5130307A (en) 1990-09-28 1992-07-14 American Home Products Corporation Aminoesters of rapamycin
US5135516A (en) 1989-12-15 1992-08-04 Boston Scientific Corporation Lubricious antithrombogenic catheters, guidewires and coatings
US5138051A (en) 1991-08-07 1992-08-11 American Home Products Corporation Rapamycin analogs as immunosuppressants and antifungals
US5151413A (en) 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
US5162333A (en) 1991-09-11 1992-11-10 American Home Products Corporation Aminodiesters of rapamycin
US5164299A (en) 1990-03-20 1992-11-17 E. I. Du Pont De Nemours And Company Use of a mixture of conjugated and unconjugated solid phase binding reagent to enhance the performance of assays
US5164399A (en) 1991-11-18 1992-11-17 American Home Products Corporation Rapamycin pyrazoles
US5177203A (en) 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
US5194447A (en) 1992-02-18 1993-03-16 American Home Products Corporation Sulfonylcarbamates of rapamycin
US5193447A (en) 1989-09-16 1993-03-16 Braun Aktiengesellschaft Citrus juicer
US5196596A (en) 1991-12-26 1993-03-23 Union Carbide Chemicals & Plastics Technology Corporation Higher aldehyde separation process
US5199951A (en) 1990-05-17 1993-04-06 Wayne State University Method of drug application in a transporting medium to an arterial wall injured during angioplasty
US5221740A (en) 1992-01-16 1993-06-22 American Home Products Corporation Oxepane isomers of rapamycin useful as immunosuppressive agents
US5221670A (en) 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5233036A (en) 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
US5252579A (en) 1993-02-16 1993-10-12 American Home Products Corporation Macrocyclic immunomodulators
US5254089A (en) 1992-04-02 1993-10-19 Boston Scientific Corp. Medication dispensing balloon catheter
US5260300A (en) 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5262423A (en) 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5269770A (en) 1990-01-10 1993-12-14 Rochester Medical Corporation Microcidal agent releasing catheter with balloon
US5302584A (en) 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5324261A (en) 1991-01-04 1994-06-28 Medtronic, Inc. Drug delivery balloon catheter with line of weakness
US5349060A (en) 1993-01-07 1994-09-20 American Home Products Corporation Rapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5373014A (en) 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5378836A (en) 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5378696A (en) 1990-09-19 1995-01-03 American Home Products Corporation Rapamycin esters
US5380299A (en) 1993-08-30 1995-01-10 Med Institute, Inc. Thrombolytic treated intravascular medical device
US5380298A (en) 1993-04-07 1995-01-10 The United States Of America As Represented By The Secretary Of The Navy Medical device with infection preventing feature
US5385908A (en) 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5385909A (en) 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5385910A (en) 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
US5387680A (en) 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
US5389639A (en) 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5391730A (en) 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5411967A (en) 1992-10-13 1995-05-02 American Home Products Corporation Carbamates of rapamycin
US5441759A (en) 1992-09-03 1995-08-15 Sherwood Medical Company Method to stabilize TDMAC heparin coating
US5463048A (en) 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US5464650A (en) 1993-04-26 1995-11-07 Medtronic, Inc. Intravascular stent and method
US5480989A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5480988A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5482945A (en) 1992-12-22 1996-01-09 American Home Products Corporation Innovative technique for immunosuppression involving administration of rapamycin loaded formed blood elements
US5489680A (en) 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5490839A (en) 1993-09-20 1996-02-13 Scimed Life Systems, Inc. Catheter balloon with retraction coating
US5491231A (en) 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5496276A (en) 1993-09-20 1996-03-05 Scimed Life Systems, Inc. Catheter balloon with retraction coating
US5504091A (en) 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
US5504092A (en) 1990-03-27 1996-04-02 Pharmacia Ab Use of Linomide to increase hemopoietic cell precursors
US5509899A (en) 1994-09-22 1996-04-23 Boston Scientific Corp. Medical device with lubricious coating
US5516781A (en) 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5525348A (en) 1989-11-02 1996-06-11 Sts Biopolymers, Inc. Coating compositions comprising pharmaceutical agents
US5525610A (en) 1994-03-31 1996-06-11 American Home Products Corporation 42-Epi-rapamycin and pharmaceutical compositions thereof
US5532355A (en) 1992-10-13 1996-07-02 American Home Products Corporation Carbamates of rapamycin
US5536729A (en) 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5559121A (en) 1993-09-30 1996-09-24 American Home Products Corporation Rapamycin formulations for oral administration
US5563145A (en) 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
US5573518A (en) 1988-05-26 1996-11-12 Haaga; John R. Sheath for wound closure caused by a medical tubular device
US5599307A (en) 1993-07-26 1997-02-04 Loyola University Of Chicago Catheter and method for the prevention and/or treatment of stenotic processes of vessels and cavities
US5607463A (en) 1993-03-30 1997-03-04 Medtronic, Inc. Intravascular medical device
US5609629A (en) 1995-06-07 1997-03-11 Med Institute, Inc. Coated implantable medical device
US5616608A (en) 1993-07-29 1997-04-01 The United States Of America As Represented By The Department Of Health And Human Services Method of treating atherosclerosis or restenosis using microtubule stabilizing agent
US5632772A (en) 1993-10-21 1997-05-27 Corvita Corporation Expandable supportive branched endoluminal grafts
US5674287A (en) 1988-08-24 1997-10-07 Endoluminal Therapeutics, Inc. Biodegradable polymeric endoluminal sealing process, apparatus and polymeric product for use therein
US5674192A (en) 1990-12-28 1997-10-07 Boston Scientific Corporation Drug delivery
US5693034A (en) 1991-12-18 1997-12-02 Scimed Life Systems, Inc. Lubricous polymer network
US5698582A (en) 1991-07-08 1997-12-16 Rhone-Poulenc Rorer S.A. Compositions containing taxane derivatives
US5702754A (en) 1995-02-22 1997-12-30 Meadox Medicals, Inc. Method of providing a substrate with a hydrophilic coating and substrates, particularly medical devices, provided with such coatings
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US5733925A (en) 1993-01-28 1998-03-31 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5738901A (en) 1993-09-20 1998-04-14 Scimed Life Systems, Inc. Catheter balloon with retraction coating
US5752930A (en) 1995-04-28 1998-05-19 Medtronic, Inc. Implantable techniques for infusing equal volumes of agents to spaced sites
US5766158A (en) 1995-02-06 1998-06-16 Surface Solutions Laboratories, Inc. Medical apparatus with scratch-resistant coating and method of making same
US5776943A (en) 1991-05-14 1998-07-07 American Home Products Corporation Rapamycin metabolites
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US5797887A (en) 1996-08-27 1998-08-25 Novovasc Llc Medical device with a surface adapted for exposure to a blood stream which is coated with a polymer containing a nitrosyl-containing organo-metallic compound which releases nitric oxide from the coating to mediate platelet aggregation
US5807306A (en) 1992-11-09 1998-09-15 Cortrak Medical, Inc. Polymer matrix drug delivery apparatus
WO1998043618A2 (en) 1997-03-31 1998-10-08 Neorx Corporation Use of cytoskeletal inhibitors for the prevention of restenosis
US5824049A (en) 1995-06-07 1998-10-20 Med Institute, Inc. Coated implantable medical device
US5827289A (en) 1994-01-26 1998-10-27 Reiley; Mark A. Inflatable device for use in surgical protocols relating to treatment of fractured or diseased bones
US5843089A (en) 1990-12-28 1998-12-01 Boston Scientific Corporation Stent lining
US5865814A (en) 1995-06-07 1999-02-02 Medtronic, Inc. Blood contacting medical device and method
US5868719A (en) 1997-01-15 1999-02-09 Boston Scientific Corporation Drug delivery balloon catheter device
US5869127A (en) 1995-02-22 1999-02-09 Boston Scientific Corporation Method of providing a substrate with a bio-active/biocompatible coating
US5879697A (en) 1997-04-30 1999-03-09 Schneider Usa Inc Drug-releasing coatings for medical devices
US5888533A (en) 1995-10-27 1999-03-30 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5893840A (en) 1991-01-04 1999-04-13 Medtronic, Inc. Releasable microcapsules on balloon catheters
US5919145A (en) 1993-12-30 1999-07-06 Boston Scientific Corporation Bodily sample collection balloon catheter
US5919570A (en) 1995-02-01 1999-07-06 Schneider Inc. Slippery, tenaciously adhering hydrogel coatings containing a polyurethane-urea polymer hydrogel commingled with a poly(N-vinylpyrrolidone) polymer hydrogel, coated polymer and metal substrate materials, and coated medical devices
US5922730A (en) 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
US5977163A (en) 1996-03-12 1999-11-02 Pg-Txl Company, L. P. Water soluble paclitaxel prodrugs
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5985325A (en) 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration
US5989591A (en) 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US6015809A (en) 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
US6020315A (en) 1997-05-15 2000-02-01 Hoechst Aktiengesellschaft Preparation having increased in vivo tolerability
US6039721A (en) 1996-07-24 2000-03-21 Cordis Corporation Method and catheter system for delivering medication with an everting balloon catheter
US6046230A (en) 1998-03-23 2000-04-04 Kyu-Nung Chung Stable injection formulation containing paclitaxel
US6050980A (en) 1998-08-03 2000-04-18 My-Tech, Inc Thromboresistant plastic article and method of manufacture
US6056722A (en) 1997-09-18 2000-05-02 Iowa-India Investments Company Limited Of Douglas Delivery mechanism for balloons, drugs, stents and other physical/mechanical agents and methods of use
US6129705A (en) 1997-10-01 2000-10-10 Medtronic Ave, Inc. Drug delivery and gene therapy delivery system
US6143037A (en) 1996-06-12 2000-11-07 The Regents Of The University Of Michigan Compositions and methods for coating medical devices
US6146358A (en) 1989-03-14 2000-11-14 Cordis Corporation Method and apparatus for delivery of therapeutic agent
US6176849B1 (en) 1999-05-21 2001-01-23 Scimed Life Systems, Inc. Hydrophilic lubricity coating for medical devices comprising a hydrophobic top coat
US6218016B1 (en) 1998-09-29 2001-04-17 Medtronic Ave, Inc. Lubricious, drug-accommodating coating
US6221425B1 (en) 1998-01-30 2001-04-24 Advanced Cardiovascular Systems, Inc. Lubricious hydrophilic coating for an intracorporeal medical device
US6221467B1 (en) 1997-06-03 2001-04-24 Scimed Life Systems, Inc. Coating gradient for lubricious coatings on balloon catheters
US6228393B1 (en) 1996-04-12 2001-05-08 Uroteq, Inc. Drug delivery via therapeutic hydrogels
US20010002435A1 (en) 1997-06-17 2001-05-31 Berg Eric P. Medical device for delivering a therapeutic substance and method therefor
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6280411B1 (en) 1998-05-18 2001-08-28 Scimed Life Systems, Inc. Localized delivery of drug agents
US20010018072A1 (en) 1997-05-13 2001-08-30 Imarx Therapeutics, Inc. Solid matrix therapeutic compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6299604B1 (en) 1998-08-20 2001-10-09 Cook Incorporated Coated implantable medical device
US6306166B1 (en) 1997-08-13 2001-10-23 Scimed Life Systems, Inc. Loading and release of water-insoluble drugs
US6306144B1 (en) 1996-11-01 2001-10-23 Scimed Life Systems, Inc. Selective coating of a balloon catheter with lubricious material for stent deployment
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US20010034363A1 (en) 1996-03-12 2001-10-25 Chun Li Water soluble paclitaxel derivatives
WO2001087368A1 (en) 2000-05-16 2001-11-22 Ortho-Mcneil Pharmaceutical, Inc. Process for coating medical devices using super-critical carbon dioxide
US6328970B1 (en) 1993-04-23 2001-12-11 American Home Products Corporation Rapamycin position 27 conjugates
US6331547B1 (en) 1999-08-18 2001-12-18 American Home Products Corporation Water soluble SDZ RAD esters
US6335029B1 (en) 1998-08-28 2002-01-01 Scimed Life Systems, Inc. Polymeric coatings for controlled delivery of active agents
US20020010419A1 (en) 1997-09-18 2002-01-24 Swaminathan Jayaraman Delivery mechanism for balloons, drugs, stents and other physical/mechanical agents and method of use
US6364856B1 (en) 1998-04-14 2002-04-02 Boston Scientific Corporation Medical device with sponge coating for controlled drug release
US6369039B1 (en) 1998-06-30 2002-04-09 Scimed Life Sytems, Inc. High efficiency local drug delivery
US20020041896A1 (en) 1999-05-27 2002-04-11 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
US6395326B1 (en) 2000-05-31 2002-05-28 Advanced Cardiovascular Systems, Inc. Apparatus and method for depositing a coating onto a surface of a prosthesis
US20020077684A1 (en) 2000-12-20 2002-06-20 Medtronic, Inc. Perfusion lead and method of use
US6419692B1 (en) 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
US20020095114A1 (en) 2001-01-17 2002-07-18 Maria Palasis Therapeutic delivery balloon
US20020098278A1 (en) 2000-10-31 2002-07-25 Cook Incorporated Coated implantable medical device
US20020102280A1 (en) 2000-11-29 2002-08-01 Anderson David M. Solvent systems for pharmaceutical agents
US6432973B1 (en) 2000-09-19 2002-08-13 Wyeth Water soluble rapamycin esters
US6444324B1 (en) 2000-12-01 2002-09-03 Scimed Life Systems, Inc. Lubricated catheter balloon
US20020138048A1 (en) 1993-04-26 2002-09-26 Tuch Ronald J. Medical device for delivering a therapeutic agent and method of preparation
DE10115740A1 (en) 2001-03-26 2002-10-02 Ulrich Speck Preparation for the prophylaxis of restenosis
US20020183380A1 (en) 1996-12-02 2002-12-05 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
US20020192280A1 (en) 2001-05-01 2002-12-19 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
US20030004209A1 (en) 1993-07-19 2003-01-02 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
EP1270018A1 (en) 2001-06-29 2003-01-02 Ethicon Inc. Sterilization of bioactive coatings
US20030008923A1 (en) 2001-06-01 2003-01-09 Wyeth Antineoplastic combinations
US6506408B1 (en) 2000-07-13 2003-01-14 Scimed Life Systems, Inc. Implantable or insertable therapeutic agent delivery device
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6524274B1 (en) 1990-12-28 2003-02-25 Scimed Life Systems, Inc. Triggered release hydrogel drug delivery system
US20030045587A1 (en) 2001-06-23 2003-03-06 David Anderson Solvent system
US20030064965A1 (en) 2001-10-02 2003-04-03 Jacob Richter Method of delivering drugs to a tissue using drug-coated medical devices
US6544544B2 (en) 1993-07-19 2003-04-08 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
US6571125B2 (en) 2001-02-12 2003-05-27 Medtronic, Inc. Drug delivery device
US20030100886A1 (en) 2001-11-29 2003-05-29 Jerome Segal Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment
US20030100577A1 (en) 2001-08-22 2003-05-29 Wyeth Rapamycin dialdehydes
US6576224B1 (en) 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US20030114477A1 (en) 2001-08-22 2003-06-19 Wyeth Rapamycin 29-Enols
US20030157161A1 (en) 2001-05-01 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
US20030157032A1 (en) 1998-04-18 2003-08-21 Pascal Cavaillon Pharmaceutical aerosol formulation
US6610035B2 (en) 1999-05-21 2003-08-26 Scimed Life Systems, Inc. Hydrophilic lubricity coating for medical devices comprising a hybrid top coat
US20030207936A1 (en) 2000-11-28 2003-11-06 Hongming Chen Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
US20030207939A1 (en) 2000-08-10 2003-11-06 Seigo Ishibuchi Novel 3-substituted urea derivatives and medicinal use thereof
US20030216699A1 (en) 2000-05-12 2003-11-20 Robert Falotico Coated medical devices for the prevention and treatment of vascular disease
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US20030235602A1 (en) 2002-06-19 2003-12-25 Schwarz Marlene C. Implantable or insertable medical devices for controlled delivery of a therapeutic agent
US20040002755A1 (en) 2002-06-28 2004-01-01 Fischell David R. Method and apparatus for treating vulnerable coronary plaques using drug-eluting stents
WO2004006976A1 (en) 2002-07-12 2004-01-22 Cook Incorporated Coated medical device
US6682545B1 (en) 1999-10-06 2004-01-27 The Penn State Research Foundation System and device for preventing restenosis in body vessels
US20040037886A1 (en) 2002-08-26 2004-02-26 Li-Chien Hsu Drug eluting coatings for medical implants
WO2004026357A1 (en) 2002-09-23 2004-04-01 Conor Medsystems, Inc. Therapeutic agent delivery device with protective separating layer
WO2004028582A1 (en) 2002-09-20 2004-04-08 Ulrich Speck Medical device for dispensing medicaments
US20040077677A1 (en) 2002-09-17 2004-04-22 Wyeth Oral formulations
US20040087902A1 (en) 2002-10-30 2004-05-06 Jacob Richter Drug eluting medical device with an expandable portion for drug release
US20040097485A1 (en) 2002-10-31 2004-05-20 Tularik Inc. Antiinflammation agents
US20040127551A1 (en) 2002-12-27 2004-07-01 Kai Zhang Taxane-based compositions and methods of use
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US20040156816A1 (en) 2002-08-06 2004-08-12 David Anderson Lipid-drug complexes in reversed liquid and liquid crystalline phases
US20040167152A1 (en) 2002-07-30 2004-08-26 Wyeth Parenteral formulations
US20040176339A1 (en) 2003-03-05 2004-09-09 Wyeth Antineoplastic combinations
US20040197408A1 (en) 2002-12-30 2004-10-07 Angiotech International Ag Amino acids in micelle preparation
US20040202712A1 (en) 1997-01-07 2004-10-14 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US20040201117A1 (en) 1997-09-09 2004-10-14 David Anderson Coated particles, methods of making and using
WO2004089291A2 (en) 2003-04-03 2004-10-21 Au Jessie L-S Tumor-targeting drug-loaded particles
US20040219214A1 (en) 2002-12-30 2004-11-04 Angiotech International Ag Tissue reactive compounds and compositions and uses thereof
US20040224001A1 (en) 2003-05-08 2004-11-11 Pacetti Stephen D. Stent coatings comprising hydrophilic additives
US20040225077A1 (en) 2002-12-30 2004-11-11 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US20040224003A1 (en) 2003-02-07 2004-11-11 Schultz Robert K. Drug formulations for coating medical devices
US20040230176A1 (en) 2003-04-23 2004-11-18 Medtronic Vascular, Inc. System for treating a vascular condition that inhibits restenosis at stent ends
US20040258662A1 (en) 2003-04-22 2004-12-23 Wyeth Antineoplastic agents
US20050010170A1 (en) 2004-02-11 2005-01-13 Shanley John F Implantable medical device with beneficial agent concentration gradient
US20050025802A1 (en) 2003-07-31 2005-02-03 Richard Robert E. Implantable or insertable medical devices containing acrylic copolymer for controlled delivery of therapeutic agent
US20050042268A1 (en) 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050049271A1 (en) 2003-09-03 2005-03-03 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions
US20050055078A1 (en) 2003-09-04 2005-03-10 Medtronic Vascular, Inc. Stent with outer slough coating
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US20050100580A1 (en) 2003-10-14 2005-05-12 Cook Incorporated Hydrophilic coated medical device
US6893431B2 (en) 2001-10-15 2005-05-17 Scimed Life Systems, Inc. Medical device for delivering patches
US6899731B2 (en) 1999-12-30 2005-05-31 Boston Scientific Scimed, Inc. Controlled delivery of therapeutic agents by insertable medical devices
US20050123582A1 (en) 1996-11-05 2005-06-09 Hsing-Wen Sung Drug-eluting stent having collagen drug carrier chemically treated with genipin
US20050152983A1 (en) 2004-01-08 2005-07-14 Wyeth Directly compressible pharmaceutical composition for the oral administration of CCI-779
US6918869B2 (en) 2002-12-02 2005-07-19 Scimed Life Systems System for administering a combination of therapies to a body lumen
US6921390B2 (en) 2001-07-23 2005-07-26 Boston Scientific Scimed, Inc. Long-term indwelling medical devices containing slow-releasing antimicrobial agents and having a surfactant surface
US20050171596A1 (en) 2004-02-03 2005-08-04 Furst Joseph G. Stents with amphiphilic copolymer coatings
US20050182361A1 (en) 1998-05-18 2005-08-18 Boston Scientific Scimed, Inc. Localized delivery of drug agents
US20050186244A1 (en) 2003-11-20 2005-08-25 Angiotech International Ag Polymer compositions and methods for their use
US20050192210A1 (en) 2004-03-01 2005-09-01 Rothbard Jonathan B. Compositions and methods for treating diseases
US6939320B2 (en) 1998-05-18 2005-09-06 Boston Scientific Scimed., Inc. Localized delivery of drug agents
US20050209664A1 (en) 2003-11-20 2005-09-22 Angiotech International Ag Electrical devices and anti-scarring agents
US20050222191A1 (en) 2004-03-31 2005-10-06 Robert Falotico Solution formulations of sirolimus and its analogs for CAD treatment
US20050234086A1 (en) 2004-04-14 2005-10-20 Wyeth Proline CCI-779, production of and uses therefor, and two-step enzymatic synthesis of proline CCI-779 and CCI-779
US20050234234A1 (en) 2004-04-14 2005-10-20 Wyeth Regiospecific synthesis of rapamycin 42-ester derivatives
US20050234087A1 (en) 2004-04-14 2005-10-20 Wyeth Process for preparing rapamycin 42-esters and FK-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies
US6958153B1 (en) 1997-11-07 2005-10-25 Wyeth Skin penetration enhancing components
US20050239178A1 (en) 2004-04-27 2005-10-27 Wyeth Labeling of rapamycin using rapamycin-specific methylases
US20050238584A1 (en) 2004-04-21 2005-10-27 Ananth Annapragada Compositions and methods for enhancing contrast in imaging
US20050246009A1 (en) 2004-03-19 2005-11-03 Toner John L Multiple drug delivery from a balloon and a prosthesis
US20050251249A1 (en) 2002-10-11 2005-11-10 Sahatjian Ronald A Endoprostheses
US20050256564A1 (en) 2004-05-13 2005-11-17 Medtronic Vascular, Inc. Intraluminal stent including therapeutic agent delivery pads, and method of manufacturing the same
US20050272758A1 (en) 2004-03-11 2005-12-08 Wyeth Antineoplastic combinations of CCI-779 and rituximab
US20050288481A1 (en) 2004-04-30 2005-12-29 Desnoyer Jessica R Design of poly(ester amides) for the control of agent-release from polymeric compositions
US20060015170A1 (en) 2004-07-16 2006-01-19 Jones Ryan A Contrast coated stent and method of fabrication
US6991809B2 (en) 2001-06-23 2006-01-31 Lyotropic Therapeutics, Inc. Particles with improved solubilization capacity
US20060040971A1 (en) 2004-08-20 2006-02-23 Wyeth Rapamycin polymorphs and uses thereof
US20060045901A1 (en) 2004-08-26 2006-03-02 Jan Weber Stents with drug eluting coatings
WO2006023859A1 (en) 2004-08-20 2006-03-02 Medtronic, Inc. Medical device with tissue-dependent drug elution
US7008411B1 (en) 2002-09-30 2006-03-07 Advanced Cardiovascular Systems, Inc. Method and apparatus for treating vulnerable plaque
US20060051392A1 (en) 2004-09-03 2006-03-09 Medtronic, Inc. Porous coatings for drug release from medical devices
US20060052744A1 (en) 2004-09-03 2006-03-09 Jan Weber Method of coating a medical device using an electrowetting process, system for using the method, and device made by the method
US20060067977A1 (en) 2004-09-28 2006-03-30 Atrium Medical Corporation Pre-dried drug delivery coating for use with a stent
US7025752B2 (en) 2002-11-06 2006-04-11 Advanced Cardiovascular Systems, Inc. Reduced slippage balloon catheter and method of using same
US20060094745A1 (en) 2004-10-28 2006-05-04 Wyeth Use of an mTOR inhibitor in treatment of uterine leiomyoma
WO2006056984A2 (en) 2004-11-26 2006-06-01 Stentomics Inc. Chelating and binding chemicals to a medical implant
US20060112536A1 (en) 2003-09-15 2006-06-01 Atrium Medical Corporation Method of coating a folded medical device
US7056550B2 (en) 2000-09-29 2006-06-06 Ethicon, Inc. - Usa Medical devices, drug coatings and methods for maintaining the drug coatings thereon
US20060121545A1 (en) 1993-04-23 2006-06-08 Wyeth Rapamycin conjugates and antibodies
US7060051B2 (en) 2002-09-24 2006-06-13 Scimed Life Systems, Inc. Multi-balloon catheter with hydrogel coating
US20060135550A1 (en) 2004-12-20 2006-06-22 Wyeth Rapamycin derivatives and the uses thereof in the treatment of neurological disorders
US20060135549A1 (en) 2004-12-20 2006-06-22 Wyeth Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative,and inflammatory disorders
US7077859B2 (en) 2000-12-22 2006-07-18 Avantec Vascular Corporation Apparatus and methods for variably controlled substance delivery from implanted prostheses
US20060165753A1 (en) 2005-01-25 2006-07-27 Richard Robert E Medical device drug release regions containing non-covalently bound polymers
US20060173528A1 (en) 2005-01-10 2006-08-03 Trireme Medical, Inc. Stent with self-deployable portion
US20060184236A1 (en) 2005-02-11 2006-08-17 Medtronic Vascular, Inc. Intraluminal device including an optimal drug release profile, and method of manufacturing the same
US20060183766A1 (en) 2005-02-15 2006-08-17 Wyeth Orally bioavailable CCI-779 formulations
US20060188543A1 (en) 2005-01-31 2006-08-24 Si-Shen Feng Nanoparticle coating for drug delivery
US20060199834A1 (en) 2005-03-07 2006-09-07 Wyeth Oxepane isomer of 42-O-(2-hydroxy)ethyl-rapamycin
US20060199954A1 (en) 2005-03-02 2006-09-07 Wyeth Purification of rapamycin
US7108684B2 (en) 2003-01-02 2006-09-19 Novoste Corporation Drug delivery balloon catheter
WO2006101573A1 (en) 2005-03-21 2006-09-28 Boston Scientific Limited Coatings for use on medical devices
US20060224237A1 (en) 2005-03-03 2006-10-05 Icon Medical Corp. Fragile structure protective coating
US20060230476A1 (en) 2005-03-30 2006-10-12 Boston Scientific Scimed, Inc. Polymeric/ceramic composite materials for use in medical devices
US20060257450A1 (en) 2005-03-21 2006-11-16 Sreenivasu Mudumba Drug delivery systems for treatment of diseases or conditions
US20060257444A1 (en) 2005-04-29 2006-11-16 Medtronic, Inc. Devices for augmentation of lumen walls
US20060257445A1 (en) 2005-04-29 2006-11-16 Medtronic, Inc. Devices for augmentation of lumen walls
WO2006124647A1 (en) 2005-05-13 2006-11-23 Cook Incorporated Medical device delivery systems that facilitate medical device placement in the presence of ultrasonic waves
US7144419B2 (en) 2003-01-24 2006-12-05 Medtronic Vascular, Inc. Drug-polymer coated stent with blended phenoxy and styrenic block copolymers
US20060282114A1 (en) 2005-06-09 2006-12-14 Medtronic Vascular, Inc. Embolic protection apparatus with vasodilator coating
US7153957B2 (en) 2003-08-07 2006-12-26 Wyeth Regioselective synthesis of CCI-779
US7160317B2 (en) 2002-01-04 2007-01-09 Boston Scientific Scimed, Inc. Multiple-wing balloon catheter to reduce damage to coated expandable medical implants
US7163555B2 (en) 2003-04-08 2007-01-16 Medtronic Vascular, Inc. Drug-eluting stent for controlled drug delivery
US20070020380A1 (en) 2005-07-25 2007-01-25 Ni Ding Methods of providing antioxidants to a drug containing product
US20070020308A1 (en) 2005-07-19 2007-01-25 Richard Robert E Polymers having covalently bound therapeutic agents
US7172619B2 (en) 2001-08-27 2007-02-06 Medinol, Ltd. Single operator stenting system
US20070032694A1 (en) 1997-04-30 2007-02-08 Ludger Dinkelborg Stents with a radioactive surface coating, processes for their production and their use for restenosis prophylaxis
US7176261B2 (en) 2004-10-21 2007-02-13 Medtronic, Inc. Angiotensin-(1-7) eluting polymer-coated medical device to reduce restenosis and improve endothelial cell function
US7175873B1 (en) 2001-06-27 2007-02-13 Advanced Cardiovascular Systems, Inc. Rate limiting barriers for implantable devices and methods for fabrication thereof
US20070050010A1 (en) 1995-06-07 2007-03-01 Cook Incorporated Coated implantable medical device
US20070059434A1 (en) 2002-07-18 2007-03-15 Roorda Wouter E Rate limiting barriers for implantable devices and methods for fabrication thereof
US20070065484A1 (en) 2005-09-21 2007-03-22 Chudzik Stephen J In situ occlusion using natural biodegradable polysaccharides
US20070073385A1 (en) 2005-09-20 2007-03-29 Cook Incorporated Eluting, implantable medical device
US7198637B2 (en) 2003-04-21 2007-04-03 Medtronic Vascular, Inc. Method and system for stent retention using an adhesive
US20070078446A1 (en) 2005-08-31 2007-04-05 Cook Ireland Limited And Cook Incorporated Stent for implantation
US20070078513A1 (en) 2002-09-18 2007-04-05 Medtronic Vascular, Inc. Controllable drug releasing gradient coatings for medical devices
US20070077347A1 (en) 1996-12-26 2007-04-05 Jacob Richter Flat process of drug coating for stents
US7208009B2 (en) 1996-12-26 2007-04-24 Medinol, Ltd. Stent fabrication method
WO2007047416A2 (en) 2005-10-14 2007-04-26 Abbott Laboratories Compositions and methods of administering rapamycin analogs with paclitaxel using medical devices
US7214198B2 (en) 2001-06-29 2007-05-08 Medtronic, Inc. Catheter system having disposable balloon
US20070117925A1 (en) 2005-11-23 2007-05-24 Strickler Frederick H Medical devices having polymeric regions that contain fluorocarbon-containing block copolymers
WO2007061529A1 (en) 2005-11-18 2007-05-31 Scidose Llc. Lyophilization process and products obtained thereby
US7226586B2 (en) 2001-10-04 2007-06-05 Medtronic Vascular, Inc. Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use
US20070128118A1 (en) 2005-12-05 2007-06-07 Nitto Denko Corporation Polyglutamate-amino acid conjugates and methods
US7232573B1 (en) 2002-09-26 2007-06-19 Advanced Cardiovascular Systems, Inc. Stent coatings containing self-assembled monolayers
US20070142422A1 (en) 2005-12-20 2007-06-21 Wyeth Control of CCI-779 dosage form stability through control of drug substance impurities
US20070142772A1 (en) 2005-12-16 2007-06-21 Medtronic Vascular, Inc. Dual-Layer Medical Balloon
US20070142905A1 (en) 2005-12-16 2007-06-21 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
US7235096B1 (en) 1998-08-25 2007-06-26 Tricardia, Llc Implantable device for promoting repair of a body lumen
US20070161967A1 (en) 1996-06-04 2007-07-12 Vance Products Inc., Dba Cook Urological Inc. Implantable medical device with pharmacologically active ingredient
US20070162103A1 (en) 2001-02-05 2007-07-12 Cook Incorporated Implantable device with remodelable material and covering material
US7244444B2 (en) 2004-03-31 2007-07-17 Cook Incorporated Graft material, stent graft and method
WO2007079560A2 (en) 2006-01-13 2007-07-19 Brz Biotecnologia Ltda Pharmaceutical compounds that contain nanoparticles useful for treating restenotic lesions
US20070167735A1 (en) 2001-11-27 2007-07-19 Sheng-Ping Zhong Implantable or insertable medical devices visible under magnetic resonance imaging
US20070168012A1 (en) 1995-06-07 2007-07-19 Med Institute, Inc. Coated implantable medical device
US7247313B2 (en) 2001-06-27 2007-07-24 Advanced Cardiovascular Systems, Inc. Polyacrylates coatings for implantable medical devices
US20070184083A1 (en) 2006-02-07 2007-08-09 Medtronic Vascular, Inc. Drug-Eluting Device for Treatment of Chronic Total Occlusions
US20070190103A1 (en) 2006-02-10 2007-08-16 Hossainy Syed F A Implantable medical device with surface-eroding polyester drug delivery coating
US20070191934A1 (en) 2006-02-10 2007-08-16 Medtronic Vascular, Inc. Medical Devices to Prevent or Inhibit Restenosis
US20070207184A1 (en) 2006-01-27 2007-09-06 Med Institute, Inc Implantable medical device coated with a bioactive agent
US20070212386A1 (en) 2006-03-08 2007-09-13 Sahajanand Medical Technologies Pvt. Ltd. Coatings for implantable medical devices
US20070212394A1 (en) 2006-03-10 2007-09-13 Cook Incorporated Taxane coatings for implantable medical devices
US20070219642A1 (en) 1998-12-03 2007-09-20 Jacob Richter Hybrid stent having a fiber or wire backbone
US20070225799A1 (en) 2006-03-24 2007-09-27 Medtronic Vascular, Inc. Stent, intraluminal stent delivery system, and method of treating a vascular condition
US20070237803A1 (en) 2006-04-11 2007-10-11 Medtronic Vascular, Inc. Biodegradable Biocompatible Amphiphilic Copolymers for Coating and Manufacturing Medical Devices
US7282213B2 (en) 2002-09-30 2007-10-16 Medtronic, Inc. Method for applying a drug coating to a medical device
US20070244548A1 (en) 2006-02-27 2007-10-18 Cook Incorporated Sugar-and drug-coated medical device
US20070244284A1 (en) 2006-04-14 2007-10-18 Medtronic Vascular, Inc. Durable Biocompatible Controlled Drug Release Polymeric Coatings for Medical Devices
US7285304B1 (en) 2003-06-25 2007-10-23 Advanced Cardiovascular Systems, Inc. Fluid treatment of a polymeric coating on an implantable medical device
US7294329B1 (en) 2002-07-18 2007-11-13 Advanced Cardiovascular Systems, Inc. Poly(vinyl acetal) coatings for implantable medical devices
US20070264307A1 (en) 2006-05-15 2007-11-15 Medtronic Vascular, Inc. Biodegradable Modified Caprolactone Polymers for Fabricating and Coating Medical Devices
US20070265565A1 (en) 2006-05-15 2007-11-15 Medtronic Vascular, Inc. Mesh-Reinforced Catheter Balloons and Methods for Making the Same
WO2007134239A2 (en) 2006-05-12 2007-11-22 Cordis Corporation Balloon expandable bioabsorbable drug eluting flexible stent
US20070276466A1 (en) 2005-08-31 2007-11-29 Vance Products Inc., D/B/A/ Cook Urological Inc. Stent for implantation
WO2007139931A2 (en) 2006-05-26 2007-12-06 Abbott Cardiovascular Systems Inc. Bioabsorbable stent with radiopaque coating
US20070282422A1 (en) 2006-05-10 2007-12-06 Cook Incorporated Medical devices and methods for local delivery of elastin-stabilizing compounds
US7306580B2 (en) 2003-04-16 2007-12-11 Cook Incorporated Medical device with therapeutic agents
US20070286814A1 (en) 2006-06-12 2007-12-13 Medispray Laboratories Pvt. Ltd. Stable aerosol pharmaceutical formulations
US20070298069A1 (en) 2006-06-26 2007-12-27 Boston Scientific Scimed, Inc. Medical devices for release of low solubility therapeutic agents
WO2007149161A2 (en) 2006-06-22 2007-12-27 Boston Scientific Scimed, Inc. Control realease drug coating for medical devices
WO2008003298A2 (en) 2006-07-03 2008-01-10 Hemoteq Ag Manufacture, method, and use of active substance-releasing medical products for permanently keeping blood vessels open
US20080038307A1 (en) 2004-02-28 2008-02-14 Erika Hoffmann Biocompatible Coating, Method, and Use of Medical Surfaces
US20080082552A1 (en) 2006-10-02 2008-04-03 Autodesk, Inc. Data locality in a serialized object stream
EP1913962A1 (en) 2006-10-22 2008-04-23 Ophir Perelson Expandable medical device for the treatment and prevention of cardiovascular diseases
US20080114331A1 (en) 2006-11-14 2008-05-15 Holman Thomas J Medical devices and related methods
US20080118544A1 (en) 2006-11-20 2008-05-22 Lixiao Wang Drug releasing coatings for medical devices
CN101185779A (en) 2007-12-19 2008-05-28 上海赢生医疗科技有限公司 Method for preparing medicine sustained-releasing bracket
WO2008063576A2 (en) 2006-11-20 2008-05-29 Lutonix, Inc. Drug releasing coatings for medical devices
US20080140002A1 (en) 2006-12-06 2008-06-12 Kamal Ramzipoor System for delivery of biologically active substances with actuating three dimensional surface
EP1510220B1 (en) 1993-05-13 2008-07-23 Poniard Pharmaceuticals, Inc. Therapeutic inhibitor of vascular smooth muscle cells
WO2008086794A2 (en) 2007-01-21 2008-07-24 Hemoteq Ag Medical product for treating stenosis of body passages and for preventing threatening restenosis
US20080183282A1 (en) 2006-03-09 2008-07-31 Saul Yedgar Use of lipid conjugates for the coating of stents and catheters
US20080194494A1 (en) 2005-04-26 2008-08-14 Microbia, Inc. 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia
US20080215137A1 (en) 2003-04-30 2008-09-04 Boston Scientific Scimed, Inc. Therapeutic driving layer for a medical device
CN101264347A (en) 2007-11-27 2008-09-17 天津百畅医疗器械科技有限公司 Drug-eluting coated on surface of sacculus catheter air bag for alleviating vascular restenosis
EP1970185A2 (en) 2007-03-14 2008-09-17 Cordis Corporation An apparatus and method for making a vascular stent
US20080233062A1 (en) 2006-08-24 2008-09-25 Venkataram Krishnan Cationic latex as a carrier for active ingredients and methods for making and using the same
WO2008114585A1 (en) 2007-03-20 2008-09-25 Terumo Kabushiki Kaisha Coating method and coating device
US20080255510A1 (en) 2006-11-20 2008-10-16 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US20080255509A1 (en) 2006-11-20 2008-10-16 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US20080255508A1 (en) 2006-11-20 2008-10-16 Lutonix, Inc. Drug releasing coatings for medical devices
US20080255658A1 (en) 2007-04-12 2008-10-16 Medtronic Vascular, Inc. Degradation Associated Drug Delivery for Drug Eluting Stent and Medical Device Coatings
US20080262412A1 (en) 2005-02-11 2008-10-23 Boston Scientific Scimed, Inc. Internal medical devices for delivery of therapeutic agent in conjunction with a source of electrical power
US20080274266A1 (en) 2007-05-02 2008-11-06 Davis Liza J Selective Application Of Therapeutic Agent to a Medical Device
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US20080317827A1 (en) 1997-04-18 2008-12-25 Cordis Corporation Methods and Devices for Delivering Therapeutic Agents to Target Vessels
US20090010987A1 (en) 2005-11-02 2009-01-08 Conor Medsystems, Inc. Methods and Devices for Reducing Tissue Damage After Ischemic Injury
US20090011116A1 (en) 2004-09-28 2009-01-08 Atrium Medical Corporation Reducing template with coating receptacle containing a medical device to be coated
US20090035390A1 (en) 2006-01-06 2009-02-05 Modak Shanta M Compositions containing zinc salts for coating medical articles
WO2009018816A2 (en) 2007-08-03 2009-02-12 Innora Gmbh Improved pharmaceutical-coated medical products, the production thereof and the use thereof
US20090047414A1 (en) 2004-09-28 2009-02-19 Atrium Medical Corporation Method and apparatus for application of a fresh coating on a medical device
US20090076448A1 (en) 2007-09-17 2009-03-19 Consigny Paul M Methods and devices for eluting agents to a vessel
US20090098176A1 (en) 2007-09-10 2009-04-16 Boston Scientific Scimed, Inc. Medical devices with triggerable bioadhesive material
US20090105686A1 (en) 2007-06-29 2009-04-23 Xtent, Inc. Adjustable-length drug delivery balloon
US20090105687A1 (en) 2007-10-05 2009-04-23 Angioscore, Inc. Scoring catheter with drug delivery membrane
US7524527B2 (en) 2003-05-19 2009-04-28 Boston Scientific Scimed, Inc. Electrostatic coating of a device
US7547294B2 (en) 2001-09-20 2009-06-16 The Regents Of The University Of California Microfabricated surgical device for interventional procedures
US20090181937A1 (en) 2004-09-28 2009-07-16 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US20090182273A1 (en) 2008-01-11 2009-07-16 Medtronic Vascular, Inc. Methods for Incorporating a Drug into an Elastomeric Medical Device
US20090187144A1 (en) 2008-01-18 2009-07-23 Swaminathan Jayaraman Delivery of therapeutic and marking substance through intra lumen expansion of a delivery device
US20090208552A1 (en) 2004-09-28 2009-08-20 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US20090215882A1 (en) 2006-01-20 2009-08-27 Eriochem, S.A. Lyophilized solid taxane composition, a process for preparing said solid composition, a pharmaceutical formulation and a kit for said formulation
US20090227949A1 (en) 2008-03-06 2009-09-10 Boston Scientific Scimed, Inc. Balloon catheter devices with folded balloons
US20090238854A1 (en) 2004-08-05 2009-09-24 Advanced Cardiovascular Systems, Inc. Plasticizers for coating compositions
US20090246252A1 (en) 2008-03-28 2009-10-01 James Howard Arps Insertable medical devices having microparticulate-associated elastic substrates and methods for drug delivery
EP2123312A2 (en) 2008-05-19 2009-11-25 Cordis Corporation Extraction of solvents from drug containing polymer reservoirs
US20090324682A1 (en) 2004-08-30 2009-12-31 Youri Popowski Medical stent provided with inhibitors of atp synthesis
WO2010009335A1 (en) 2008-07-17 2010-01-21 Micell Technologies, Inc. Drug delivery medical device
US20100030183A1 (en) 2004-03-19 2010-02-04 Toner John L Method of treating vascular disease at a bifurcated vessel using a coated balloon
US20100055294A1 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US20100063570A1 (en) 2008-09-05 2010-03-11 Pacetti Stephen D Coating on a balloon comprising a polymer and a drug
US20100068170A1 (en) 2008-09-15 2010-03-18 Michal Eugene T Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US20100068238A1 (en) 2005-07-15 2010-03-18 Nandkishore Managoli Implantable Medical Devices Comprising a Flavonoid or Derivative Thereof for Prevention of Restenosis
US20100069838A1 (en) 2008-09-12 2010-03-18 Boston Scientific Scimed, Inc. Devices and systems for delivery of therapeutic agents to body lumens
US20100069879A1 (en) 2008-09-15 2010-03-18 Michal Eugene T Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
EP1576970B1 (en) 2001-11-08 2010-03-24 Ziscoat N.V. Intraluminal device with a coating containing a therapeutic agent
US20100081992A1 (en) 2008-09-26 2010-04-01 Ehrenreich Kevin J Expandable Member Formed Of A Fibrous Matrix For Intraluminal Drug Delivery
US20100087783A1 (en) 2008-10-07 2010-04-08 Boston Scientific Scimed, Inc. Medical devices for delivery of therapeutic agents to body lumens
US20100198190A1 (en) 2008-09-15 2010-08-05 Michal Eugene T Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US20100198150A1 (en) 2008-09-15 2010-08-05 Michal Eugene T Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US20100209472A1 (en) 2006-11-20 2010-08-19 Lixiao Wang Drug releasing coatings for medical devices
US20100272773A1 (en) 2009-04-24 2010-10-28 Boston Scientific Scimed, Inc. Use of Drug Polymorphs to Achieve Controlled Drug Delivery From a Coated Medical Device
US20100285085A1 (en) 2009-05-07 2010-11-11 Abbott Cardiovascular Systems Inc. Balloon coating with drug transfer control via coating thickness
US20100324645A1 (en) 2009-06-17 2010-12-23 John Stankus Drug coated balloon catheter and pharmacokinetic profile
US20100331816A1 (en) 2008-03-31 2010-12-30 Dadino Ronald C Rapamycin coated expandable devices
EP1586338B1 (en) 2004-04-14 2011-01-26 Cordis Corporation The use of antioxidants to prevent oxidation and reduce drug degradation in drug eluting medical devices
US20110054396A1 (en) 2009-08-27 2011-03-03 Boston Scientific Scimed, Inc. Balloon Catheter Devices With Drug-Coated Sheath
US20110060275A1 (en) 2007-09-12 2011-03-10 Cook Incorporated Drug Eluting Balloon
US20110129514A1 (en) 2007-09-06 2011-06-02 Hossainy Syed F A Hygroscopic coating on a balloon device
US20110137243A1 (en) 2007-09-06 2011-06-09 Abbott Cardiovascular Systems Inc. Coating On A Balloon Device
US20110144577A1 (en) 2009-12-11 2011-06-16 John Stankus Hydrophilic coatings with tunable composition for drug coated balloon
US20110143014A1 (en) 2009-12-11 2011-06-16 John Stankus Coatings with tunable molecular architecture for drug-coated balloon
US20110144578A1 (en) 2009-12-11 2011-06-16 Stephen Pacetti Hydrophobic therapueutic agent and solid emulsifier coating for drug coated balloon
US20110152906A1 (en) 2006-06-30 2011-06-23 Atheromed, Inc. Devices, systems, and methods for debulking restenosis of a blood vessel
US20110178503A1 (en) 2010-01-21 2011-07-21 Boston Scientific Scimed, Inc. Balloon catheters with therapeutic agent in balloon folds and methods of making the same
US20110190863A1 (en) 2010-02-03 2011-08-04 Boston Scientific Scimed, Inc. Therapeutic Balloon with Systemic Drug Loss Protection and Controlled Particle Size Release
EP1468660B1 (en) 2003-04-15 2011-12-21 Medtronic Vascular, Inc. Stent delivery system, device, and method for coating
US20120143132A1 (en) 2009-04-24 2012-06-07 Eurocor Gmbh Shellac and paclitaxel coated catheter balloons
US20130197434A1 (en) 2006-11-20 2013-08-01 Lutonix, Inc. Drug releasing coatings for balloon catheters
US9072812B2 (en) 2010-04-19 2015-07-07 Angioscore, Inc. Coating formulations for scoring or cutting balloon catheters
WO2016015874A1 (en) 2014-08-01 2016-02-04 Lvd Biotech S.L. Paclitaxel-eluting balloon and method for manufacturing the same

Patent Citations (549)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929992A (en) 1972-09-29 1975-12-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US3993749A (en) 1974-04-12 1976-11-23 Ayerst Mckenna And Harrison Ltd. Rapamycin and process of preparation
US4308184A (en) 1978-04-01 1981-12-29 Bayer Aktiengesellschaft Heat cross linkable polyurethane coating compositions
US4364921A (en) 1979-03-08 1982-12-21 Schering, Aktiengesellschaft Novel triiodinated isophthalic acid diamides as nonionic X-ray contrast media
US4252969A (en) 1979-09-27 1981-02-24 National Distillers And Chemical Corp. Process for regulating particle size of finely divided thermoplastic resins
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4921483A (en) 1985-12-19 1990-05-01 Leocor, Inc. Angioplasty catheter
US5061738A (en) 1988-04-18 1991-10-29 Becton, Dickinson And Company Blood compatible, lubricious article and composition and method therefor
US5573518A (en) 1988-05-26 1996-11-12 Haaga; John R. Sheath for wound closure caused by a medical tubular device
US20020099332A1 (en) 1988-08-24 2002-07-25 Slepian Marvin J. Biodegradable polymeric endoluminal sealing process, apparatus and polymeric products for use therein
US6443941B1 (en) 1988-08-24 2002-09-03 Endoluminal Therapeutics, Inc. Biodegradable polymeric endoluminal sealing process, apparatus and polymeric products for use therein
US6699272B2 (en) 1988-08-24 2004-03-02 Endoluminal Therapeutics, Inc. Biodegradable polymeric endoluminal sealing process, apparatus and polymeric products for use therein
US5674287A (en) 1988-08-24 1997-10-07 Endoluminal Therapeutics, Inc. Biodegradable polymeric endoluminal sealing process, apparatus and polymeric product for use therein
US5947977A (en) 1988-08-24 1999-09-07 Endoluminal Therapeutics, Inc. Apparatus and polymeric endoluminal sealing
US6146358A (en) 1989-03-14 2000-11-14 Cordis Corporation Method and apparatus for delivery of therapeutic agent
US6616650B1 (en) 1989-03-14 2003-09-09 Cordis Corporation Method and apparatus for delivery of therapeutic agent
US5026607A (en) 1989-06-23 1991-06-25 C. R. Bard, Inc. Medical apparatus having protective, lubricious coating
US5193447A (en) 1989-09-16 1993-03-16 Braun Aktiengesellschaft Citrus juicer
US5193447B1 (en) 1989-09-16 1999-06-22 Braun Ag Citrus juicer
US5525348A (en) 1989-11-02 1996-06-11 Sts Biopolymers, Inc. Coating compositions comprising pharmaceutical agents
US6409716B1 (en) 1989-12-15 2002-06-25 Scimed Life Systems, Inc. Drug delivery
US6890339B2 (en) 1989-12-15 2005-05-10 Scimed Life Systems, Inc. Stent lining
US5135516A (en) 1989-12-15 1992-08-04 Boston Scientific Corporation Lubricious antithrombogenic catheters, guidewires and coatings
US5269770A (en) 1990-01-10 1993-12-14 Rochester Medical Corporation Microcidal agent releasing catheter with balloon
US5164299A (en) 1990-03-20 1992-11-17 E. I. Du Pont De Nemours And Company Use of a mixture of conjugated and unconjugated solid phase binding reagent to enhance the performance of assays
US5504092A (en) 1990-03-27 1996-04-02 Pharmacia Ab Use of Linomide to increase hemopoietic cell precursors
US5092841A (en) 1990-05-17 1992-03-03 Wayne State University Method for treating an arterial wall injured during angioplasty
US5199951A (en) 1990-05-17 1993-04-06 Wayne State University Method of drug application in a transporting medium to an arterial wall injured during angioplasty
US5120322A (en) 1990-06-13 1992-06-09 Lathrotec, Inc. Method and apparatus for treatment of fibrotic lesions
US5023264A (en) 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
US5023263A (en) 1990-08-09 1991-06-11 American Home Products Corporation 42-oxorapamycin
US5023262A (en) 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
US5221670A (en) 1990-09-19 1993-06-22 American Home Products Corporation Rapamycin esters
US5378696A (en) 1990-09-19 1995-01-03 American Home Products Corporation Rapamycin esters
US5130307A (en) 1990-09-28 1992-07-14 American Home Products Corporation Aminoesters of rapamycin
US5233036A (en) 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
US5674192A (en) 1990-12-28 1997-10-07 Boston Scientific Corporation Drug delivery
US7066904B2 (en) 1990-12-28 2006-06-27 Boston Scientific Scimed, Inc. Triggered release hydrogel drug delivery system
US5843089A (en) 1990-12-28 1998-12-01 Boston Scientific Corporation Stent lining
US5954706A (en) 1990-12-28 1999-09-21 Boston Scientific Corporation Drug delivery
US6524274B1 (en) 1990-12-28 2003-02-25 Scimed Life Systems, Inc. Triggered release hydrogel drug delivery system
US20030114791A1 (en) 1990-12-28 2003-06-19 Arthur Rosenthal Triggered release hydrogel drug delivery system
US6364893B1 (en) 1990-12-28 2002-04-02 Scimed Life Systems, Inc. Stent lining
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5102402A (en) 1991-01-04 1992-04-07 Medtronic, Inc. Releasable coatings on balloon catheters
US5893840A (en) 1991-01-04 1999-04-13 Medtronic, Inc. Releasable microcapsules on balloon catheters
US5370614A (en) 1991-01-04 1994-12-06 Medtronic, Inc. Method for making a drug delivery balloon catheter
US5324261A (en) 1991-01-04 1994-06-28 Medtronic, Inc. Drug delivery balloon catheter with line of weakness
US5080899A (en) 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5120726A (en) 1991-03-08 1992-06-09 American Home Products Corporation Rapamycin hydrazones
US5120842B1 (en) 1991-04-01 1993-07-06 A Failli Amedeo
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5102876A (en) 1991-05-07 1992-04-07 American Home Products Corporation Reduction products of rapamycin
US5776943A (en) 1991-05-14 1998-07-07 American Home Products Corporation Rapamycin metabolites
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5120725A (en) 1991-05-29 1992-06-09 American Home Products Corporation Bicyclic rapamycins
US5120727A (en) 1991-05-29 1992-06-09 American Home Products Corporation Rapamycin dimers
US5698582A (en) 1991-07-08 1997-12-16 Rhone-Poulenc Rorer S.A. Compositions containing taxane derivatives
US5138051A (en) 1991-08-07 1992-08-11 American Home Products Corporation Rapamycin analogs as immunosuppressants and antifungals
US5162333A (en) 1991-09-11 1992-11-10 American Home Products Corporation Aminodiesters of rapamycin
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6268390B1 (en) 1991-09-27 2001-07-31 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6074659A (en) 1991-09-27 2000-06-13 Noerx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5151413A (en) 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
US5164399A (en) 1991-11-18 1992-11-17 American Home Products Corporation Rapamycin pyrazoles
US5693034A (en) 1991-12-18 1997-12-02 Scimed Life Systems, Inc. Lubricous polymer network
US5196596A (en) 1991-12-26 1993-03-23 Union Carbide Chemicals & Plastics Technology Corporation Higher aldehyde separation process
US5563146A (en) 1992-01-09 1996-10-08 American Home Products Corporation Method of treating hyperproliferative vascular disease
US5516781A (en) 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5221740A (en) 1992-01-16 1993-06-22 American Home Products Corporation Oxepane isomers of rapamycin useful as immunosuppressive agents
US5194447A (en) 1992-02-18 1993-03-16 American Home Products Corporation Sulfonylcarbamates of rapamycin
US5346893A (en) 1992-03-05 1994-09-13 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carbalkoxy) sulfamates useful as immunosuppressive agents
US5177203A (en) 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
US5254089A (en) 1992-04-02 1993-10-19 Boston Scientific Corp. Medication dispensing balloon catheter
US5441759A (en) 1992-09-03 1995-08-15 Sherwood Medical Company Method to stabilize TDMAC heparin coating
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5567709A (en) 1992-10-13 1996-10-22 American Home Products Corporation Carbamates of rapamycin
US5411967A (en) 1992-10-13 1995-05-02 American Home Products Corporation Carbamates of rapamycin
US5302584A (en) 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5508399A (en) 1992-10-13 1996-04-16 American Home Products Corporation Carbamates of rapamycin
US5504204A (en) 1992-10-13 1996-04-02 American Home Products Corporation Carbamates of rapamycin
US5530121A (en) 1992-10-13 1996-06-25 American Home Products Corporation Carbamates of rapamycin
US5530007A (en) 1992-10-13 1996-06-25 American Home Products Corporation Carbamates of rapamycin
US5532355A (en) 1992-10-13 1996-07-02 American Home Products Corporation Carbamates of rapamycin
US5480988A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5559227A (en) 1992-10-13 1996-09-24 American Home Products Corporation Carbamates of rapaycin
US5489680A (en) 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5262423A (en) 1992-10-29 1993-11-16 American Home Products Corporation Rapamycin arylcarbonyl and alkoxycarbonyl carbamates as immunosuppressive and antifungal agents
US5807306A (en) 1992-11-09 1998-09-15 Cortrak Medical, Inc. Polymer matrix drug delivery apparatus
US5260300A (en) 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5482945A (en) 1992-12-22 1996-01-09 American Home Products Corporation Innovative technique for immunosuppression involving administration of rapamycin loaded formed blood elements
US5349060A (en) 1993-01-07 1994-09-20 American Home Products Corporation Rapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5733925A (en) 1993-01-28 1998-03-31 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5252579A (en) 1993-02-16 1993-10-12 American Home Products Corporation Macrocyclic immunomodulators
US5607463A (en) 1993-03-30 1997-03-04 Medtronic, Inc. Intravascular medical device
US5380298A (en) 1993-04-07 1995-01-10 The United States Of America As Represented By The Secretary Of The Navy Medical device with infection preventing feature
US20060121545A1 (en) 1993-04-23 2006-06-08 Wyeth Rapamycin conjugates and antibodies
US5504091A (en) 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
US6328970B1 (en) 1993-04-23 2001-12-11 American Home Products Corporation Rapamycin position 27 conjugates
US5464650A (en) 1993-04-26 1995-11-07 Medtronic, Inc. Intravascular stent and method
US5679400A (en) 1993-04-26 1997-10-21 Medtronic, Inc. Intravascular stent and method
US6997949B2 (en) 1993-04-26 2006-02-14 Medtronic, Inc. Medical device for delivering a therapeutic agent and method of preparation
US5776184A (en) 1993-04-26 1998-07-07 Medtronic, Inc. Intravasoular stent and method
US20020138048A1 (en) 1993-04-26 2002-09-26 Tuch Ronald J. Medical device for delivering a therapeutic agent and method of preparation
EP1510220B1 (en) 1993-05-13 2008-07-23 Poniard Pharmaceuticals, Inc. Therapeutic inhibitor of vascular smooth muscle cells
US20060240113A1 (en) 1993-07-19 2006-10-26 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
US20070003629A1 (en) 1993-07-19 2007-01-04 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
US20040076672A1 (en) 1993-07-19 2004-04-22 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
US6544544B2 (en) 1993-07-19 2003-04-08 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
US20030004209A1 (en) 1993-07-19 2003-01-02 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US20060121117A1 (en) 1993-07-19 2006-06-08 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
US20040062810A1 (en) 1993-07-19 2004-04-01 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
US20070003630A1 (en) 1993-07-19 2007-01-04 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
US20060127445A1 (en) 1993-07-19 2006-06-15 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
US5599307A (en) 1993-07-26 1997-02-04 Loyola University Of Chicago Catheter and method for the prevention and/or treatment of stenotic processes of vessels and cavities
EP1118325B1 (en) 1993-07-29 2006-01-04 The United States of America, represented by the Secretary, Department of Health and Human Services Use of Paclitaxel and its derivatives in the manufacture of a medicament for treating restenosis.
US5616608A (en) 1993-07-29 1997-04-01 The United States Of America As Represented By The Department Of Health And Human Services Method of treating atherosclerosis or restenosis using microtubule stabilizing agent
EP1649853A2 (en) 1993-07-29 2006-04-26 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Microtubule stabilizing agents for treating atherosclerosis or restenosis
US5387680A (en) 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
US5380299A (en) 1993-08-30 1995-01-10 Med Institute, Inc. Thrombolytic treated intravascular medical device
US5496276A (en) 1993-09-20 1996-03-05 Scimed Life Systems, Inc. Catheter balloon with retraction coating
US5490839A (en) 1993-09-20 1996-02-13 Scimed Life Systems, Inc. Catheter balloon with retraction coating
US5738901A (en) 1993-09-20 1998-04-14 Scimed Life Systems, Inc. Catheter balloon with retraction coating
US5536729A (en) 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5559121A (en) 1993-09-30 1996-09-24 American Home Products Corporation Rapamycin formulations for oral administration
US5373014A (en) 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5446048A (en) 1993-10-08 1995-08-29 American Home Products Corporation Rapamycin oximes
US5391730A (en) 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5378836A (en) 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5632772A (en) 1993-10-21 1997-05-27 Corvita Corporation Expandable supportive branched endoluminal grafts
US5385908A (en) 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5385910A (en) 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
US5385909A (en) 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5389639A (en) 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5919145A (en) 1993-12-30 1999-07-06 Boston Scientific Corporation Bodily sample collection balloon catheter
US5827289A (en) 1994-01-26 1998-10-27 Reiley; Mark A. Inflatable device for use in surgical protocols relating to treatment of fractured or diseased bones
US5525610A (en) 1994-03-31 1996-06-11 American Home Products Corporation 42-Epi-rapamycin and pharmaceutical compositions thereof
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5463048A (en) 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US5509899A (en) 1994-09-22 1996-04-23 Boston Scientific Corp. Medical device with lubricious coating
US5491231A (en) 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5563145A (en) 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
US5919570A (en) 1995-02-01 1999-07-06 Schneider Inc. Slippery, tenaciously adhering hydrogel coatings containing a polyurethane-urea polymer hydrogel commingled with a poly(N-vinylpyrrolidone) polymer hydrogel, coated polymer and metal substrate materials, and coated medical devices
US6120904A (en) 1995-02-01 2000-09-19 Schneider (Usa) Inc. Medical device coated with interpenetrating network of hydrogel polymers
US5766158A (en) 1995-02-06 1998-06-16 Surface Solutions Laboratories, Inc. Medical apparatus with scratch-resistant coating and method of making same
US5702754A (en) 1995-02-22 1997-12-30 Meadox Medicals, Inc. Method of providing a substrate with a hydrophilic coating and substrates, particularly medical devices, provided with such coatings
US5869127A (en) 1995-02-22 1999-02-09 Boston Scientific Corporation Method of providing a substrate with a bio-active/biocompatible coating
US6458138B1 (en) 1995-03-24 2002-10-01 Scimed Life Systems, Inc. Selective coating of a balloon catheter with lubricious material for stent deployment
US20050080477A1 (en) 1995-03-24 2005-04-14 Sydney Gregory T. Selective coating of a balloon catheter with lubricious material for stent deployment
US5752930A (en) 1995-04-28 1998-05-19 Medtronic, Inc. Implantable techniques for infusing equal volumes of agents to spaced sites
US6096070A (en) 1995-06-07 2000-08-01 Med Institute Inc. Coated implantable medical device
US5609629A (en) 1995-06-07 1997-03-11 Med Institute, Inc. Coated implantable medical device
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US20070050010A1 (en) 1995-06-07 2007-03-01 Cook Incorporated Coated implantable medical device
US20070150047A1 (en) 1995-06-07 2007-06-28 Med Institute, Inc. Implantable medical device with bioabsorbable coating
US5824049A (en) 1995-06-07 1998-10-20 Med Institute, Inc. Coated implantable medical device
US5865814A (en) 1995-06-07 1999-02-02 Medtronic, Inc. Blood contacting medical device and method
US5873904A (en) 1995-06-07 1999-02-23 Cook Incorporated Silver implantable medical device
US20070168012A1 (en) 1995-06-07 2007-07-19 Med Institute, Inc. Coated implantable medical device
US5888533A (en) 1995-10-27 1999-03-30 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US5977163A (en) 1996-03-12 1999-11-02 Pg-Txl Company, L. P. Water soluble paclitaxel prodrugs
US20010034363A1 (en) 1996-03-12 2001-10-25 Chun Li Water soluble paclitaxel derivatives
US6228393B1 (en) 1996-04-12 2001-05-08 Uroteq, Inc. Drug delivery via therapeutic hydrogels
US20070161967A1 (en) 1996-06-04 2007-07-12 Vance Products Inc., Dba Cook Urological Inc. Implantable medical device with pharmacologically active ingredient
US6143037A (en) 1996-06-12 2000-11-07 The Regents Of The University Of Michigan Compositions and methods for coating medical devices
US6039721A (en) 1996-07-24 2000-03-21 Cordis Corporation Method and catheter system for delivering medication with an everting balloon catheter
US5797887A (en) 1996-08-27 1998-08-25 Novovasc Llc Medical device with a surface adapted for exposure to a blood stream which is coated with a polymer containing a nitrosyl-containing organo-metallic compound which releases nitric oxide from the coating to mediate platelet aggregation
US5922730A (en) 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
US6306144B1 (en) 1996-11-01 2001-10-23 Scimed Life Systems, Inc. Selective coating of a balloon catheter with lubricious material for stent deployment
US20050123582A1 (en) 1996-11-05 2005-06-09 Hsing-Wen Sung Drug-eluting stent having collagen drug carrier chemically treated with genipin
US20020183380A1 (en) 1996-12-02 2002-12-05 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
US7208009B2 (en) 1996-12-26 2007-04-24 Medinol, Ltd. Stent fabrication method
US20070077347A1 (en) 1996-12-26 2007-04-05 Jacob Richter Flat process of drug coating for stents
US20040202712A1 (en) 1997-01-07 2004-10-14 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US5868719A (en) 1997-01-15 1999-02-09 Boston Scientific Corporation Drug delivery balloon catheter device
US5989591A (en) 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
WO1998043618A2 (en) 1997-03-31 1998-10-08 Neorx Corporation Use of cytoskeletal inhibitors for the prevention of restenosis
US20080317827A1 (en) 1997-04-18 2008-12-25 Cordis Corporation Methods and Devices for Delivering Therapeutic Agents to Target Vessels
US20070032694A1 (en) 1997-04-30 2007-02-08 Ludger Dinkelborg Stents with a radioactive surface coating, processes for their production and their use for restenosis prophylaxis
US5879697A (en) 1997-04-30 1999-03-09 Schneider Usa Inc Drug-releasing coatings for medical devices
US6042875A (en) 1997-04-30 2000-03-28 Schneider (Usa) Inc. Drug-releasing coatings for medical devices
US20010018072A1 (en) 1997-05-13 2001-08-30 Imarx Therapeutics, Inc. Solid matrix therapeutic compositions
US20020039594A1 (en) 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same
US6020315A (en) 1997-05-15 2000-02-01 Hoechst Aktiengesellschaft Preparation having increased in vivo tolerability
US6261630B1 (en) 1997-06-03 2001-07-17 Scimed Life Systems, Inc. Coating gradient for lubricious coatings on balloon catheters
US6221467B1 (en) 1997-06-03 2001-04-24 Scimed Life Systems, Inc. Coating gradient for lubricious coatings on balloon catheters
US6528150B2 (en) 1997-06-03 2003-03-04 Scimed Life Systems, Inc. Coating gradient for lubricious coatings on balloon catheters
US5985325A (en) 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration
US20010002435A1 (en) 1997-06-17 2001-05-31 Berg Eric P. Medical device for delivering a therapeutic substance and method therefor
US6306166B1 (en) 1997-08-13 2001-10-23 Scimed Life Systems, Inc. Loading and release of water-insoluble drugs
US20080021385A1 (en) 1997-08-13 2008-01-24 Scimed Life Systems, Inc. Loading and release of water-insoluble drugs
US20040201117A1 (en) 1997-09-09 2004-10-14 David Anderson Coated particles, methods of making and using
US6056722A (en) 1997-09-18 2000-05-02 Iowa-India Investments Company Limited Of Douglas Delivery mechanism for balloons, drugs, stents and other physical/mechanical agents and methods of use
US20020010419A1 (en) 1997-09-18 2002-01-24 Swaminathan Jayaraman Delivery mechanism for balloons, drugs, stents and other physical/mechanical agents and method of use
US6592548B2 (en) 1997-09-18 2003-07-15 Iowa-India Investments Company Limited Of Douglas Delivery mechanism for balloons, drugs, stents and other physical/mechanical agents and method of use
US6312406B1 (en) 1997-09-18 2001-11-06 Iowa-India Investments Company Limited Delivery mechanism for balloons, drugs, stents and other physical/mechanical agents and method of use
US6129705A (en) 1997-10-01 2000-10-10 Medtronic Ave, Inc. Drug delivery and gene therapy delivery system
US6958153B1 (en) 1997-11-07 2005-10-25 Wyeth Skin penetration enhancing components
US6287285B1 (en) 1998-01-30 2001-09-11 Advanced Cardiovascular Systems, Inc. Therapeutic, diagnostic, or hydrophilic coating for an intracorporeal medical device
US6221425B1 (en) 1998-01-30 2001-04-24 Advanced Cardiovascular Systems, Inc. Lubricious hydrophilic coating for an intracorporeal medical device
JP2002501788A (en) 1998-01-30 2002-01-22 アドヴァンスト カーディオヴァスキュラー システムズ インコーポレーテッド Hydrophilic coatings for medical devices for the body
US20020002353A1 (en) 1998-01-30 2002-01-03 Advanced Cardiovascular Systems, Inc. Therapeutic, diagnostic, or hydrophilic coating for an intracorporeal medical device
US6046230A (en) 1998-03-23 2000-04-04 Kyu-Nung Chung Stable injection formulation containing paclitaxel
US20090069883A1 (en) 1998-04-14 2009-03-12 Ni Ding Medical device with sponge coating for controlled drug release
US6364856B1 (en) 1998-04-14 2002-04-02 Boston Scientific Corporation Medical device with sponge coating for controlled drug release
US20020082552A1 (en) 1998-04-14 2002-06-27 Schneider (Usa) Inc. Medical device with sponge coating for controlled drug release
US20030157032A1 (en) 1998-04-18 2003-08-21 Pascal Cavaillon Pharmaceutical aerosol formulation
US20050182361A1 (en) 1998-05-18 2005-08-18 Boston Scientific Scimed, Inc. Localized delivery of drug agents
US6939320B2 (en) 1998-05-18 2005-09-06 Boston Scientific Scimed., Inc. Localized delivery of drug agents
US6280411B1 (en) 1998-05-18 2001-08-28 Scimed Life Systems, Inc. Localized delivery of drug agents
US6369039B1 (en) 1998-06-30 2002-04-09 Scimed Life Sytems, Inc. High efficiency local drug delivery
US6050980A (en) 1998-08-03 2000-04-18 My-Tech, Inc Thromboresistant plastic article and method of manufacture
US6015809A (en) 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
US6730064B2 (en) 1998-08-20 2004-05-04 Cook Incorporated Coated implantable medical device
US6299604B1 (en) 1998-08-20 2001-10-09 Cook Incorporated Coated implantable medical device
US7235096B1 (en) 1998-08-25 2007-06-26 Tricardia, Llc Implantable device for promoting repair of a body lumen
US6589546B2 (en) 1998-08-28 2003-07-08 Scimed Life Systems, Inc. Polymeric coatings for controlled delivery of active agents
US6335029B1 (en) 1998-08-28 2002-01-01 Scimed Life Systems, Inc. Polymeric coatings for controlled delivery of active agents
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US6218016B1 (en) 1998-09-29 2001-04-17 Medtronic Ave, Inc. Lubricious, drug-accommodating coating
US6299980B1 (en) 1998-09-29 2001-10-09 Medtronic Ave, Inc. One step lubricious coating
US20070219642A1 (en) 1998-12-03 2007-09-20 Jacob Richter Hybrid stent having a fiber or wire backbone
US20020151844A1 (en) 1999-02-03 2002-10-17 Scimed Life Systems, Inc., A Subsidiary Of Boston Scientific Corporation. Dual surface protection coating for drug delivery balloon catheters and stents
US6656156B2 (en) 1999-02-03 2003-12-02 Scimed Life Systems, Inc. Dual surface protection coating for drug delivery balloon catheters and stents
US6419692B1 (en) 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6176849B1 (en) 1999-05-21 2001-01-23 Scimed Life Systems, Inc. Hydrophilic lubricity coating for medical devices comprising a hydrophobic top coat
US6589215B2 (en) 1999-05-21 2003-07-08 Scimed Life Systems, Inc. Hydrophilic lubricity coating for medical devices comprising a hydrophobic top coat
US6610035B2 (en) 1999-05-21 2003-08-26 Scimed Life Systems, Inc. Hydrophilic lubricity coating for medical devices comprising a hybrid top coat
US20020041896A1 (en) 1999-05-27 2002-04-11 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
US6576224B1 (en) 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6331547B1 (en) 1999-08-18 2001-12-18 American Home Products Corporation Water soluble SDZ RAD esters
US6682545B1 (en) 1999-10-06 2004-01-27 The Penn State Research Foundation System and device for preventing restenosis in body vessels
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6899731B2 (en) 1999-12-30 2005-05-31 Boston Scientific Scimed, Inc. Controlled delivery of therapeutic agents by insertable medical devices
US20030216699A1 (en) 2000-05-12 2003-11-20 Robert Falotico Coated medical devices for the prevention and treatment of vascular disease
JP2003533286A (en) 2000-05-16 2003-11-11 オーソーマクニール ファーマシューティカル, インコーポレイテッド Coating methods of medical devices using a supercritical carbon dioxide
WO2001087368A1 (en) 2000-05-16 2001-11-22 Ortho-Mcneil Pharmaceutical, Inc. Process for coating medical devices using super-critical carbon dioxide
US20040018296A1 (en) 2000-05-31 2004-01-29 Daniel Castro Method for depositing a coating onto a surface of a prosthesis
US6395326B1 (en) 2000-05-31 2002-05-28 Advanced Cardiovascular Systems, Inc. Apparatus and method for depositing a coating onto a surface of a prosthesis
US6506408B1 (en) 2000-07-13 2003-01-14 Scimed Life Systems, Inc. Implantable or insertable therapeutic agent delivery device
US20030207939A1 (en) 2000-08-10 2003-11-06 Seigo Ishibuchi Novel 3-substituted urea derivatives and medicinal use thereof
US6432973B1 (en) 2000-09-19 2002-08-13 Wyeth Water soluble rapamycin esters
US7056550B2 (en) 2000-09-29 2006-06-06 Ethicon, Inc. - Usa Medical devices, drug coatings and methods for maintaining the drug coatings thereon
US20020098278A1 (en) 2000-10-31 2002-07-25 Cook Incorporated Coated implantable medical device
US20090136560A1 (en) 2000-10-31 2009-05-28 Bates Brian L Coated medical device
US20050278021A1 (en) 2000-10-31 2005-12-15 Med Institute, Inc. Coated medical device
US20050191323A1 (en) 2000-11-28 2005-09-01 Hongming Chen Pharmaceutical formulations comprising paclitaxel, derivatives and pharmaceutically acceptable salts thereof
US20030207936A1 (en) 2000-11-28 2003-11-06 Hongming Chen Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
US20020102280A1 (en) 2000-11-29 2002-08-01 Anderson David M. Solvent systems for pharmaceutical agents
US6444324B1 (en) 2000-12-01 2002-09-03 Scimed Life Systems, Inc. Lubricated catheter balloon
US20020077684A1 (en) 2000-12-20 2002-06-20 Medtronic, Inc. Perfusion lead and method of use
US7077859B2 (en) 2000-12-22 2006-07-18 Avantec Vascular Corporation Apparatus and methods for variably controlled substance delivery from implanted prostheses
US7179251B2 (en) 2001-01-17 2007-02-20 Boston Scientific Scimed, Inc. Therapeutic delivery balloon
US20020095114A1 (en) 2001-01-17 2002-07-18 Maria Palasis Therapeutic delivery balloon
US20070162103A1 (en) 2001-02-05 2007-07-12 Cook Incorporated Implantable device with remodelable material and covering material
US6571125B2 (en) 2001-02-12 2003-05-27 Medtronic, Inc. Drug delivery device
EP1372737B1 (en) 2001-03-26 2006-08-02 Ulrich Speck Preparation for the prophylaxis of restenosis
EP1669092B1 (en) 2001-03-26 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Preparation for the prophylaxis of restenose
US20080102034A1 (en) 2001-03-26 2008-05-01 Ulrich Speck Preparation for the prophylaxis of restenosis
US20050250672A9 (en) 2001-03-26 2005-11-10 Ulrich Speck Preparation for the prophylaxis of restenosis
US20050101522A1 (en) 2001-03-26 2005-05-12 Ulrich Speck Preparation for the prophylaxis of restenosis
DE10115740A1 (en) 2001-03-26 2002-10-02 Ulrich Speck Preparation for the prophylaxis of restenosis
EP1666071B1 (en) 2001-03-26 2007-08-15 Bayer Schering Pharma Aktiengesellschaft Preparation for the prophylaxis of restenose
EP1666070B1 (en) 2001-03-26 2007-09-05 Bayer Schering Pharma Aktiengesellschaft Preparation for the prophylaxis of restenose
US20080102033A1 (en) 2001-03-26 2008-05-01 Ulrich Speck Preparation for the prophylaxis of restenosis
US20030157161A1 (en) 2001-05-01 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
US20020192280A1 (en) 2001-05-01 2002-12-19 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
US20030008923A1 (en) 2001-06-01 2003-01-09 Wyeth Antineoplastic combinations
US6991809B2 (en) 2001-06-23 2006-01-31 Lyotropic Therapeutics, Inc. Particles with improved solubilization capacity
US20030045587A1 (en) 2001-06-23 2003-03-06 David Anderson Solvent system
US7175873B1 (en) 2001-06-27 2007-02-13 Advanced Cardiovascular Systems, Inc. Rate limiting barriers for implantable devices and methods for fabrication thereof
US7247313B2 (en) 2001-06-27 2007-07-24 Advanced Cardiovascular Systems, Inc. Polyacrylates coatings for implantable medical devices
EP1270018A1 (en) 2001-06-29 2003-01-02 Ethicon Inc. Sterilization of bioactive coatings
US7214198B2 (en) 2001-06-29 2007-05-08 Medtronic, Inc. Catheter system having disposable balloon
US6921390B2 (en) 2001-07-23 2005-07-26 Boston Scientific Scimed, Inc. Long-term indwelling medical devices containing slow-releasing antimicrobial agents and having a surfactant surface
US6680330B2 (en) 2001-08-22 2004-01-20 Wyeth Rapamycin dialdehydes
US20030114477A1 (en) 2001-08-22 2003-06-19 Wyeth Rapamycin 29-Enols
US20030100577A1 (en) 2001-08-22 2003-05-29 Wyeth Rapamycin dialdehydes
US6677357B2 (en) 2001-08-22 2004-01-13 Wyeth Rapamycin 29-enols
US7172619B2 (en) 2001-08-27 2007-02-06 Medinol, Ltd. Single operator stenting system
US20070150043A1 (en) 2001-08-27 2007-06-28 Jacob Richter Single Operator Stenting System
US7547294B2 (en) 2001-09-20 2009-06-16 The Regents Of The University Of California Microfabricated surgical device for interventional procedures
US20030064965A1 (en) 2001-10-02 2003-04-03 Jacob Richter Method of delivering drugs to a tissue using drug-coated medical devices
US7226586B2 (en) 2001-10-04 2007-06-05 Medtronic Vascular, Inc. Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use
US6893431B2 (en) 2001-10-15 2005-05-17 Scimed Life Systems, Inc. Medical device for delivering patches
EP1576970B1 (en) 2001-11-08 2010-03-24 Ziscoat N.V. Intraluminal device with a coating containing a therapeutic agent
US20070167735A1 (en) 2001-11-27 2007-07-19 Sheng-Ping Zhong Implantable or insertable medical devices visible under magnetic resonance imaging
US20050159704A1 (en) 2001-11-29 2005-07-21 Neal Scott High concentration medicament and polymer coated device for passive diffusional medicament delivery
US7292885B2 (en) 2001-11-29 2007-11-06 Boston Scientific Scimed, Inc. Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment
US20030100887A1 (en) 2001-11-29 2003-05-29 Neal Scott Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment
US20030100886A1 (en) 2001-11-29 2003-05-29 Jerome Segal Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment
US20050054978A1 (en) 2001-11-29 2005-03-10 Jerome Segal Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment
US20050038409A1 (en) 2001-11-29 2005-02-17 Jerome Segal Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment
US7160317B2 (en) 2002-01-04 2007-01-09 Boston Scientific Scimed, Inc. Multiple-wing balloon catheter to reduce damage to coated expandable medical implants
US20030235602A1 (en) 2002-06-19 2003-12-25 Schwarz Marlene C. Implantable or insertable medical devices for controlled delivery of a therapeutic agent
US20040002755A1 (en) 2002-06-28 2004-01-01 Fischell David R. Method and apparatus for treating vulnerable coronary plaques using drug-eluting stents
US20060020331A1 (en) 2002-07-12 2006-01-26 Cook Incorporated Coated medical device
WO2004006976A1 (en) 2002-07-12 2004-01-22 Cook Incorporated Coated medical device
US20040073284A1 (en) 2002-07-12 2004-04-15 Cook Incorporated Coated medical device
US7294329B1 (en) 2002-07-18 2007-11-13 Advanced Cardiovascular Systems, Inc. Poly(vinyl acetal) coatings for implantable medical devices
US20070059434A1 (en) 2002-07-18 2007-03-15 Roorda Wouter E Rate limiting barriers for implantable devices and methods for fabrication thereof
US20040167152A1 (en) 2002-07-30 2004-08-26 Wyeth Parenteral formulations
US20040156816A1 (en) 2002-08-06 2004-08-12 David Anderson Lipid-drug complexes in reversed liquid and liquid crystalline phases
US20050191333A1 (en) 2002-08-26 2005-09-01 Biotegra, Inc. Drug eluting coatings for medical implants and methods of use
US20040037886A1 (en) 2002-08-26 2004-02-26 Li-Chien Hsu Drug eluting coatings for medical implants
US20040077677A1 (en) 2002-09-17 2004-04-22 Wyeth Oral formulations
US20070078513A1 (en) 2002-09-18 2007-04-05 Medtronic Vascular, Inc. Controllable drug releasing gradient coatings for medical devices
WO2004028582A1 (en) 2002-09-20 2004-04-08 Ulrich Speck Medical device for dispensing medicaments
WO2004028610A2 (en) 2002-09-20 2004-04-08 Bavaria Medizin Technologie Gmbh Medical device for dispensing medicaments
EP1539266B1 (en) 2002-09-20 2008-04-09 Bayer Schering Pharma Aktiengesellschaft Medical device for dispensing medicaments
EP1539267A2 (en) 2002-09-20 2005-06-15 Bavaria Medizin Technologie GmbH Medical device for dispensing medicaments
EP1857127A1 (en) 2002-09-20 2007-11-21 Bayer Schering Pharma Aktiengesellschaft Bolloon catheter for Paclitaxel-release
US20060020243A1 (en) 2002-09-20 2006-01-26 Ulrich Speck Medical device for dispensing medicaments
WO2004026357A1 (en) 2002-09-23 2004-04-01 Conor Medsystems, Inc. Therapeutic agent delivery device with protective separating layer
US7060051B2 (en) 2002-09-24 2006-06-13 Scimed Life Systems, Inc. Multi-balloon catheter with hydrogel coating
US7232573B1 (en) 2002-09-26 2007-06-19 Advanced Cardiovascular Systems, Inc. Stent coatings containing self-assembled monolayers
US20070218246A1 (en) 2002-09-26 2007-09-20 Advanced Cardiovascular Systems, Inc. Stent coatings containing self-assembled monolayers
US7008411B1 (en) 2002-09-30 2006-03-07 Advanced Cardiovascular Systems, Inc. Method and apparatus for treating vulnerable plaque
US7282213B2 (en) 2002-09-30 2007-10-16 Medtronic, Inc. Method for applying a drug coating to a medical device
US20050251249A1 (en) 2002-10-11 2005-11-10 Sahatjian Ronald A Endoprostheses
US7048714B2 (en) 2002-10-30 2006-05-23 Biorest Ltd. Drug eluting medical device with an expandable portion for drug release
US20040087902A1 (en) 2002-10-30 2004-05-06 Jacob Richter Drug eluting medical device with an expandable portion for drug release
US20040097485A1 (en) 2002-10-31 2004-05-20 Tularik Inc. Antiinflammation agents
US7025752B2 (en) 2002-11-06 2006-04-11 Advanced Cardiovascular Systems, Inc. Reduced slippage balloon catheter and method of using same
US6918869B2 (en) 2002-12-02 2005-07-19 Scimed Life Systems System for administering a combination of therapies to a body lumen
US20040127551A1 (en) 2002-12-27 2004-07-01 Kai Zhang Taxane-based compositions and methods of use
US20040225077A1 (en) 2002-12-30 2004-11-11 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US20040197408A1 (en) 2002-12-30 2004-10-07 Angiotech International Ag Amino acids in micelle preparation
US20040219214A1 (en) 2002-12-30 2004-11-04 Angiotech International Ag Tissue reactive compounds and compositions and uses thereof
US7108684B2 (en) 2003-01-02 2006-09-19 Novoste Corporation Drug delivery balloon catheter
US7144419B2 (en) 2003-01-24 2006-12-05 Medtronic Vascular, Inc. Drug-polymer coated stent with blended phenoxy and styrenic block copolymers
US20040224003A1 (en) 2003-02-07 2004-11-11 Schultz Robert K. Drug formulations for coating medical devices
US20080274159A1 (en) 2003-02-07 2008-11-06 Reva Medical, Inc. Drug formulations for coating medical devices
US20040176339A1 (en) 2003-03-05 2004-09-09 Wyeth Antineoplastic combinations
WO2004089291A2 (en) 2003-04-03 2004-10-21 Au Jessie L-S Tumor-targeting drug-loaded particles
US7163555B2 (en) 2003-04-08 2007-01-16 Medtronic Vascular, Inc. Drug-eluting stent for controlled drug delivery
EP1468660B1 (en) 2003-04-15 2011-12-21 Medtronic Vascular, Inc. Stent delivery system, device, and method for coating
US7306580B2 (en) 2003-04-16 2007-12-11 Cook Incorporated Medical device with therapeutic agents
US7198637B2 (en) 2003-04-21 2007-04-03 Medtronic Vascular, Inc. Method and system for stent retention using an adhesive
US20040258662A1 (en) 2003-04-22 2004-12-23 Wyeth Antineoplastic agents
US20040230176A1 (en) 2003-04-23 2004-11-18 Medtronic Vascular, Inc. System for treating a vascular condition that inhibits restenosis at stent ends
US20080215137A1 (en) 2003-04-30 2008-09-04 Boston Scientific Scimed, Inc. Therapeutic driving layer for a medical device
US20040224001A1 (en) 2003-05-08 2004-11-11 Pacetti Stephen D. Stent coatings comprising hydrophilic additives
US7524527B2 (en) 2003-05-19 2009-04-28 Boston Scientific Scimed, Inc. Electrostatic coating of a device
US7285304B1 (en) 2003-06-25 2007-10-23 Advanced Cardiovascular Systems, Inc. Fluid treatment of a polymeric coating on an implantable medical device
US20050042268A1 (en) 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
WO2005011769A2 (en) 2003-07-31 2005-02-10 Scimed Life Systems, Inc. Implantable or insertable medical devices containing acrylic copolymer for controlled delivery of therapeutic agent
US20050025802A1 (en) 2003-07-31 2005-02-03 Richard Robert E. Implantable or insertable medical devices containing acrylic copolymer for controlled delivery of therapeutic agent
US7153957B2 (en) 2003-08-07 2006-12-26 Wyeth Regioselective synthesis of CCI-779
US20050049271A1 (en) 2003-09-03 2005-03-03 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions
US20050055078A1 (en) 2003-09-04 2005-03-10 Medtronic Vascular, Inc. Stent with outer slough coating
US20060112536A1 (en) 2003-09-15 2006-06-01 Atrium Medical Corporation Method of coating a folded medical device
US20050100580A1 (en) 2003-10-14 2005-05-12 Cook Incorporated Hydrophilic coated medical device
US20050209664A1 (en) 2003-11-20 2005-09-22 Angiotech International Ag Electrical devices and anti-scarring agents
US20050186244A1 (en) 2003-11-20 2005-08-25 Angiotech International Ag Polymer compositions and methods for their use
US20050152983A1 (en) 2004-01-08 2005-07-14 Wyeth Directly compressible pharmaceutical composition for the oral administration of CCI-779
US20050171596A1 (en) 2004-02-03 2005-08-04 Furst Joseph G. Stents with amphiphilic copolymer coatings
US20050010170A1 (en) 2004-02-11 2005-01-13 Shanley John F Implantable medical device with beneficial agent concentration gradient
US20080038307A1 (en) 2004-02-28 2008-02-14 Erika Hoffmann Biocompatible Coating, Method, and Use of Medical Surfaces
US20050192210A1 (en) 2004-03-01 2005-09-01 Rothbard Jonathan B. Compositions and methods for treating diseases
US7557087B2 (en) 2004-03-01 2009-07-07 Lumen Therapeutics, Llc Compositions and methods for treating diseases
US20050272758A1 (en) 2004-03-11 2005-12-08 Wyeth Antineoplastic combinations of CCI-779 and rituximab
US20100030183A1 (en) 2004-03-19 2010-02-04 Toner John L Method of treating vascular disease at a bifurcated vessel using a coated balloon
US20050246009A1 (en) 2004-03-19 2005-11-03 Toner John L Multiple drug delivery from a balloon and a prosthesis
US20050222191A1 (en) 2004-03-31 2005-10-06 Robert Falotico Solution formulations of sirolimus and its analogs for CAD treatment
US7244444B2 (en) 2004-03-31 2007-07-17 Cook Incorporated Graft material, stent graft and method
US20050234234A1 (en) 2004-04-14 2005-10-20 Wyeth Regiospecific synthesis of rapamycin 42-ester derivatives
US20050234087A1 (en) 2004-04-14 2005-10-20 Wyeth Process for preparing rapamycin 42-esters and FK-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies
EP1586338B1 (en) 2004-04-14 2011-01-26 Cordis Corporation The use of antioxidants to prevent oxidation and reduce drug degradation in drug eluting medical devices
US20050234086A1 (en) 2004-04-14 2005-10-20 Wyeth Proline CCI-779, production of and uses therefor, and two-step enzymatic synthesis of proline CCI-779 and CCI-779
US20050238584A1 (en) 2004-04-21 2005-10-27 Ananth Annapragada Compositions and methods for enhancing contrast in imaging
US20050239178A1 (en) 2004-04-27 2005-10-27 Wyeth Labeling of rapamycin using rapamycin-specific methylases
US20050288481A1 (en) 2004-04-30 2005-12-29 Desnoyer Jessica R Design of poly(ester amides) for the control of agent-release from polymeric compositions
US20050256564A1 (en) 2004-05-13 2005-11-17 Medtronic Vascular, Inc. Intraluminal stent including therapeutic agent delivery pads, and method of manufacturing the same
US20060015170A1 (en) 2004-07-16 2006-01-19 Jones Ryan A Contrast coated stent and method of fabrication
US20090238854A1 (en) 2004-08-05 2009-09-24 Advanced Cardiovascular Systems, Inc. Plasticizers for coating compositions
US20060040971A1 (en) 2004-08-20 2006-02-23 Wyeth Rapamycin polymorphs and uses thereof
WO2006023859A1 (en) 2004-08-20 2006-03-02 Medtronic, Inc. Medical device with tissue-dependent drug elution
US20060045901A1 (en) 2004-08-26 2006-03-02 Jan Weber Stents with drug eluting coatings
US20090324682A1 (en) 2004-08-30 2009-12-31 Youri Popowski Medical stent provided with inhibitors of atp synthesis
US20060051392A1 (en) 2004-09-03 2006-03-09 Medtronic, Inc. Porous coatings for drug release from medical devices
US20060052744A1 (en) 2004-09-03 2006-03-09 Jan Weber Method of coating a medical device using an electrowetting process, system for using the method, and device made by the method
US7507433B2 (en) 2004-09-03 2009-03-24 Boston Scientific Scimed, Inc. Method of coating a medical device using an electrowetting process
US20090208552A1 (en) 2004-09-28 2009-08-20 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US20060067977A1 (en) 2004-09-28 2006-03-30 Atrium Medical Corporation Pre-dried drug delivery coating for use with a stent
US20090047414A1 (en) 2004-09-28 2009-02-19 Atrium Medical Corporation Method and apparatus for application of a fresh coating on a medical device
US20090181937A1 (en) 2004-09-28 2009-07-16 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US20090011116A1 (en) 2004-09-28 2009-01-08 Atrium Medical Corporation Reducing template with coating receptacle containing a medical device to be coated
US7176261B2 (en) 2004-10-21 2007-02-13 Medtronic, Inc. Angiotensin-(1-7) eluting polymer-coated medical device to reduce restenosis and improve endothelial cell function
US20060094745A1 (en) 2004-10-28 2006-05-04 Wyeth Use of an mTOR inhibitor in treatment of uterine leiomyoma
WO2006056984A2 (en) 2004-11-26 2006-06-01 Stentomics Inc. Chelating and binding chemicals to a medical implant
US20060135550A1 (en) 2004-12-20 2006-06-22 Wyeth Rapamycin derivatives and the uses thereof in the treatment of neurological disorders
US20060135549A1 (en) 2004-12-20 2006-06-22 Wyeth Rapamycin analogues and the uses thereof in the treatment of neurological, proliferative,and inflammatory disorders
US20060173528A1 (en) 2005-01-10 2006-08-03 Trireme Medical, Inc. Stent with self-deployable portion
US20060165753A1 (en) 2005-01-25 2006-07-27 Richard Robert E Medical device drug release regions containing non-covalently bound polymers
WO2006081210A2 (en) 2005-01-25 2006-08-03 Boston Scientific Scimed, Inc. Medical device with drug release regions containing pseudo - block copolymers
US20060188543A1 (en) 2005-01-31 2006-08-24 Si-Shen Feng Nanoparticle coating for drug delivery
US20060184236A1 (en) 2005-02-11 2006-08-17 Medtronic Vascular, Inc. Intraluminal device including an optimal drug release profile, and method of manufacturing the same
US20080262412A1 (en) 2005-02-11 2008-10-23 Boston Scientific Scimed, Inc. Internal medical devices for delivery of therapeutic agent in conjunction with a source of electrical power
US20060183766A1 (en) 2005-02-15 2006-08-17 Wyeth Orally bioavailable CCI-779 formulations
US20060199954A1 (en) 2005-03-02 2006-09-07 Wyeth Purification of rapamycin
US20060224237A1 (en) 2005-03-03 2006-10-05 Icon Medical Corp. Fragile structure protective coating
US20060199834A1 (en) 2005-03-07 2006-09-07 Wyeth Oxepane isomer of 42-O-(2-hydroxy)ethyl-rapamycin
WO2006101573A1 (en) 2005-03-21 2006-09-28 Boston Scientific Limited Coatings for use on medical devices
US20060257450A1 (en) 2005-03-21 2006-11-16 Sreenivasu Mudumba Drug delivery systems for treatment of diseases or conditions
US20060230476A1 (en) 2005-03-30 2006-10-12 Boston Scientific Scimed, Inc. Polymeric/ceramic composite materials for use in medical devices
US20080194494A1 (en) 2005-04-26 2008-08-14 Microbia, Inc. 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia
US20060257445A1 (en) 2005-04-29 2006-11-16 Medtronic, Inc. Devices for augmentation of lumen walls
US20060257444A1 (en) 2005-04-29 2006-11-16 Medtronic, Inc. Devices for augmentation of lumen walls
WO2006124647A1 (en) 2005-05-13 2006-11-23 Cook Incorporated Medical device delivery systems that facilitate medical device placement in the presence of ultrasonic waves
US20060282114A1 (en) 2005-06-09 2006-12-14 Medtronic Vascular, Inc. Embolic protection apparatus with vasodilator coating
US20100068238A1 (en) 2005-07-15 2010-03-18 Nandkishore Managoli Implantable Medical Devices Comprising a Flavonoid or Derivative Thereof for Prevention of Restenosis
US20070020308A1 (en) 2005-07-19 2007-01-25 Richard Robert E Polymers having covalently bound therapeutic agents
US20070020380A1 (en) 2005-07-25 2007-01-25 Ni Ding Methods of providing antioxidants to a drug containing product
US20070198080A1 (en) 2005-07-25 2007-08-23 Ni Ding Coatings including an antioxidant
US20070078446A1 (en) 2005-08-31 2007-04-05 Cook Ireland Limited And Cook Incorporated Stent for implantation
US20070276466A1 (en) 2005-08-31 2007-11-29 Vance Products Inc., D/B/A/ Cook Urological Inc. Stent for implantation
US20070073385A1 (en) 2005-09-20 2007-03-29 Cook Incorporated Eluting, implantable medical device
US20070065484A1 (en) 2005-09-21 2007-03-22 Chudzik Stephen J In situ occlusion using natural biodegradable polysaccharides
WO2007047416A2 (en) 2005-10-14 2007-04-26 Abbott Laboratories Compositions and methods of administering rapamycin analogs with paclitaxel using medical devices
US20090010987A1 (en) 2005-11-02 2009-01-08 Conor Medsystems, Inc. Methods and Devices for Reducing Tissue Damage After Ischemic Injury
WO2007061529A1 (en) 2005-11-18 2007-05-31 Scidose Llc. Lyophilization process and products obtained thereby
US20070117925A1 (en) 2005-11-23 2007-05-24 Strickler Frederick H Medical devices having polymeric regions that contain fluorocarbon-containing block copolymers
US20070128118A1 (en) 2005-12-05 2007-06-07 Nitto Denko Corporation Polyglutamate-amino acid conjugates and methods
US20070142772A1 (en) 2005-12-16 2007-06-21 Medtronic Vascular, Inc. Dual-Layer Medical Balloon
US20070142905A1 (en) 2005-12-16 2007-06-21 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
US20070142422A1 (en) 2005-12-20 2007-06-21 Wyeth Control of CCI-779 dosage form stability through control of drug substance impurities
US20090035390A1 (en) 2006-01-06 2009-02-05 Modak Shanta M Compositions containing zinc salts for coating medical articles
WO2007079560A2 (en) 2006-01-13 2007-07-19 Brz Biotecnologia Ltda Pharmaceutical compounds that contain nanoparticles useful for treating restenotic lesions
US20090215882A1 (en) 2006-01-20 2009-08-27 Eriochem, S.A. Lyophilized solid taxane composition, a process for preparing said solid composition, a pharmaceutical formulation and a kit for said formulation
US20070207184A1 (en) 2006-01-27 2007-09-06 Med Institute, Inc Implantable medical device coated with a bioactive agent
US20070184083A1 (en) 2006-02-07 2007-08-09 Medtronic Vascular, Inc. Drug-Eluting Device for Treatment of Chronic Total Occlusions
US20070190103A1 (en) 2006-02-10 2007-08-16 Hossainy Syed F A Implantable medical device with surface-eroding polyester drug delivery coating
US20070191934A1 (en) 2006-02-10 2007-08-16 Medtronic Vascular, Inc. Medical Devices to Prevent or Inhibit Restenosis
US20070244548A1 (en) 2006-02-27 2007-10-18 Cook Incorporated Sugar-and drug-coated medical device
US20070212386A1 (en) 2006-03-08 2007-09-13 Sahajanand Medical Technologies Pvt. Ltd. Coatings for implantable medical devices
US20080183282A1 (en) 2006-03-09 2008-07-31 Saul Yedgar Use of lipid conjugates for the coating of stents and catheters
US20070212394A1 (en) 2006-03-10 2007-09-13 Cook Incorporated Taxane coatings for implantable medical devices
US20070225799A1 (en) 2006-03-24 2007-09-27 Medtronic Vascular, Inc. Stent, intraluminal stent delivery system, and method of treating a vascular condition
US20070237803A1 (en) 2006-04-11 2007-10-11 Medtronic Vascular, Inc. Biodegradable Biocompatible Amphiphilic Copolymers for Coating and Manufacturing Medical Devices
US20070244284A1 (en) 2006-04-14 2007-10-18 Medtronic Vascular, Inc. Durable Biocompatible Controlled Drug Release Polymeric Coatings for Medical Devices
US20070282422A1 (en) 2006-05-10 2007-12-06 Cook Incorporated Medical devices and methods for local delivery of elastin-stabilizing compounds
WO2007134239A2 (en) 2006-05-12 2007-11-22 Cordis Corporation Balloon expandable bioabsorbable drug eluting flexible stent
US20070265565A1 (en) 2006-05-15 2007-11-15 Medtronic Vascular, Inc. Mesh-Reinforced Catheter Balloons and Methods for Making the Same
US20070264307A1 (en) 2006-05-15 2007-11-15 Medtronic Vascular, Inc. Biodegradable Modified Caprolactone Polymers for Fabricating and Coating Medical Devices
WO2007139931A2 (en) 2006-05-26 2007-12-06 Abbott Cardiovascular Systems Inc. Bioabsorbable stent with radiopaque coating
US20070286814A1 (en) 2006-06-12 2007-12-13 Medispray Laboratories Pvt. Ltd. Stable aerosol pharmaceutical formulations
WO2007149161A2 (en) 2006-06-22 2007-12-27 Boston Scientific Scimed, Inc. Control realease drug coating for medical devices
US20070298069A1 (en) 2006-06-26 2007-12-27 Boston Scientific Scimed, Inc. Medical devices for release of low solubility therapeutic agents
US20110152907A1 (en) 2006-06-30 2011-06-23 Atheromed, Inc. Devices, systems, and methods for performing atherectomy including delivery of a bioactive material
US20110152906A1 (en) 2006-06-30 2011-06-23 Atheromed, Inc. Devices, systems, and methods for debulking restenosis of a blood vessel
WO2008003298A2 (en) 2006-07-03 2008-01-10 Hemoteq Ag Manufacture, method, and use of active substance-releasing medical products for permanently keeping blood vessels open
US20080233062A1 (en) 2006-08-24 2008-09-25 Venkataram Krishnan Cationic latex as a carrier for active ingredients and methods for making and using the same
US20080082552A1 (en) 2006-10-02 2008-04-03 Autodesk, Inc. Data locality in a serialized object stream
EP1913962A1 (en) 2006-10-22 2008-04-23 Ophir Perelson Expandable medical device for the treatment and prevention of cardiovascular diseases
US20080114331A1 (en) 2006-11-14 2008-05-15 Holman Thomas J Medical devices and related methods
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20130261603A1 (en) 2006-11-20 2013-10-03 Lutonix, Inc. Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US20130197436A1 (en) 2006-11-20 2013-08-01 Lutonix, Inc. Drug releasing coatings for medical devices
US20130197434A1 (en) 2006-11-20 2013-08-01 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20110166548A1 (en) 2006-11-20 2011-07-07 Lixiao Wang Drug releasing coatings for medical devices
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US9289539B2 (en) 2006-11-20 2016-03-22 Lutonix, Inc. Drug releasing coatings for medical devices
WO2008063576A2 (en) 2006-11-20 2008-05-29 Lutonix, Inc. Drug releasing coatings for medical devices
US20130197435A1 (en) 2006-11-20 2013-08-01 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US20080118544A1 (en) 2006-11-20 2008-05-22 Lixiao Wang Drug releasing coatings for medical devices
US20130189190A1 (en) 2006-11-20 2013-07-25 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US20130189329A1 (en) 2006-11-20 2013-07-25 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20110160660A1 (en) 2006-11-20 2011-06-30 Lutonix, Inc. Drug releasing coatings for medical devices
US8241249B2 (en) 2006-11-20 2012-08-14 Lutonix, Inc. Drug releasing coatings for medical devices
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20120029426A1 (en) 2006-11-20 2012-02-02 Lutonix, Inc. Drug releasing coatings for medical devices
US8932561B2 (en) 2006-11-20 2015-01-13 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US20080255510A1 (en) 2006-11-20 2008-10-16 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8404300B2 (en) 2006-11-20 2013-03-26 Lutonix, Inc. Drug releasing coatings for medical devices
US8403910B2 (en) 2006-11-20 2013-03-26 Lutonix, Inc. Drug releasing coatings for medical devices
US20080255509A1 (en) 2006-11-20 2008-10-16 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US20080255508A1 (en) 2006-11-20 2008-10-16 Lutonix, Inc. Drug releasing coatings for medical devices
US8366660B2 (en) 2006-11-20 2013-02-05 Lutonix, Inc. Drug releasing coatings for medical devices
US20110159169A1 (en) 2006-11-20 2011-06-30 Lutonix, Inc. Drug releasing coatings for medical devices
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8366662B2 (en) 2006-11-20 2013-02-05 Lutonix, Inc. Drug releasing coatings for medical devices
US8244344B2 (en) 2006-11-20 2012-08-14 Lutonix, Inc. Drug releasing coatings for medical devices
US20100209472A1 (en) 2006-11-20 2010-08-19 Lixiao Wang Drug releasing coatings for medical devices
US20130197431A1 (en) 2006-11-20 2013-08-01 Lutonix, Inc. Drug releasing coatings for medical devices
US20120035530A1 (en) 2006-11-20 2012-02-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20110160658A1 (en) 2006-11-20 2011-06-30 Lutonix, Inc. Drug releasing coatings for medical devices
US20080140002A1 (en) 2006-12-06 2008-06-12 Kamal Ramzipoor System for delivery of biologically active substances with actuating three dimensional surface
US20100179475A1 (en) 2007-01-21 2010-07-15 Erika Hoffmann Medical product for treating stenosis of body passages and for preventing threatening restenosis
WO2008086794A2 (en) 2007-01-21 2008-07-24 Hemoteq Ag Medical product for treating stenosis of body passages and for preventing threatening restenosis
EP1970185A2 (en) 2007-03-14 2008-09-17 Cordis Corporation An apparatus and method for making a vascular stent
WO2008114585A1 (en) 2007-03-20 2008-09-25 Terumo Kabushiki Kaisha Coating method and coating device
EP2127617A1 (en) 2007-03-20 2009-12-02 Terumo Kabushiki Kaisha Coating method and coating device
US20080255658A1 (en) 2007-04-12 2008-10-16 Medtronic Vascular, Inc. Degradation Associated Drug Delivery for Drug Eluting Stent and Medical Device Coatings
US20080274266A1 (en) 2007-05-02 2008-11-06 Davis Liza J Selective Application Of Therapeutic Agent to a Medical Device
US20090105686A1 (en) 2007-06-29 2009-04-23 Xtent, Inc. Adjustable-length drug delivery balloon
US9220875B2 (en) 2007-08-03 2015-12-29 Invatec Technology Center Gmbh Pharmaceutical-coated medical products, the production thereof and the use thereof
WO2009018816A2 (en) 2007-08-03 2009-02-12 Innora Gmbh Improved pharmaceutical-coated medical products, the production thereof and the use thereof
US20110137243A1 (en) 2007-09-06 2011-06-09 Abbott Cardiovascular Systems Inc. Coating On A Balloon Device
US20110129514A1 (en) 2007-09-06 2011-06-02 Hossainy Syed F A Hygroscopic coating on a balloon device
US20090098176A1 (en) 2007-09-10 2009-04-16 Boston Scientific Scimed, Inc. Medical devices with triggerable bioadhesive material
US20110060275A1 (en) 2007-09-12 2011-03-10 Cook Incorporated Drug Eluting Balloon
US20090076448A1 (en) 2007-09-17 2009-03-19 Consigny Paul M Methods and devices for eluting agents to a vessel
US20090105687A1 (en) 2007-10-05 2009-04-23 Angioscore, Inc. Scoring catheter with drug delivery membrane
CN101264347A (en) 2007-11-27 2008-09-17 天津百畅医疗器械科技有限公司 Drug-eluting coated on surface of sacculus catheter air bag for alleviating vascular restenosis
CN101185779A (en) 2007-12-19 2008-05-28 上海赢生医疗科技有限公司 Method for preparing medicine sustained-releasing bracket
US20090182273A1 (en) 2008-01-11 2009-07-16 Medtronic Vascular, Inc. Methods for Incorporating a Drug into an Elastomeric Medical Device
US20090187144A1 (en) 2008-01-18 2009-07-23 Swaminathan Jayaraman Delivery of therapeutic and marking substance through intra lumen expansion of a delivery device
US20090227949A1 (en) 2008-03-06 2009-09-10 Boston Scientific Scimed, Inc. Balloon catheter devices with folded balloons
US20090227948A1 (en) 2008-03-06 2009-09-10 Boston Scientific Scimed, Inc. Balloon catheter devices with sheath covering
US20090246252A1 (en) 2008-03-28 2009-10-01 James Howard Arps Insertable medical devices having microparticulate-associated elastic substrates and methods for drug delivery
US20100331816A1 (en) 2008-03-31 2010-12-30 Dadino Ronald C Rapamycin coated expandable devices
EP2123312A2 (en) 2008-05-19 2009-11-25 Cordis Corporation Extraction of solvents from drug containing polymer reservoirs
WO2010009335A1 (en) 2008-07-17 2010-01-21 Micell Technologies, Inc. Drug delivery medical device
US20100055294A1 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US20100063570A1 (en) 2008-09-05 2010-03-11 Pacetti Stephen D Coating on a balloon comprising a polymer and a drug
US20100069838A1 (en) 2008-09-12 2010-03-18 Boston Scientific Scimed, Inc. Devices and systems for delivery of therapeutic agents to body lumens
US20100198190A1 (en) 2008-09-15 2010-08-05 Michal Eugene T Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US20100198150A1 (en) 2008-09-15 2010-08-05 Michal Eugene T Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US20100069879A1 (en) 2008-09-15 2010-03-18 Michal Eugene T Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US20100068170A1 (en) 2008-09-15 2010-03-18 Michal Eugene T Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US20100081992A1 (en) 2008-09-26 2010-04-01 Ehrenreich Kevin J Expandable Member Formed Of A Fibrous Matrix For Intraluminal Drug Delivery
US20100087783A1 (en) 2008-10-07 2010-04-08 Boston Scientific Scimed, Inc. Medical devices for delivery of therapeutic agents to body lumens
US20120143132A1 (en) 2009-04-24 2012-06-07 Eurocor Gmbh Shellac and paclitaxel coated catheter balloons
US20100272773A1 (en) 2009-04-24 2010-10-28 Boston Scientific Scimed, Inc. Use of Drug Polymorphs to Achieve Controlled Drug Delivery From a Coated Medical Device
US20100285085A1 (en) 2009-05-07 2010-11-11 Abbott Cardiovascular Systems Inc. Balloon coating with drug transfer control via coating thickness
US20100324645A1 (en) 2009-06-17 2010-12-23 John Stankus Drug coated balloon catheter and pharmacokinetic profile
US20110054396A1 (en) 2009-08-27 2011-03-03 Boston Scientific Scimed, Inc. Balloon Catheter Devices With Drug-Coated Sheath
US20110144577A1 (en) 2009-12-11 2011-06-16 John Stankus Hydrophilic coatings with tunable composition for drug coated balloon
US20110144578A1 (en) 2009-12-11 2011-06-16 Stephen Pacetti Hydrophobic therapueutic agent and solid emulsifier coating for drug coated balloon
US20110143014A1 (en) 2009-12-11 2011-06-16 John Stankus Coatings with tunable molecular architecture for drug-coated balloon
US20110178503A1 (en) 2010-01-21 2011-07-21 Boston Scientific Scimed, Inc. Balloon catheters with therapeutic agent in balloon folds and methods of making the same
US20110190863A1 (en) 2010-02-03 2011-08-04 Boston Scientific Scimed, Inc. Therapeutic Balloon with Systemic Drug Loss Protection and Controlled Particle Size Release
US9072812B2 (en) 2010-04-19 2015-07-07 Angioscore, Inc. Coating formulations for scoring or cutting balloon catheters
WO2016015874A1 (en) 2014-08-01 2016-02-04 Lvd Biotech S.L. Paclitaxel-eluting balloon and method for manufacturing the same

Non-Patent Citations (64)

* Cited by examiner, † Cited by third party
Title
"Literature Alerts", Journal of Microencapsulation, vol. 17, No. 6, pp. 789-799 (2000).
Baumbach et al., "Local Drug Delivery: Impact of Pressure Substance Characteristics, and Stenting on Drug Transfer Into the Arterial Wall," Catheterization and Cardiovascular Interventions, vol. 47, pp. 102-106 (1999).
Bruno Scheller, M.D., Christoph Hehrlein, M.D., Wolfgang Bocksch, M.D., Wolfgang Rutsch, M.D., Dariush Haghi, M.D., Ulrich Dietz, M.D., Michael Bohm, M.D., and Ulrich Speck, Ph.D.; Treatment of Coronary In-Stent Restenosis with a Paclitaxel-Coated Balloon Catheter; The New England Journal of Medicine; Nov. 16, 2006; pp. 2113-2124.
Bruno Scheller, Ulrich Speck, Michael Böhm; Prevention of restenosis: is angioplasty the answer? Heart Journal, 2007; vol. 93; No. 5; pp. 539-541.
Charles et al., "Ceramide-Coated Balloon Catheters Limit Neointimal Hyperplasia After Stretch Injury in Carotid Arteries," Circulation Research published by the American Heart Association, 87, pp. 282-288 (2000).
Chun Li, et al, "Synthesis, Biodistribution and Imaging Properties of Indium-111-DTPA-Paclitaxel in Mice Bearing Mammary Tumors," The Journal of Nuclear Medicine, vol. 38, No. 7, Jul. 1997, 1042-1047.
Creel, C.J., et al., "Arterial Paclitaxel Distribution and Deposition", Circ Res, vol. 86, pp. 879-884 (2000).
D. M. Long et al., "Perflurocarbon Compounds as X-Ray Contrast Media in the Lungs," Bulletin de la Societe Internationale De Chirurgie, vol. 2, 1975, 137-141.
D.M. Jackson et al., "Current usage of contract agents, anticoagulant and antiplatelet drugs in angiography and angioplasty in the UK," Department of Diagnostic Radiology, Hammersmith Hospital, London, UK, Clinical Radiology (1995), 50, pp. 699-704.
English Language Abstract for DE 101 15 740, Oct. 2, 2002.
English Language Abstract for EP 1 372 737 A2, Jan. 20, 2004.
English Language Abstract for EP 1 539 266 A1, Jun. 15, 2005.
English Language Abstract for EP 1 539 267, Jun. 15, 2005.
English Language Abstract for EP 1 666 070 A1, Jun. 7, 2006.
English Language Abstract for EP 1 669 092 A1, Jun. 14, 2006.
English Language Abstract for EP 1 857 127, Nov. 21, 2007.
English Language Abstract for WO 02/076509, Oct. 3, 2002.
English Language Abstract for WO 2004/028582, Apr. 8, 2004.
English Language Abstract for WO 2004/028610, Apr. 8, 2004.
English Language Abstract for WO 2008/003298 A2, Jan. 10, 2008.
English Language Abstract for WO 2008/086794 , Jul. 24, 2008.
European Search Report for EP 09156858, Jul. 21, 2009.
European Search Report for EP 09160605, Jul. 20, 2009.
European Search Report for EP 10168411, Nov. 30, 2010.
European Search Report for EP 10168412, Nov. 30, 2010.
European Search Report for EP 10189393, Apr. 4, 2011.
Gyula Ostoros et al., "Fatal Pulmonary Fibrosis Induced Paclitaxel: A Case Report and Review of the Literature," International Journal of Gynecological Cancer, vol. 16, Suppl. 1, Jan. 2006, at pp. 391-393.
Gyula Ostoros et al., "Paclitaxel Induced Pulmonary Fibrosis," Lung Cancer, Elsevier, Amsterdam, NL, vol. 41, Aug. 1, 2003, at p. S280.
Herdeg et al., "Paclitaxel: Ein Chemotherapeuticum zum Restenoseprophylaxe? Experimentell Untersuchungen in vitro and in vivo," Z Kardiol, vol. 89 (2000) pp. 390-397.
Hershberger et al "Calcitriol (1, 25-dihydroxy cholecalciferol) Enhances Paclitaxel Antitumor Activity in Vitro and in Vivo and Accelerates Paclitaxel-Induced Apoptosis," Clin. Can. Res. 7: 1043-1051 (Apr. 2001).
International Search Report for International Application No. PCT/US2007/024108, Aug. 7, 2008.
International Search Report for International Application No. PCT/US2007/024116, Nov. 20, 2008.
International Search Report for International Application No. PCT/US2008/006348, Jan. 28, 2009.
International Search Report for International Application No. PCT/US2008/006348, May 16, 2008.
International Search Report for International Application No. PCT/US2008/006348, Nov. 26, 2008.
International Search Report for International Application No. PCT/US2008/006415, May 20, 2008.
International Search Report for International Application No. PCT/US2008/006415, Nov. 24, 2008.
International Search Report for International Application No. PCT/US2008/006417, May 20, 2008.
International Search Report for International Application No. PCT/US2008/006417, Nov. 24, 2008.
International Search Report for International Application No. PCT/US2008/007177, Dec. 2, 2008.
International Search Report for International Application No. PCT/US2008/007177, Sep. 16, 2008.
International Search Report for International Application No. PCT/US2009/004868, Jan. 1, 2010.
International Search Report for International Application No. PCT/US2009/004868, Jan. 4, 2010.
International Search Report for International Application No. PCT/US2009/004868, May 21, 2010.
International Search Report for International Application No. PCT/US2010/028599, Dec. 21, 2010.
J.F. Mitchel et al., "Inhibition of Platelet Deposition and Lysis of Intracoronary Thrombus During Balloon Angioplasty Using Urokinase-Coated Hydrogel Balloons." Circulation 90, (Oct. 1994), pp. 1979-1988.
J.H. Baron, et al., "In vitro evaluation of c7E3-Fab (ReoPro) eluting polymer-coated coronary stents." Cardiovascular Research, 46 (2000) pp. 585-594.
K. Kandarpa et al., "Mural Delivery of Iloprost with Use of Hydrogel-coated Balloon Catheters Suppresses Local Platelet Aggregation." J. Vasc. Interv. Radiol. 8, pp. 997-1004, Nov./Dec. 1997.
K. Kandarpa et al., "Site-specific Delivery of Iloprost during Experimental Angioplasty Suppresses Smooth Muscle Cell Proliferation." J. Vasc. Interv. Radiol. 9, pp. 487-493, (1998).
Ken Iwai, et al., "Use of oily contrast medium for selective drug targeting to tumor: Enhanced therapeutic effect and X-ray image," Cancer Research, 44, 2115-2121, May 1994.
Laure Champion et al., "Brief Communication: Sirolimus-Associated Pneumonitis: 24 Cases in Renal Transplant Recipients," Annals of Internal Medicine, vol. 144, No. 7, Apr. 4, 2006, at pp. 505-509.
Leo, A., et al., "Partition coefficients and their uses." Chem Rev, vol. 71 (6), pp. 525-537 (1971).
Li J. Chiang et al., "Potent inhibition of tumor survival in vivo by β-lapachone plus taxol: Combining drugs imposes different artificial checkpoints," PNAS, vol. 96, No. 23, Nov. 9, 1999, at pp. 13369-13374.
New England Journal of Medicine, 1995, 332: 1004-1014.
PPD "Evaluation of Butanol-Buffer Distribution Properties of C6-Ceraminde." PPD Project No. 7557-001, Aug. 20, 2008, pp. 1-14.
Prashant N. Chhajed et al., "Patterns of Pulmonary Complications Associated with Sirolimus," Respiration: International Review of Thoracic Diseases, vol. 73, No. 3, Mar. 2006, at pp. 367-374.
Rowinsky, E. K., et al., "Drug therapy: paclitaxel (taxol)", Review Article, N Engl J Med, vol. 332, No. 15, pp. 1004-1014, (1995).
Sangster, James, "Octanol-Water Partition Coefficients: Fundamentals and Physical Chemistry", Wiley Series in Solution Chemistry vol. 2, Chichester: John Wiley & Sons, vol. 2, Chapter 1 (1997).
Scheller et al., Paclitaxel Balloon Coating, a Novel Method for Prevention and Therapy of Restenosis, Circulation 2004;110;810-814; originally published online Aug. 9, 2004.
Seymour R. Halpin SF et al., "Corticosteroid prophylaxis for patients with increased risk of adverse reactions to intravascular contrast agents: a survey of current practice in the UK," Department of Radiology, University Hospital of Wales, Heath Park, Cardiff, Clinical Radiology (1994), 49, pp. 791-795.
Sylvia S.W. Ng, William D. Figg, Alex Sparreboom; Taxane-Mediated Antiangiogenesis in Vitro: Influence of Formulation Vehicles and Binding Proteins; Cancer Research; Feb. 1, 2004; pp. 821-824.
Terwogt et al; "Alternative formulations of paclitaxel," Cancer Treatment Reviews (1997); 23: 87-95.
Toshimitsu Konno, M.D., et al., "Selective targeting of anti-cancer drug and simultaneous imaging enhancement in solid tumors by arterially administered lipid contrast medium," Cancer 54:2367-2374, 1984.
Yushmanov, et al., "Dipyridamole Interacts with the Polar Part of Cationic Reversed Micelles in Chloroform: 1H NMR and ESR Evidence", J. Colloid Interface Sci., vol. 191(2), pp. 384-390 (1997).

Also Published As

Publication number Publication date Type
US20180028791A1 (en) 2018-02-01 application
US20160250452A1 (en) 2016-09-01 application

Similar Documents

Publication Publication Date Title
US7572245B2 (en) Application of a therapeutic substance to a tissue location using an expandable medical device
US20090208552A1 (en) Cross-linked fatty acid-based biomaterials
US20100068170A1 (en) Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US20100198190A1 (en) Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
US20070212394A1 (en) Taxane coatings for implantable medical devices
US20040126400A1 (en) Delivery of therapeutic compounds via microparticles or microbubbles
US20080206305A1 (en) Implantable barrier device
US20090054837A1 (en) Coating Method for a Folded Balloon
US8273404B2 (en) Extraction of solvents from drug containing polymer reservoirs
US20080124400A1 (en) Microparticles With High Loadings Of A Bioactive Agent
US20080020013A1 (en) Methods of manufacturing and modifying taxane coatings for implantable medical devices
US20050244363A1 (en) Hyaluronic acid based copolymers
US20060083768A1 (en) Method of thickening a coating using a drug
US20070202149A1 (en) Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
US20060121081A1 (en) Application of a coating on a medical device
US20110143014A1 (en) Coatings with tunable molecular architecture for drug-coated balloon
WO2009018816A2 (en) Improved pharmaceutical-coated medical products, the production thereof and the use thereof
US20060112536A1 (en) Method of coating a folded medical device
WO2002087545A1 (en) Composition and methods for treatment of hyperplasia
US20060110457A1 (en) Heat cured gel and method of making
WO2008086794A2 (en) Medical product for treating stenosis of body passages and for preventing threatening restenosis
WO2008003298A2 (en) Manufacture, method, and use of active substance-releasing medical products for permanently keeping blood vessels open
US20110144578A1 (en) Hydrophobic therapueutic agent and solid emulsifier coating for drug coated balloon
US20040197408A1 (en) Amino acids in micelle preparation
WO2004028583A2 (en) Perivascular wraps